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Abstract
The etiology of the autoimmune disease rheumatoid arthritis (RA) is unknown, but the role of cytokines,
including IFN-g, as effectors of immune cell function has been established by the examination of cytokine
production in RA patients and through the use of animal models. C57BL/6 (B6) mice that express MHC
class II molecules of the b haplotype (I-Ab) are not typically susceptible to collagen-induced arthritis (CIA),
the most widely studied animal model of RA. When the gene encoding IFN-g is removed by genetic
deletion, however, susceptibility to CIA is conferred. In addition, T cell responses against the immunogen
that stimulates CIA, type II collagen (CII), are reduced in the B6 strain when compared to susceptible
mouse strains that express differing MHC haplotypes such as the I-Aq-expressing DBA mouse. These
observations led to the development of the following hypothesis. IFN-g functions as a regulator of T cell
responses to weak determinants, and I-Ab MHC class II molecules have low affinity for collagen
autoantigen determinants. In the IFN-g-/- B6 mouse, the absence of IFN-g alters T cell function and
cytokine production following immunization with CII, disrupting normal immune function and allowing the
development of CIA.
To reveal the pathogenic mechanisms that mediate susceptibility to arthritis in the B6 IFN-g-/- mouse we
examined several aspects of the immune response that follows immunization with CII. Firstly, alterations
in cellular immune responses between wild type and B6 IFN-g-/-mice were examined following
immunization with CII. Secondly, an antigenic determinant present in bovine CII that stimulates T cell
response in mice expressing I-Ab was identified. This determinant was identified by the use of direct
binding assays between I-Ab and CII derived peptides as well as by the generation of T hybridomas
generated in I-Ab-expressing mice that respond to CII. In a second series of experiments, the role of IFN-g
in modulating disease progression was examined by the use of microarray analysis to identify genes that
are altered between wild type and IFN‑g‑/‑ B6 mice immunized with CII in CFA emulsion. This allowed the
identification of IL-17 and IL-18 Binding Protein (IL-18 BP) as differentially expressed between the two
strains. When IL-18 BP was given exogenously to IFN-g-/- B6 mice immunized with CII, the mice were
protected from the development of CIA.
These results indicate that a CII determinant is present in bovine CII and the low immunogenic properties
of this determinant may be responsible for the lack of arthritis development in wild type B6 mice. In the
absence of IFN-g, there is disregulation of immune function exhibited as decreased expression of IL-18
BP and increased expression of IL-17. This disregulation allows T cell responses to weakly antigenic CII
determinants to progress, thus promoting the development of autoimmune arthritis.
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Abstract
The etiology of the autoimmune disease rheumatoid arthritis (RA) is unknown,
but the role of cytokines, including IFN- , as effectors of immune cell function has been
established by the examination of cytokine production in RA patients and through the use
of animal models. C57BL/6 (B6) mice that express MHC class II molecules of the b
haplotype (I-Ab) are not typically susceptible to collagen-induced arthritis (CIA), the
most widely studied animal model of RA. When the gene encoding IFN- is removed by
genetic deletion, however, susceptibility to CIA is conferred. In addition, T cell
responses against the immunogen that stimulates CIA, type II collagen (CII), are reduced
in the B6 strain when compared to susceptible mouse strains that express differing MHC
haplotypes such as the I-Aq-expressing DBA mouse. These observations led to the
development of the following hypothesis. IFN- functions as a regulator of T cell
responses to weak determinants, and I-Ab MHC class II molecules have low affinity for
collagen autoantigen determinants. In the IFN- -/- B6 mouse, the absence of IFN- alters
T cell function and cytokine production following immunization with CII, disrupting
normal immune function and allowing the development of CIA.
To reveal the pathogenic mechanisms that mediate susceptibility to arthritis in the
B6 IFN- -/- mouse we examined several aspects of the immune response that follows
immunization with CII. Firstly, alterations in cellular immune responses between wild
type and B6 IFN- -/-mice were examined following immunization with CII. Secondly, an
antigenic determinant present in bovine CII that stimulates T cell response in mice
expressing I-Ab was identified. This determinant was identified by the use of direct
binding assays between I-Ab and CII derived peptides as well as by the generation of T
hybridomas generated in I-Ab-expressing mice that respond to CII. In a second series of
experiments, the role of IFN- in modulating disease progression was examined by the
use of microarray analysis to identify genes that are altered between wild type and
IFN- -/- B6 mice immunized with CII in CFA emulsion. This allowed the identification
of IL-17 and IL-18 Binding Protein (IL-18 BP) as differentially expressed between the
two strains. When IL-18 BP was given exogenously to IFN- -/- B6 mice immunized with
CII, the mice were protected from the development of CIA.
These results indicate that a CII determinant is present in bovine CII and the low
immunogenic properties of this determinant may be responsible for the lack of arthritis
development in wild type B6 mice. In the absence of IFN- , there is disregulation of
immune function exhibited as decreased expression of IL-18 BP and increased expression
of IL-17. This disregulation allows T cell responses to weakly antigenic CII determinants
to progress, thus promoting the development of autoimmune arthritis.
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Chapter 1. Introduction
The Immune System and the Origins of Autoimmunity
Protection from invading pathogenic microorganisms, and from the development
of cancer is critical to homeostasis in vertebrate organisms. In order to combat these
potentially deadly threats, a complex adaptive immune system has evolved that is capable
of recognizing and neutralizing an enormous variety of foreign invaders. An important
function of the adaptive immune system is the distinction of foreign and self, in other
words, the distinction of pathogenic organisms from cells and tissue native to a healthy
organism. It does this by a mechanism that can distinguish subtle chemical differences
between molecules, known as antigens, that are produced by foreign pathogens and
native cells produced by the host organism. Once a foreign pathogen is recognized, the
immune system responds with an interconnected network of cellular and chemical
mediators that conjunctively work to eliminate or neutralize the threat. However, the
potency of the immune system is a double-edged sword. The same mechanisms that have
evolved to protect against invasion of pathogenic microorganisms can become
disregulated, turn against host tissues, and cause disease in a process known as
autoimmunity. Autoimmunity occurs when immune cells incorrectly recognize selfantigens (autoantigens) as foreign and mount an immune response against host tissue.
The initiating causes of autoimmunity remain elusive to scientific inquiry, but a number
of factors are believed to contribute to disease susceptibility and pathogenesis. These can
include genetic predisposition, environmental factors such as infectious agents, diet,
exercise, and even cigarette smoking (1).
The process by which autoimmunity develops has been an ongoing focus of
research since Paul Ehrlich first postulated the concept of horror autotoxicus in the early
1900’s (2). Since that time, a number of advances in genetics and biological methods
have allowed the identification of risk factors for the development of autoimmunity.
Many mechanisms of autoimmunity have also been discovered, though much work
remains to completely understand the pathogenesis of autoimmune diseases, especially
the initiating events. It is likely that autoimmunity stems from a combination of both
genetic and environmental factors. Probably the most important factor in the
predisposition to autoimmune disease is genetic background. The influence of genetics
on the development of autoimmunity can be simple in the case of single gene mutations
that cause increased risk to specific autoimmune diseases, or complex as in the case of
multiple susceptibility alleles that interact with environmental factors to confer increased
risk of disease (3). One of the most important genetic factors linked to autoimmune
susceptibility is the expression of specific class II major histocompatibility complex
(MHC) alleles that are associated at high levels to various autoimmune diseases. For
example, susceptibility to the autoimmune disease rheumatoid arthritis is strongly linked
to the expression of specific HLA-DR1 and DR4 alleles (4). To understand how these
DR alleles mediate this susceptibility, a considerable effort has been made to understand
how immune cells recognize and respond to antigen presented by these molecules, and to
identify the control mechanisms that regulate these immune responses.
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One of the first steps in an adaptive immune response is the activation of T cells
to antigens that have been processed and displayed on the surface of antigen presenting
cells. The molecules that mediate this process are the aforementioned MHC molecules
and the T cell receptor (TCR). Each TCR contains a variable region that during T cell
maturation is altered by genetic recombination. This process produces a multitude of T
cell clones that each express a unique TCR with a different specificity for antigen.
Structurally, MHC molecules contain an open groove that binds peptide fragments of
proteins generated in endosomic vesicles. This peptide/MHC complex is then transported
to the surface of the cell where it is made available to binding by the TCR. If the TCR
expressed by a T cell matches the unique structure of the peptide/MHC complex, it binds
and forms a supramolecular structure known as a T cell receptor complex. The formation
of the TCR complex initiates signaling cascades within the T cell that leads to its
activation and development as an effector T cell.
There are two predominant types of classical MHC molecules, MHC class I and
MHC class II, and each has a distinct role in the presentation of antigen to a T cell. Class
I molecules bind peptide antigens that are derived predominantly from intracellular
proteins, such as would be produced by intracellular pathogens like viruses or in cancer
cells. MHC class I is expressed on all cells and binds to TCR present on CD8-expressing
T cells known as cytotoxic T cells (Tc) (5). These cells have the ability to either kill
infected target cells or to cause the release of substances in the target cell that is harmful
to an infectious agent. In contrast, MHC class II binds peptides predominantly derived
from proteins produced outside of the antigen presenting cell and presents them to CD4expressing T cells (6). MHC class II, unlike MHC class I, is expressed on only a limited
set of cells including those known as professional antigen presenting cells (APC). These
cells include macrophages, dendritic cells, and Langerhans cells (7). Also, B cells, in a
mechanism related to their immune effector function of antibody production, express
MHC class II and present antigens to CD4+ T cells (8). CD4+ T cells do not act directly
on infected target cells like Tc cells. Rather they serve to promote activation of other
immune cells like antibody producing B cells or to stimulate antigen presenting cells to
alter their function. They perform this either by direct cell to cell contact or by the
production of small intercellular signaling molecules called cytokines. Since CD4+ T
cells promote the effector function of other immune cells they are referred to as T helper
cells (Th).
CD4-expressing Th cells can be further characterized by their division into subsets
based on the types of cytokines they produce and the nature of the immune response that
follows their activation. The production of cytokines is crucial to regulation of the
immune response and can have major effects on the activation, proliferation, and
response of both immune and accessory cells. Subsets of Th cells include Th1, Th2, and
Th17 cells. Th1 cells are identified by the production of the cytokine IFN- following
antigen stimulation and they promote inflammatory immune responses (9, 10). In
contrast, Th2 cells express IL-4, IL-5, and IL-13 following antigen stimulation and
promote humoral immune responses (9, 11). Th17 cells are a recently described subclass
of Th cells that produce IL-17 upon activation (12, 13). IL-17 was previously known as a
proinflammatory cytokine (14), and the identification of an IL-17 producing cell subset
helps to explain some contradictory findings about the role of Th1 cells in chronic
2

autoimmune and inflammatory disease. For example, administration of exogenous IFNcan assuage some autoimmune diseases, while its removal can exacerbate it. This
phenomenon can be observed in the autoimmune diseases multiple sclerosis (MS) (8),
and RA (15) and rodent models of these diseases including experimental autoimmune
encephalomyelitis (EAE) (16) and CIA (17). The use of rodent models in the study of
RA identified the overexpression of proinflammatory cytokines including TNF- , IL-1 ,
lymphotoxin- , and IFN- , whose expression is mediated by Th1 cells (9, 18, 19).
Initially, this gave rise to the theory that RA was a Th1 mediated disease. However, there
is mounting evidence that Th17 cells play a crucial role in the development of RA as well
as many other autoimmune diseases. When genes encoding IFN- , its receptor, or IL-12
are removed, the incidence of disease is exacerbated (17, 20, 21). Since these genes are
associated with Th1 cell function, the increase in arthritis activity indicated a role for
other cells in the pathogenesis of immune arthritis. Several lines of evidence support
Th17 cells as mediators of autoimmune arthritis. IL-17 expression is increased in the
joint synovium of RA patients and stimulates production of IL-6, IL-8, IL-1 , and TNF(22). In animal models, blockage of IL-17 by genetic deletion or anti-IL-17 antibodies
inhibits arthritis development (23, 24). One explanation for this observation is that
autoimmune disorders previously thought meditated by Th1 cells may in fact be
dependent on Th17 cell function. For this reason, the identification of Th17 as a
proinflammatory subset of Th cells has caused a re-examination of the role of Th1 cells in
chronic inflammatory disease (25).
While the TCR/MHC interaction is the mechanism by which T cells recognize
antigens, the mechanisms of self-tolerance regulate the development of self-reactive T
cell responses. Self-tolerance can be thought of as a balance between functional
immunocompetence and prevention of autoimmunity. It is the process by which immune
cells “learn” what antigens are native to the host and therefore not appropriate targets of
immune response. For T cells, there are two mechanisms of self-tolerance, central
tolerance and peripheral tolerance. In the process of central tolerance, T cells are
positively and negatively selected to produce cells that interact with self-MHC molecules,
but not to self-antigen presented by these MHC molecules. This process is largely
mediated by the affinity between the MHC, the peptide ligand, and the TCR. During
maturation in the thymus T cells are first positively selected, they are presented with
peptides, of poorly defined origin, bound to the MHC molecules of cortical thymic
epithelium. The T cells must bind to these MHC/peptide complexes, indicating that they
express functional TCR, to be “positively” selected for survival (26, 27). Those cells that
survive positive selection are next presented with self-antigen/MHC and the
costimulatory molecules CD80 and CD86 by medullary thymic epithelium and dendritic
cells, and if they have high binding affinities for self-peptide/MHC complexes, they are
deleted by apoptosis. It is at this stage that T cells with specificity to autoantigens can
escape self-tolerance and leave the thymus as mature self-reactive cells (28). One can
imagine a scenario where T cells with intermediate to low affinity for self-peptide/MHC
do not have a high enough affinity to be deleted during negative selection and escape to
the periphery (29-31). To minimize these self-reactive T cells as a source of autoimmune
reactions, mechanisms of peripheral tolerance have evolved. These mechanisms include
anergy, deletion, and suppression by regulatory T cells (Treg) (32). Although peripheral
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tolerance can in part be antigen mediated, these processes are largely dependent on
cytokine signaling and costimulation between the APC or Treg cells and the self-reactive
Th cell. Ultimately, the loss of self-tolerance by these self-reactive T cells is one
potential mechanism of autoimmunity. The mechanism by which this loss of tolerance
occurs is not entirely understood, but due to the major role of binding affinity in T cell
development and the role of cytokines in the mechanisms of tolerance, it is likely that
both the affinity of the TCR for peptide/MHC and cytokine signaling is involved in this
process.

Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that serves as an
example of how the development of autoimmunity is dependent both on the activation of
CD4+ T cells and by cytokine signaling. RA affects over 2 million people in the United
States, and about 1-2% (33) of the population worldwide. A primary effect of the disease
is the destruction of articular cartilage and ankylosis of diarthroidal joints by a
progressive proliferative synovitis. The inflammation of RA is not limited to the joint
however, and can affect the skin, vasculature, heart, lung, and muscle (34). Destruction
of synovial joints is marked by radical changes in joint morphology. These changes
include edema, loss of cartilage and bone, and hyperplasia of the synovium. The
synovial membrane becomes infiltrated with lymphoid cells, plasma cells, and
macrophages, and exhibits increased vascularity. Neutrophils are also present in the
normally acellular synovial fluid. Bone resorption by osteoclast activity is increased
causing articular erosions and osteoporosis, and allowing the synovium to enter the bone
and form subchondral cysts. Ultimately, the joint structure is destroyed by the formation
of a pannus. Inflammatory cells, fibroblasts, and granulomatous tissue produce a
fibrocellular mass of tissue that gradually degrades the cartilage lining the bone surfaces
and bridges the joint space resulting in ankylosis (34).
Though the etiology of RA remains unknown, there are a number of factors that
contribute to its development. The incidence of RA is more prevalent in women than in
men. The exact figures vary from population to population worldwide, but in women RA
occurs 2 to 3 times more often (35-37). A number of other genetic factors are also linked
to the development of RA. There is evidence that the risk of RA is increased along
familial lines. In one study in the UK, it was found that if an individual in a pair of
identical twins develops RA, the chance of the other twin also developing RA is 15%
(38), a nearly 20 fold increase from the 0.8% (36) risk in the general population. In
addition to the familial link to RA susceptibility, the most significant genetic factor that
correlates with the advent of RA is human MHC lymphocyte antigen (HLA) genotype.
The discovery that expression of HLA-DR4 (39) and HLA-DRB1 (40-42) is linked to RA
has an important implication in the pathogenesis of RA. HLA-DR4 and HLA-DRB1 are
MHC class II molecules that present peptide antigens to CD4+ T cells. Therefore, RA
pathogenesis is likely mediated by Th subsets of CD4+ T cells.
Functional and structural studies of the HLA alleles that are genetically linked to
RA enabled the development of the “shared epitope hypothesis” (43). This hypothesis
4

provides a potential framework for understanding how RA arises as an autoimmune
disease. It is based on the assumption that, initiation of the immune response in RA
requires T cell activation via engagement of the T cell receptor with antigen presented by
MHC class II molecules. Due to this requirement, alterations in MHC class II structure
can influence antigen presentation that ultimately affects how T cells differentiate and
activate in response to antigen. A number of HLA-DR alleles are linked to RA including
*0101, *0102, *0401, *0404, *0405, *0408, *1001, and *1402 (44). The structure of
MHC class II molecules is such that in the DR 1 molecule the point of contact with
antigen contains three regions in which the amino acid sequence is hypervariable
(polymorphic) among different alleles. This is an evolutionary mechanism for increasing
the diversity of peptide determinants that can bind MHC molecules. Among the HLADRB alleles that are linked to RA, the third hypervariable region is highly conserved
(43). As a result, the surface of the binding groove in the MHC that carries the antigen is
similar in that region. This may affect RA pathogenesis either by limiting the MHC to
selectively bind autoantigen determinants, or by influencing the presentation of antigen to
potentially self-reactive T cells.

Cytokines in the Pathogenesis of Rheumatoid Arthritis
One of the hallmarks of RA is an abundance of cytokine expression. The
pathogenesis of RA involves immune processes that are closely regulated by cytokine
signaling between immune cells, accessory cells, and the cells of the joint synovium. The
pathogenesis of RA requires the development of autoimmunity in which T and B cell
tolerance is broken, allowing them to respond to self-antigens. Chronic inflammation of
the joint synovium that leads to destruction of articular tissue requires maintenance of
proinflammatory signals. The onset of clinical disease in RA, coincides with the
infiltration of immune cells into the normally hypocellular joint synovium. A broad
selection of immune cells including CD4+ and CD8+ T cells, B and plasma cells,
macrophages, mast cells, NK cells, and NKT cells invade the joint synovium and
promote articular destruction via the stimulation of tissue modeling cells, including
osteoclasts, chondrocytes, and synovial fibroblasts. The pathogenic mechanisms of RA,
autoimmunity, chronic inflammation, and joint destruction are all regulated by cytokine
signaling (45).
One mechanism by which autoimmunity may arise is when there is an imbalance
between proinflammatory and anti-inflammatory cytokines. The cytokine milieu present
in the synovium of RA contains proinflammatory IL-1 , IL-6, IL-7, IL-12, IL-15, IL-18,
IL-23p19, and TGF produced by macrophage cells and synovial fibroblasts (45). These
cytokines promote the proliferation and differentiation of IFN- producing Th1 and IL-17
producing Th17 T cell subsets. Conversely, there is decreased expression of the antiinflammatory cytokines IL-4 and IL-13 in established RA. However, the expression of
these cytokines is biphasic, in very early RA synovial expression of IL-4 and IL-13 is
increased (46). This is perhaps a self-regulatory mechanism in which the immune system
attempts to neutralize the development of an autoimmune response. Nonetheless,
effector T cells are produced in RA, though whether Th1 or Th17 predominate has not
been definitively concluded. Similarly, the role of IFN- remains controversial. IFN5

promotes production of complement fixing IgG subclasses (47), causes increased MHC
class II expression in APC (48), and induces production of IL-1 in macrophages and
cytokine production by synovial fibroblasts. By its support of Th1 differentiation it
contributes to the production of the proinflammatory cytokines TNF- and GM-CSF.
Th17 derived IL-17 has potent effects on inflammatory mechanisms present in RA.
Neutrophil, monocyte, and fibroblast activation and cytokine production are stimulated
by IL-17 (49). The proinflammatory properties of IL-17 are amplified when coexpressed
with other inflammatory cytokines such as IL-1 and TNF initiating signaling cascades
that promote destructive inflammation in the joint synovium (50).
In addition to the production of complement activating autoantibodies, B cells are
regulated by and can contribute to the pathogenesis of RA through the production of
cytokines in the joint synovium. In culture, exposure of synovial fibroblasts to TNF and
IFN- induced production of B cell activating factor (BAFF) which supports B cell
survival and differentiation (51). Activated B cells produce IL-6, IL-10, and
lymphotoxin- (LT ) as well as chemokines including CXCL13 and CCL21. The
chemokines and LT promote the formation of germinal centers within the synovium
(52, 53). LT also promotes the production of IL-1, IL-6, GM-CSF, CCL2, CCL5 and
matrix metalloproteinases by synovial fibroblasts (54). The formation of germinal
centers and the production of inflammatory cytokines by synovial tissues can support T
cell activation and effector function within the joint, demonstrating a role for cytokine
regulation in the pathogenesis of RA.

Collagen-Induced Arthritis, an Animal Model of Rheumatoid Arthritis
As discussed above, both antigen stimulation of T cells and cytokine signaling are
strong candidates as mediators of the autoimmune pathogenesis in RA. Therefore, in
order to determine pathogenic mechanisms of RA we sought to identify how the cytokine
milieu at the time of antigen exposure affects the activation of T cells to drive an
autoimmune response. In order to do this, a mouse model of RA was used.
Immunization with type II collagen (CII) in an emulsion of complete Freund’s adjuvant
(CFA) results in the development of an autoimmune arthritis in genetically susceptible
mouse strains. This model is known as Collagen-Induced Arthritis (CIA) and is the most
widely studied model of RA. CIA mirrors RA in many aspects and the use of this model
allows insight into the pathogenic mechanisms of RA. As in RA, susceptibility to CIA is
strongly linked to MHC class II molecule haplotype. DBA/1 and B10.Q strains (I-Aq) as
well as B10.RIII (I-Ar) are susceptible to CIA, developing autoimmune disease at a high
incidence (55, 56). In contrast, strains of mice expressing other MHC class II alleles are
resistant to CIA such as the Balb/c (I-Ad) and C57BL/6 (I-Ab) strains. These mouse
susceptibility markers mirror the genetic susceptibility of RA in humans where the
incidence of RA is linked to the expression of certain HLA-DR alleles. In fact, when the
human class II molecules HLA-DRB1*0101 or HLA-DRB1*0404, both linked to the
development of RA, are expressed in a CIA non-susceptible mouse strain, B10.M (I-Af),
susceptibility to CIA is conferred (57).
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An additional model of RA that is a derivative of CIA is the IFN- -/- C57BL/6
model. C57BL/6 mice express MHC of the I-Ab haplotype and are normally resistant to
CIA, developing arthritis only rarely and exhibiting low severity. However, when the
gene encoding the cytokine IFN- is removed by genetic ablation the strain becomes fully
susceptible to CIA and exhibits arthritis at high incidence and severity (17). This model
provides a unique opportunity to study the role of the cytokine milieu on autoimmune
pathogenesis. In mouse strains susceptible to CIA, the linkage of arthritis susceptibility
to specific class II MHC genes indicates a role for CD4+ CII-specific Th cells. These CIIspecific T cells are identified as predominantly of the Th1 subset by their production of
IL-2 and IFN- . One important consequence of IFN- production in the pathogenesis of
CIA is the IFN- mediated class switching of Ig to the complement-fixing IgG2a subtype
(58-60). In addition, in CIA, inflammation is largely mediated by the cytokines TNF- ,
IL-1 , and IL-6 (60, 61). Despite a need for complement-fixing CII-specific antibodies
and the production of proinflammatory cytokines driven by a strong Th1 response, the
absence of IFN- is able to convert the non-susceptible C57BL/6 strain of mouse to full
susceptibility. Explanation of how this conversion occurs is needed and could provide
insight into mechanisms of autoimmune pathogenesis. Some of the mechanisms of CIA
pathogenesis in the B6 IFN- -/- model may include disregulation of immune regulatory
mechanisms dependent on IFN- , increased influence of Th17 or Th2 cell subsets due to
reduced Th1 cell numbers or effector function, or altered antigen presentation by APC
due to IFN- ’s regulatory effects on class II MHC expression.
The chapters that follow relate how the absence of IFN- results in immune
disregulation and promotes the development of autoimmunity. By using CIA in the B6
IFN- -/- mouse as a model of RA, experimental systems were designed to determine how
the absence of IFN- affects such immune processes immune cell activation,
proliferation, and effector function. Also, since T cell activation is dependent on the
interaction of the TCR with antigen presented by MHC, the effects of IFN- on T cell
activation to autoimmune CII determinants was examined. Since an I-Ab CII determinant
was not previously known, the first step in this process was to identify amino acid
sequences present in CII to which auto-reactive T cells activate to cause an autoimmune
response. Finally, an IFN- mediated regulatory cytokine network was identified that in
the absence of IFN- is disregulated and promotes the development of autoimmunity.
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Chapter 2. Materials and Methods
Mice
The following mice were obtained from The Jackson Laboratory, Bar Harbor,
ME:
C57BL/6J (B6) (I-Ab)
B6.129S7-Ifngtm1Ts/J (B6 IFN- -/-) (I-Ab)
CXB2/ByJ (CXB2) (I-Ab)
D1Lac.Cg-Tg(Tcra,Tcrb)24Efro/J (qCII24) (I-Aq)
B6.129S2-H2dlAb1-Ea/J (I-A-/-)

stock # 000664
stock # 002287
stock # 000352
stock # 005694
stock # 003584

B10.M I-A-/- DR1 mice were produced by crossing I-A null B6.129S2-H2dlAb1-Ea/J
with DR1*0101-expressing B10.M/J-TgN-DR1 (57) and backcrossed with B10.M/JTgN-DR1 mice for 5 generations to produce DR1*0101-expressing mice without
endogenous MHC class II expression. For all experiments, mice were bred and
maintained at the Veterans Affairs Medical Center of Memphis in Memphis, TN
(VAMC) in a specific pathogen free environment, and sentinel mice were routinely tested
for the presence of mouse hepatitis and Sendai viruses.

Cell Culture
HL-1 Media: (Lonza, Walkersville, MD) was supplemented with 50 units/ml
penicillin (Invitrogen, Grand Island, NY) 50 mg/ml streptomycin (Invitrogen, Grand
Island, NY), 4 M L-glutamine (Invitrogen, Grand Island, NY), 50 M 2mercaptoethanol (Sigma, Saint Louis, MO), and 0.1% electrophoresis grade BSA
minimum 96% (Sigma, Saint Louis, MO) to make complete HL-1 Media.
DMEM: (Lonza, Walkersville, MD) was supplemented with 100 units/ml
penicillin (Invitrogen, Grand Island, NY) 100 mg/ml streptomycin (Invitrogen, Grand
Island, NY), 2 mM L-glutamine (Invitrogen, Grand Island, NY), 50 M
2-mercaptoethanol (Sigma, Saint Louis, MO), and 10% fetal bovine serum (Hyclone,
Logan, UT) to make complete DMEM media.
Schneider’s Drosophila Medium, Modified: (Cambrex Bio Science, Walkersville,
MD) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) and 50 units/ml
penicillin (Invitrogen, Grand Island, NY) 50 mg/ml streptomycin (Invitrogen, Grand
Island, NY).
TNM-FH insect media: (#554760, BD biosciences, San Diego, CA).
SF-900 II: (#10902, Gibco, Grand Island, NY) supplemented with 5% fetal
bovine serum (FBS) (Hyclone, Logan, UT), 50 units/ml penicillin (Invitrogen, Grand
Island, NY), and 50 mg/ml streptomycin (Invitrogen, Grand Island, NY)
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Mammalian cell lines were cultured in supplemented DMEM at 37º C and 10%
CO2. Ex vivo lymphocyte cell cultures were cultured in supplemented HL-1 media at 37º
C and 5% CO2. S2 drosophila cells were cultured in supplemented Schneider’s
Drosophila Medium, Modified at 25º C. SF9 cells were cultured in either TNM-FH
insect media or SF-900 II supplemented with 5% FBS at 27º C.

Type II Collagen
The amino acid sequence of type II collagen from chicken, mouse, cow, and
human were obtained from the National Centers for Biotechnology Information (NCBI)
database and are as follows: chicken CII accession # NM 204426, bovine CII accession #
NP 001001135, human CII accession # NM 001844, and mouse CII accession # NM
031163
Bovine and chicken type II collagen (CII) was prepared locally by the VAMC
Collagen Core laboratory. Bovine 1(II) was prepared from native bovine type II
collagen by heat denaturation at 45 C and purification of monomeric 1 subunits by
separation on a carboxymethylcellulose column (62). Human type II collagen was a kind
gift of Dr. Andrew Kang (VAMC, Memphis, TN)

Peptides
Both biotinylated and unmodified peptides with free end groups were synthesized
by Sigma-Genosys (The Woodlands, TX). Biotinylated analogs consist of the peptide
plus biotin covalently attached to the N terminus. Peptide sequences are as follows:
CII(512-526)
CII(512-528)
CytC(43-58)
Mog(35-55)
CII(257-274)

H-AQGLQGPRGL(Hyp)GT(Hyp)G-OH
H-AQGLQGPRGL(Hyp)GT(Hyp)GTD-OH
H-AEGFSYTDANKNKGIT-OH
H-MEVGWYRSPFSRVVHLYRNGK-OH
H-E(Hyp)GIAGFKGEQGPKGE(Hyp)G-OH.

The mature form of human CII (GenBank accession # NM 001844) minus the
globular terminal ends found in procollagen, amino acids 1-185 at the amino terminal end
and amino acids 1230-1487 at the carboxyl terminus, was used as a template to produce a
library of 344 15-mer peptides that progressively overlap by 12 amino acids (Mimotopes,
Clayton Victoria, Australia). The sequence in the peptides is numbered according to
convention with the first amino acid in the peptide library numbered as -15, which
corresponds to amino acid 186 of the procollagen sequence. Peptides contain a free
amino group at the N-terminus and a diketopiperazine group at the C-terminus.
The amino acid sequence of the I-Ab collagen determinant representing amino
acids (512-526) of mature CII was used to produce a substituted library of 15 peptides
with each position of the sequence AQGLQGPRGL(Hyp)GT(Hyp)G substituted with
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alanine. Peptides were synthesized with free N- and C-termini (Mimotopes, Clayton
Victoria, Australia).

Antigen Emulsions
Mice were immunized with emulsions of antigen in CFA. To produce CFA, heat
killed Mycobacterium tuberculosis (Mtb), strain H37RA, (Difco Laboratories, Detroit,
MI) was ground to a fine powder with a mortar and pestle and added to incomplete
Freund’s adjuvant (IFA) consisting of 15% Arlacel A in heavy paraffin oil (David Brand,
VAMC Memphis, TN) at a concentration of 4 mg/ml. Equal volumes of CFA and
antigen solution, 4 mg/ml CII in 10 mM acetic acid or 2 mg/ml peptide in PBS, were
placed in a 3 ml syringe (BD, Franklin Lakes, NJ) with the end sealed using Dura Seal
(Diversified Biotech, Boston, MA) and a plastic cap. Emulsion was created by mixing at
high speed with a tissue homogenizer (IKA, Wilmington, NC) on ice for 2-3 min then
centrifuging at low speed for 1 min to remove air bubbles. The quality of the emulsion
was then determined by placing a drop of emulsion in a beaker of water. If the emulsion
held together for at least 3 min it was considered stable. The emulsion was then
transferred into a 1 ml syringe and capped with a 0.5 inch 26 gauge needle and stored on
ice until immunizations were performed. Mice anesthetized with isofluorane were
immunized in one of two locations. For experiments requiring the induction of CIA, 100
µl of emulsion was injected subdermally at a location 2-3 cm from the base of the tail.
For experiments requiring the later removal of draining lymph nodes mice were
immunized subdermally with 50 µl emulsion into both rear footpads.

Collagen-Induced Arthritis
For the induction of CIA, mice aged 8-16 weeks were immunized subdermally in
the tail with 100 µl of CFA emulsion containing 2 mg/ml CII and 2 mg/ml Mtb. The
development of arthritis was monitored visually 2-3 times per week. The severity of
arthritis was determined by noting the swelling and joint involvement of each paw using
the following scoring system: 0 no erythema and swelling; 1 erythema and swelling
confined to mid foot or ankle joint; 2 erythema and moderate swelling extending from the
ankle to the metatarsal joints; 3 erythema and severe swelling that encompasses the ankle,
foot, and digits; 4 extreme erythema and swelling encompassing all joints of the foot.
Mice were monitored until maximal scores were achieved or past 65 days. Data is
expressed as the severity and incidence of arthritis exhibited. The nature of the scoring
system results in a severity score that ranges from 0 to 16 with 4 points contributed by
each paw. 0 represents no arthritis development and 16 represents maximum edema and
erythema in all joints of all limbs. To obtain an overall severity score in a particular
experimental group the highest severity scores of arthritic mice only were averaged.
Incidence is expressed as the percentage of mice in each group that received a severity
score of 1 or higher.
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FACS Analysis
Wild type or IFN- -/- B6 mice were immunized with bovine CII/CFA emulsion
and lymphocytes were recovered from the draining popliteal lymph nodes ten days later
by mechanical disruption with forceps. The lymphocytes were then washed two times in
PBS 0.1% NaAzide and resuspended at 5x106 cells in PBS 0.1% NaAzide. The cells
were then stained with the following fluorescently labeled monoclonal antibodies: antiTCR FITC (#553171, BD Biosciences, San Diego, CA), anti-CD8a PerCP (#551162, BD
Biosciences, San Diego, CA), anti-CD19 APC (#550992, BD Biosciences, San Diego,
CA), and anti-CD4 Pacific Blue (#558116, BD Biosciences, San Diego, CA). Staining of
cells was performed by adding 0.5 µl of monoclonal antibody conjugated to a fluorescent
label to 5x105 cells in 100 µl PBS 0.1% NaAzide and incubating at 4º C for 20 min. The
cells were then washed three times with PBS 0.1% NaAzide to remove unbound antibody
and resuspended in 300 µl PBS 0.1% NaAzide. The cells were then analyzed with an
LSR II flow cytometer (BD Biosciences, San Diego, CA).

Quantification and Isotyping of Anti-CII Antibodies
Blood samples were collected from immunized mice via the retro orbital plexus.
The blood was allowed to clot by incubation at room temperature for 6 hours and sera
were obtained by centrifugation at 300 g for 10 min. A CII ELISA was performed by
coating 96 well vinyl plates (#2797, Costar, Cambridge, MA) with 100 l of 5 mg/ml
bovine CII in Jerry Gross buffer (127 mM Na2HPO4, 3.4 mM KH2PO4, pH 7.6) overnight
at 4 C. The plates were then washed three times with wash buffer (154 mM NaCl,
0.05% Tween-20), and blocked with 2% BSA in ELISA buffer (PBS, 1% Tween-20, pH
7.4) for 30 minutes at 4 C. The plates were then washed three times with wash buffer.
Mouse sera was then diluted 1:2000 with ELISA buffer supplemented with 2% normal
goat serum (NGS) (#32128-5, Pel-Freez, Rogers, AR) and 100 l was two-fold serially
diluted over 8 wells in the CII coated plates. Anti-CII antibody standards previously
purified from mouse sera by CII conjugated column chromatography were also serially
diluted in CII coated plates as a positive control. The plates were then incubated
overnight at 4 C. The plates were washed three times with wash buffer and followed by
the addition of a 1:2000 dilution of goat anti-mouse polyvalent immunoglobulins (IgG,
IgA, IgM) peroxidase conjugate (#A 0412, Sigma, Saint Louis, MO) as 2 antibody in
ELISA buffer supplemented with 2% NGS. The 2 antibody was incubated for 2 hours at
4 C and washed three times with wash buffer. 100 l of HRP substrate was then added.
Substrate consists of substrate buffer (25 mM citric acid, 50 mM Na2HPO4, 0.018%
H2O2) containing 0.5 mg/ml o-phenylenediamine dihydrochloride (OPD) (#P-8287,
Sigma, Saint Louis, MO). The reaction progressed for 30 minutes at which point 50 l of
stopping buffer (2.5 N H2SO4) was added. The absorbance at 490-650 nm was then
measured using a Spectramax 340PC spectrophotometer (Molecular Devices, Sunnyvale,
CA).
ELISA to determine CII-specific IgG subclass was performed as above with the
following differences. To blocked CII coated plates, mouse sera diluted 1:1000 in
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ELISA buffer supplemented with 2% NGS were added and two-fold serially diluted over
8 wells. Following incubation and wash steps, HRP conjugated 2 antibodies with
specificity for mouse IgG1, IgG2a, IgG2c, and IgG3 from a IgG subclass isotyping kit
(#5300-05, Southern Biotech, Birmingham, AL) were diluted 1:500 in ELISA buffer
supplemented with 2% NGS, and incubated 2 hours at room temp. Following incubation
the plates were washed, developed, and absorbance measured by spectrophotometry as
above.

Proliferation Assays
Lymphocytes were isolated from the draining lymph nodes 10 days after
immunization by disrupting excised lymph nodes with forceps, and washing two times in
HL-1 media. Antigenic stimulation of lymphocytes was performed by culturing the cells
in 96 well culture plates (#92096, TPP, Switzerland) at 5x105 cells/well in 300 l
complete HL-1 media at 37 C and 5% CO2 with or without antigen stimulation. After
three days of stimulation 1 Ci of 3H-thymidine (#NET027A001MC, Perkin Elmer,
Boston, MA) was added to each well and allowed to incubate for an additional 18 hours.
The cells were then collected onto a glass fiber membrane via aspiration and allowed to
dry. The activity of each culture was then measured with a Matrix 96 Direct Beta
Counter (Packard, Meriden, CT).
Prior to in vitro stimulation, some lymphocytes were enriched for CD4 expression
by magnetic bead cell sorting (MACS). CD4 (L3T4) Microbeads (#130-049-201,
Miltenyi Biotec, Auburn, CA) were used to magnetically label lymphocytes obtained
from immunized mice. 10 l of CD4 Microbeads were added to 1x107 lymphocytes in
90 ml of autoMACS Rinsing Solution (#130-091-376) supplemented with 2% BSA, and
incubated at 4 C for 15 minutes. The cells were then washed with 2 ml of buffer and
peleted by centrifugation at 300 g for 10 minutes, and resuspended in 500 l of buffer.
The labeled cells were then positively selected using the “Possel” program of an
autoMACS Separator (Miltenyi Biotec, Auburn, CA). This program operates the
autoMACS Separator to retain (positively select) magnetically labeled cells while
washing out the unlabeled cells. Following separation, the CD4 enriched lymphocytes
were washed two times in complete HL-1 media and stimulated for proliferation as
above. Analysis of sorting efficiency was performed by FACS analysis as above using a
fluorescently labeled anti-CD4 monoclonal antibody.
Lymphocytes prepared as above from immunized wild type B6, IFN- -/- B6,
CXB2, and B10.M I-A-/- DR1 *0101 or splenocytes from naïve qCII24 mice were
prepared by mincing spleens and treating with GEY’S solution for 5 min at 4 C to lyse
red blood cells (RBC). Gey’s Solution was prepared in three parts; Part A: 654 mM
NH4Cl, 24.7 mM KCl, 7.6 mM Na2HPO4 7H2O, 1.0 mM KH2PO4, 27.7 mM Glucose in
H2O; Part B: 20.6 mM MgCl2 6H2O, 5.7 mM MgSO4 7H2O, 30.6 mM CaCl2 2H2O; Part
C: 267.8 mM NaHCO3. Just prior to use, 1.0 ml of Part A, 250 µl Part B, and 250 µl Part
C was added to 3.5 ml of H2O and added to the splenocytes in 1 ml HL-1 media.
Following incubation the cells were then washed three times with HL-1 media. 5x104
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splenocytes/well were then stimulated for proliferation with 75 g of each peptide in the
CII peptide library in 300 l of complete HL-1 media for three days followed by the
addition of 3H-thymidine as above.

Production of T Cell Hybridomas
To produce T cell hybridomas, mice were immunized with 50 l of bovine CII in
CFA emulsion. Ten days post immunization, mice were euthanized and the draining
popliteal lymph nodes were removed. Lymph nodes were disrupted with forceps and the
released lymphocytes were collected and washed two times in HL-1 media.
Lymphocytes were then cultured at 37 C at 5% CO2 in 96 well culture plates for four
days at a concentration of 5x104 cells/well in 300 l of complete HL-1 medium
containing 100 g of the purified 1(II) chain of bovine CII. Following antigen selective
expansion, the lymphocytes in 800 l HL-1 media were added to 300 l Lympholyte-M
(#CL5030, Cedarlane Laboratories, Burlington, NC) for purification by density gradient
centrifugation. The cells were washed three times in HL-1 media, and expanded in
culture for three days at 5x104 cells/well in 300 l complete HL-1 media containing 5
ng/ml IL-2 (#200-02, PeproTech, Rocky Hill, NJ).
Following IL-2 expansion, T cells were washed in serum free media and mixed
with BW5147 cells at a ratio of 2:1. Fusion of cells was induced by the addition of 1.5
ml PEG 1500 (Roche; Indianapolis, IN) warmed to 37 C dropwise over 30 seconds, and
followed by the addition of 50 ml warm serum free DMEM. After 30 minutes, the cells
were pelleted by centrifugation and the serum free DMEM was replaced with complete
DMEM containing 10% FBS, and the cells were distributed in 96 well plates. Two days
later, DMEM supplemented with HAT selection media (Sigma, Saint Louis, MO) was
added to fused T cell/BW5147 hybrid cultures and cultured at 37 C in 10% CO2 until
cells reached 50% confluence. At this point the T cell hybridomas were tested for
responsiveness to antigen stimulation and weaned off of the HAT selection media by the
gradual replacement with complete DMEM supplemented with HT (Sigma, Saint Louis,
MO) and then complete DMEM over several weeks as the cells were passed.

Antigen Presentation to T Cell Hybridomas
Antigen was presented to T cell hybridomas using splenocytes from CXB2 mice
as APC. To prepare splenocytes, the spleen was removed, placed in 1 ml of HL-1 media,
and then disrupted mechanically with forceps. To remove RBC, the cells were incubated
for 4 min at 4º C in Gey’s solution as above. Following incubation with Gey’s solution,
the cells were washed three times and resuspended in complete HL-1 media. 100 g
1(II), 100 g bovine CII, 75 g CII-library peptides, or a titration of alanine substituted
CII(512-526) peptides ranging from 50 g to 0.188 g were used to stimulate T cell
hybridoma cells. In 96 well culture plates, 4x105 splenocytes and 1x105 T hybridoma
cells were added to antigen in 300 l complete DMEM media, and cultured for 24 hours
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at 37 C in 10% CO2. The supernatants from the cultures were then assayed for IL-2 as
follows.
Culture supernatants from stimulated T cell hybridoma cultures were two-fold
serially diluted in 80 l complete DMEM down 8 wells in a 96 well culture plate. In
addition, 50 ng IL-2 was also titrated as a positive control. HT-2 cells, which require
IL-2 for survival, were then added to the diluted culture supernatants at a concentration of
5x103 cells/well and incubated at 37 C for 18 hours in 10% CO2. Survival of HT-2 cells
was then assayed by the addition of 10 l of 5 mg/ml thiazolyl blue tetrazolium bromide
(#M5655, Sigma, Saint Louis, MO) in PBS, which is converted to MTT by living cells,
and further incubation at 37 C for 3 hours. Supernatants were then removed and MTT
was solubilized by the addition of 200 l 2-propanol containing 0.02 N HCl. Once the
MTT was dissolved, absorbance at 570 nm minus 690 nm was quantitated using a
Spectramax spectrophotometer. Wells that exhibited absorbance values twice that of
negative control wells were considered positive for HT-2 cell survival and therefore
indicated the presence of IL-2 produced by the T cell hybridomas in response to antigen.

Induction of Tolerance in CXB2 Mice with Determinant Peptides
CXB2 mice were injected in the orbital plexus with 100 l of 1 mg/ml CII(512528) in PBS, or PBS alone. Three days later, the tolerized mice were immunized in the
tail with 100 l of 2 mg/ml bovine CII/CFA emulsion to induce CIA. The mice were
then monitored for development of CIA as described above.

Production of Soluble MHC Class II Molecules
Soluble I-Ab and DR1 were purified from supernatants of S2 drosophila cells
transfected with recombinant I-Ab or DR1 in which the cytoplasmic and transmembrane
portions had been removed by PCR, replaced with a leucine zipper, and cloned into the
Drosophila expression vector pRmHA-3. S2 cells were transfected with the cDNA
encoding the and subunits of I-Ab or DR1 at a 10:1 ratio of each to the neomycin
resistance vector, pUChsNeo, via calcium phosphate precipitation. Soluble MHC class II
production was induced by addition of 1% CuSO4 and five days later culture supernatants
were collected, and modified to contain 1% octyl b-D-gluco-pyranoside (OcG) (#O8001,
Sigma, Saint Louis, MO) and 0.1% NaAzide at pH 8.0.
Soluble MHC class II was purified by passing the supernatant over an affinity
column coupled with the DR1-binding monoclonal antibody LB3.1 or I-Ab-binding
monoclonal antibody M5/114.5.2. The column was then washed with PBS containing
0.05% OcG, pH 7.5, followed by PBS plus 0.5 M NaCl and 0.05% OcG, pH 7.5, and then
10 mM TRIS in 0.5 M NaCl, pH 7.5. Soluble MHC was then eluted from the column
with 100 mM tris in 0.5 M NaCl, pH 11.2 and immediately neutralized with acetic acid.
Soluble MHC class II molecules recovered were quantitated by OD 280 absorption and
concentrated using an Amicon Stirred Cell (Amicon; Beverly, MA). The quality of the
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concentrated soluble class II was monitored by SDS-PAGE containing 12.5%
polyacrylamide.
Soluble I-Ab was also produced in SF9 cells using a baculovirus expression
system (#552846, BD Biosciences, San Diego, CA). A gene encoding soluble I-Ab was
cloned into the transfer vector pVL1392 (BD Biosciences; San Diego, CA). This I-Ab
gene was previously modified by the replacement of the transmembrane and cytoplasmic
domains with a leucine zipper. SF9 cells were then co-transfected with I-Ab or I-Ab in
the transfer vector plus BD BaculoGold Bright DNA (#51-552846, BD Biosciences, San
Diego, CA) via calcium phosphate precipitation and cultured in TNM-FH insect medium
(#554760, BD Biosciences, San Diego, CA) at 27 C. After five days, supernatants were
collected and virus titers were determined by plaque assay. To perform the plaque assay,
9x105 SF9 cells in 2 ml TMN-FH media were adhered to 12 well plates and inoculated
with 20 µl of virus containing culture supernatants and incubated for 4 hours. Following
incubation, supernatants were removed by aspiration and 2 ml of TMN-FH media
containing 1% plaque assay agarose (#554766, BD Biosciences, San Diego, CA). Plates
were then cultured 4-5 days at 27º C after which 200 µl of 5 mg/ml thiazolyl blue
tetrazolium bromide was added to the wells and allowed to react for 6 hours. Plaques
were then visually counted. Virus titer was repeatedly amplified via infection of fresh
SF9 cells with virus laden culture supernatants at a multiplicity of infection (MOI) less
than one. When virus titers reached 1x108/ml, SF9 cells cultured in supplemented SF900 II were infected with both I-Ab chains at a MOI of five. After five days, virus
supernatants were collected and soluble I-Ab was purified via column chromatography as
in the S2 derived I-Ab.

Binding Assays
I-Ab Binding of CytC(43-58), Mog(35-55), and CII(257-274)
Capture plates were prepared by coating Immulon 2 flat bottom microtiter plates
(Dynex Technologies INC. Chantilly, VA) with 100 l of 5 g/ml I-Ab-binding
monoclonal antibody, M5/114.5.2, in PBS overnight at 4 C and then blocked for 1 hour
at room temperature with 1% BSA. Capture plates were then washed three times with
150 l PBS containing 0.05% Tween-20 and buffered with 50 l of 50 mM TRIS
containing 1% OcG at pH 8.0.
Biotinylated peptides CytC(43-58), Mog(35-55), or CII(257-274) peptides were
titrated from 30 M to 0.1 nM in binding buffer (PBS containing 1% OcG and adjusted
to pH 6.5 with 0.1 M potassium phosphate). 100 l of the titrated peptides was added to
50 µl of 15 nM soluble I-Ab produced by S2 or SF9 insect cells, and incubated overnight
at 37 C in 96 well round bottom polypropylene plates (#3365, Corning, Corning, NY).
50 l of the binding reaction was then added to the buffered capture plates for 2 hours at
4 C.
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Following binding to the capture plate, I-Ab peptide complexes were washed three
times with PBS containing 0.05% Tween-20 and the biotin groups on bound peptide were
labeled with 100 ng/ml europium conjugated streptavidin (Perkin Elmer #1224-360) in
125 m DELPHIA Assay Buffer (Perkin Elmer #1244-111) by incubation at room
temperature for 2 hours. Plates were then washed with 100 l DELPHIA wash buffer
(Perkin Elmer #1244-114) and 150 l of DELPHIA Enhancement Solution (Perkin Elmer
#1244-105) was added. Time delayed fluorescence (excitation/emission 315/615 nm)
was then quantified using a microplate flurometer (Fluromark, BioRad, Hercules, CA).

Binding of CII Peptide Array to I-Ab and DR1
Capture plates were prepared by adding 100 l 5 g/ml I-Ab-specific M5/114.5.2
or DR1-specific LB3.1 monoclonal antibody in PBS containing 0.05% NaAzide to
Immulon 2 flat bottom microtiter plates (Dynex Technologies INC., Chantilly, VA)
overnight at 4 C. The plates were them blocked with 250 l 1% BSA in PBS containing
0.05% NaAzide for 2 hours at room temperature. The plates were then washed three
times with wash buffer (150 l PBS containing 0.05% Tween-20), and buffered with 50
l of 50 mM TRIS pH 8.0 containing 1% OcG.
Soluble I-Ab or DR1 was prepared at 15 nM and 10 nM respectively in binding
buffer (PBS containing 1% OcG adjusted to pH 6.5 with 0.1 M KH2PO4). I-Ab or DR1
was then incubated with 30 nM biotinylated peptides Mog(43-58) or CII(257-274) and 5
m of each peptide in the CII peptide array overnight at 37 C in 96 well polypropylene
round bottom plates (Corning, NY). Following incubation, 50 l of the binding reaction
was added to the capture plates and incubated at 4 C for 2 hours, washed three times
with wash buffer, and developed using DELPHIA reagents.
Biotin groups on peptides bound to I-Ab or DR1 were labeled with 100 ng/ml
europium conjugated streptavidin (Perkin Elmer #1224-360) in 125 m DELPHIA Assay
Buffer (Perkin Elmer #1244-111) by incubation at room temperature for 2 hours. Plates
were then washed three times with 100 l DELPHIA wash buffer (Perkin Elmer #1244114) and 150 l of DELPHIA Enhancement Solution (Perkin Elmer #1244-105) was
added. Time delayed fluorescence (excitation/emission 315/615 nm) was then quantified
using a microplate flurometer (Fluromark, BioRad, Hercules, CA).

Microarray Analysis
Female B6 and B6 IFN- -/- mice between the ages of three and four months were
immunized in the footpads of each hind limb with 50 µl of bovine CII/CFA emulsion. 10
days post immunization, mice were euthanized and the draining popliteal lymph nodes
were collected. The lymph nodes were minced with forceps to release lymphocytes and
washed in ice cold PBS. An RNeasy kit (#74124, Qiagen, Valencia, CA) was used to
prepare mRNA according to the manufacturer’s protocol from the total cells recovered
from the nodes. Quantity and purity of the recovered RNA was analyzed by absorbance
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at 260 nm and the 260/280 nm absorbance ratio with an acceptable range of 1.8 to 2.0.
RNA was then concentrated by ethanol/sodium acetate precipitation and dissolved in
RNase free water at 2 g/µl. Potential degradation of RNA was monitored by analysis of
the ratio of 28S/18S rRNA subunits via electrophoresis using an Agilent 2100
Bioanalyser (Agilent, Santa Clara, CA). mRNA was then submitted to the microarray
core facility at VAMC Memphis for expression analysis using an Affymetrix GeneChip
Mouse Genome 430 2.0 Array on a Affymetrix 7G Plus GeneChip Scanner. The data
was then analyzed for statistical significance and cluster analysis via the use of
Genespring software produced by Agilent Technologies.

Real Time PCR
RNA was isolated from lymph node derived lymphocytes recovered from
immunized mice using an RNeasy kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocol. MultiScribe reverse transcriptase (Applied Biosystems, Foster
City, CA) was then used to convert 1 g of mRNA to cDNA according to the
manufacturer’s protocol, and used for real time PCR analysis by the VAMC molecular
core facility. Amplitaq Gold (Applied Biosystems), 50 ng of cDNA, and Taqman probes
(Applied Biosystems) specific for the transcripts of mouse IL-17A, IL-5, IL-1 , IL-6, IL4, GM-CSF, TGF 1, IL-18, TNF- , IL-15, IL-10, IL-12 , IL-18 BP, were then used to
quantify gene expression using an ABI Prism 7900HT Sequence Detection System
(Applied Biosystems) to perform the real time PCR. Ct values were obtained by
measuring the cycle times required to reach a threshold value of fluorescence for each
probe. These ct values were then normalized to the expression of actin to compare the
relative expression of each gene. Data are expressed as the ct. This value represents
the difference in cycle times required for each reaction to reach the threshold value and is
calculated by subtracting the housekeeping actin ct value from the experimental ct
value to obtain the ct, and then subtracting the ct value of the IFN- -/- real time PCR
from the wild type. This value represents the difference in cycle times between the two
groups required to reach the threshold fluorescence value.
For microfluidics based real time PCR, RNA was isolated from the lymphocytes
recovered from immunized mice using an RNeasy kit (Qiagen, Valencia, CA) according
to the manufacturer’s protocol. The RNA was converted to cDNA as described above
and used for real time PCR analysis by the VAMC molecular core facility using 200 ng
cDNA, Amplitaq Gold, a Taqman Gene Signature Array, Mouse Immune Panel (Applied
Biosystems) and an ABI Prism 7900HT Sequence Detection System (Applied
Biosystems, Foster City, CA). Ct values of each gene in the array were normalized to the
expression of the housekeeping gene GAPDH. Data is expressed as the ct value,
calculated as above.
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Treatment of Mice with IL-18 BP
Recombinant IL-18 BPd (#122-BP, R&D Systems, Minneapolis, MN) was
dissolved in PBS at a concentration of 1 mg/ml. 10 IFN- -/- B6 mice were then injected
intraperitoneally with 200 l of IL-18 BPd solution or PBS every 24 hours for 10 days.
On the second day of this regimen, the mice were immunized with 100 l of CII/CFA
emulsion containing 2 mg/ml bovine CII and 2 mg/ml Mtb subdermally at the base of the
tail. Mice were then monitored for the development of CIA.

Anti-CD3/CD28 Stimulation Assay
Splenocytes from naïve wild type or IFN- -/- B6 mice were cultured in 300 µl
complete HL-1 media at 1x105 cells per well in 96 well plates previously coated with
anti-CD3 and anti-CD28 monoclonal antibodies. To prepare antibody coated plates, antiCD3 and anti-CD28 monoclonal antibodies produced from B cell hybridoma clones 1452C11 and HB-12352 (ATCC, Manassas, VA) by the VAMC RDRCC Collagen Core
were dissolved in PBS 0.1% NaAzide at a concentration of 5 µg/ml. 100 µl of antibody
solution was incubated in 96 well culture plates overnight at 4º C. Following incubation
the plates were washed two times with PBS. Splenocytes were cultured at 1x105 cells per
well in the antibody coated plates in 300 l of complete HL-1 media containing 5 g/ml
IL-18 BPd (#122-BP, R&D Systems, Minneapolis, MN), 6 ng/ml IFN- (#485-MI, R&D
Systems, Minneapolis, MN), 240 ng/ml IL-18 (#B004-2, R&D Systems, Minneapolis,
MN), 8 ng/ml IL-17 (# 421-ML, R&D Systems, Minneapolis, MN), or media only. Cells
were cultured for three days at 37 C in 5% CO2 at which point 1 Cu of 3H-thymidine
was added to each well and incubated for 18 hours at 37 C in 5% CO2. Following
incubation the cells were collected onto a glass fiber membrane and activity was read
using a Matrix 96 Direct Beta Counter (Packard, Meriden, CT). Some cells were
cultured for four days at which point supernatants were collected for cytokine
quantification.

BioPlex Cytokine Assay
Cytokines produced by splenocytes in culture were measured using a 13-plex
multiplex bead based cytokine assay kit (BioRad, Hercules, CA) containing development
reagents, cytokine standards, and beads conjugated with antibodies specific for IL-1 , IL2, IL-4, IL-5, IL-6, IL-13, IL-17, GM-CSF, IFN- , TNF- , IL-15, IL-18, and M-CSF. 50
l of multiplex beads containing 2 l of conjugated beads and 48 l of BioPlex assay
buffer was added to each well of a pre-wetted Multiscreen HTS 96 well filter plate
(#MSBVN1210, Millipore, Bedford, MA). The buffer was removed by vacuum filtration
and washed two times with 100 l BioPlex wash buffer. 50 l of the cell culture
supernatants was added to the plates in addition to 50 l of the cytokine standards titrated
1:4 in complete HL-1 media over 8 wells. The plate was incubated at room temperature
on a plate shaker set to 1,100 RPM (IKA-MTS 4 S2, Staufen, Germany) for 30 minutes.
The buffer was removed by vacuum filtration and washed three times with 100 l
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BioPlex wash buffer. 25 l of multiplex detection antibody containing biotin conjugated
2 antibodies diluted in detection antibody diluent was added, and incubated at room
temperature for 30 minutes with agitation at 1,100 rpm. The buffer was removed by
vacuum filtration and the plate was washed three times with BioPlex wash buffer. 50 l
of streptavidin-PE diluted 1:100 in BioPlex assay buffer was added and incubated for 10
minutes at room temperature while agitated at 1,100 rpm on the plate shaker. The plate
was washed three times with BioPlex wash buffer followed by resuspension of the beads
in 125 l BioPlex assay buffer. The samples were analyzed using a Luminex 100
BioPlex System (Luminex, Austin, TX). To determine concentration of experimental
cytokines in pg/ml, a standard curve was created using the fluorescence data obtained
from the cytokine standards.
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Chapter 3. Modulation of Arthritis Pathogenesis by Variable
T Cell Receptor Complex Interaction with Type II Collagen
Determinants
Introduction
The initial events that trigger the development of autoimmunity remain
incompletely understood. IFN- , a proinflammatory cytokine produced by cells of both
the innate and acquired immune system, has been implicated in the pathogenesis of a
number of inflammatory autoimmune diseases including rheumatoid arthritis, multiple
sclerosis, uveitis (63), and type 1 diabetes . However, contrary to a proinflammatory role
for IFN- , in animal models of autoimmune diseases targeting IFN- with neutralizing
antibodies or genetic ablation of IFN- or its receptor, IFN- R, has been shown to
exacerbate disease incidence and severity (17, 20).
This paradoxical role of IFN- as a Th1 cytokine has also been observed in a
mouse model of rheumatoid arthritis, CIA. In this model, IFN- regulates susceptibility
to arthritis. For example, B6 mice are resistant to CIA. However, when expression of
IFN- or its receptor is removed by genetic ablation, these mice become fully susceptible
to CIA (17, 20, 64). Prior to the discovery that B6 mice lacking IFN- were susceptible
to CIA, a prevailing hypothesis was that among various mouse strains susceptibility to
CIA was largely dependent on the expression of MHC class II susceptibility alleles. The
hypothesis for MHC-based susceptibility to autoimmune disease was that the susceptible
alleles bound and presented the autoantigens that drove the autoimmune T cell response.
In contrast, non-susceptible alleles are incapable of binding these autoantigenic peptides,
thus conferring resistance. For example, in the CIA model, mouse strains that express
I-Aq or I-Ar bind CII determinants with sufficient affinity to stimulate T cell activation
and drive the development of CIA at high incidence. Mice expressing other MHC class
II haplotypes, such as I-Ab in the B6 mouse strain, either fail to bind or bind CII peptides
at a very low affinity and therefore fail to stimulate T cell activation and thus are resistant
to CIA.
Recently, it has become clear that the immunological basis for resistance or
susceptibility to autoimmunity is much more complex than the ability of an antigenic
peptide to bind to an MHC molecule. In a number of mouse models of autoimmunity, it
has been demonstrated that resistant mouse strains can be converted to susceptible by
altering the cytokine environment of the mouse during disease initiation. For example,
B6 mice genetically deficient for the production of IFN- are fully susceptible to CIA,
whereas wild type B6 mice are resistant (17). These data indicate that both T cell and B
cell responses to CII autoantigens develop in B6 mice, thus the “resistant” I-Ab molecule
binds and presents the CII autoantigen peptides.
One explanation for the altered immune response of B6 IFN- -/- mice is that IFNhas a regulatory role for T cell responses, and that this regulation is most apparent for low
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affinity T cell determinants. In this model, T cell activation against CII in B6 mice is
weak and suppressed by IFN- , however, in the absence of IFN- , disregulation of the
immune response occurs allowing T cell activation against weak CII antigens and
autoimmunity develops. Therefore, to explain the differential susceptibility to CIA
observed in the B6 IFN- -/- mouse we developed the following hypothesis. If IFNfunctions as a regulator of T cell responses to weakly immunogenic, low affinity
determinants, and I-Ab MHC class II molecules have low affinity for collagen
autoantigen determinants, then in the IFN- -/- B6 mouse, the absence of IFN- alters T
cell function and the cytokine response following immunization with CII, disrupting
normal immune regulation and allowing the development of CIA.
To address IFN- ’s role in regulating T cell responses to collagen and ultimately
the development of autoimmunity a set of specific aims were developed.
1. Identify the alterations in the immune response of B6 IFN- -/- mice in
response to immunization with CII, including alterations in the differentiation,
proliferation, and cytokine production of CII-specific T cells and accessory
cells.
2. Identify the CII determinants to which I-Ab-expressing mice mount an
immune response.
3. Determine the significance of CII determinants in the development of arthritis
in the B6 IFN- -/- mouse.
4. Determine the affinity of CII determinants for I-Ab.
These aims address both the mechanism of T cell activation in response to
stimulation with CII and how IFN- potentially mediates susceptibility to autoimmunity.
IFN- has broad regulatory control of immune function. Therefore, its absence has the
potential to alter immune functions including cellular differentiation, proliferation of CIIspecific T cells, and cytokine production by immune and accessory cells. Skewed
numbers of immune cell populations as a result of disregulation due to the absence of
IFN- could alter the course of the autoimmune response and thus affect pathogenesis.
Previous data indicates that IFN- deficient mice have increased T cell proliferative
response to antigen (65). Increased numbers of CII-reactive T cells may contribute to
arthritis susceptibility. Another aspect of immune cell function that may be altered by the
absence of IFN- is the production of cytokines in response to CII immunization.
Cytokines are key mediators of immune response development, and the intercellular
communication between T cells, B cells, APC, and accessory cells directs the immune
response in terms of cellular differentiation, activation, and function. All of these
immune processes can potentially contribute to the pathogenesis of CIA, so
understanding how the immune response in the IFN- -/- mouse is altered in response to
antigen stimulation broadens our understanding of the immune mechanisms by which
autoimmunity develops.
A stipulation of the hypothesis that IFN- regulates activation of T cells against
weak antigens is that CII contains autoantigen determinants to which T cells recognize
and respond when disregulation of the immune response is induced by the absence of
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IFN- . The nature of the immune system is such that the potential for the development of
autoimmunity is tightly controlled at many levels. For example, mechanisms of selftolerance have evolved that protect the immune system from mounting a response to selfantigens (27). Clonal selection of T cells in the thymus and peripheral mechanisms, such
as anergy or Treg cell suppression of effector T cell activation, minimize T cell activation
to self-antigens (32). Both the maturation of T cells in the thymus and activation of
effector T cells in the periphery is largely dependent on the affinity and interaction of the
TCR with determinants presented by MHC. There is evidence that subsets of Treg cells
also exhibit antigen specificity (66-68), indicating that there may be a role for CII
determinants in Treg cell differentiation. Therefore, to understand how autoantigen
determinants present in CII contribute to T cell activation and subsequently autoimmune
development, we sought to identify CII determinants in I-Ab-expressing mice, determine
the affinity of those determinants for the components of the TCR complex, and assess the
contribution of those determinants to the pathogenesis of CIA.

Results
IFN- Regulates Susceptibility to Autoimmune Arthritis in C57BL/6 Mice
It has been shown previously that mice of different genetic backgrounds exhibit
differential susceptibility to CIA (17, 69, 70). The development of CIA requires an
autoimmune T cell response directed against a processed antigen associated with MHC
on the surface of an antigen presenting cell (71). The structure of a given MHC allele
limits the diversity of peptide antigens available to bind and be presented by that MHC
molecule. MHC haplotype strongly associates with susceptibility to CIA. I-Aq (69) or
I-Ar -expressing (70, 72) mice such as DBA1/J or B.10RIII are fully susceptible to CIA
whereas mice expressing other I-A haplotypes, such as I-Ab in the C57BL/6 mouse, are
resistant to CIA. However, in the B6 background, the deletion of a single gene, IFN- ,
confers susceptibility to CIA. The wild type B6 mouse is considered non-susceptible to
CIA as following immunization with CII these mice develop arthritis only rarely, with
less than 10% incidence (73). In addition, the arthritis exhibited in those mice that do
develop disease is of low severity. In contrast, B6 IFN- -/- mice are highly susceptible
developing arthritis at a high incidence and severity in comparison to the wild type mice
(17). B6 IFN- -/- mice develop arthritis at an 80-100% incidence within 3-4 weeks
following immunization with CII. The first mice develop arthritis two to three weeks
after immunization with CII/CFA emulsion, and all affected mice developing arthritis
after one month. Multiple limbs of the IFN- -/- B6 mice are affected, exhibiting high
severity as measured by the extent of inflammation and the number of joints involved.
B6 and B6 IFN- -/- mouse strains were immunized with CII for the development of CIA
(Fig 3.1, 3.2). Maximum severity scores for each arthritic mouse ranged from 8 to 12
and averaged 9.0 ± 1.41 with an average of 2.43 ± 0.49 limbs affected. Only 10% of the
B6 wild type group developed arthritis with the affected mouse developing a single
arthritic limb on day 52 while greater than 80% of IFN- -/- mice developed arthritis in
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Figure 3.1
IFN- -/- Mice Exhibit Increased Susceptibility to CIA.
B6 IFN- -/- mice are highly susceptible to CIA, and develop arthritis at an earlier time
point exhibiting high incidence and severity compared to wild type B6 mice following
immunization with CII/CFA emulsion. A. 87.5% (N = 8) of B6 IFN- -/- developed
arthritis between days 14-22 versus 10% (N = 10) incidence in B6 wild type mice on day
52. B. Severity score of arthritis per arthritic mouse. Arthritic B6 IFN- -/- mice
developed arthritis with a mean severity score of 8 out of a maximum 16 possible, while
the B6 wild type mouse developed arthritis with a score of 4.
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Figure 3.2
Severity of Arthritis in B6 and B6 IFN- -/- Mice.
B6 IFN- -/- mice exhibit a severe arthritis with multiple affected limbs when immunized
with CII/CFA. Rare arthritis occurrence in B6 wild type is of low severity and limb
involvement. A. Average highest severity reached in B6 wild type and B6 IFN- -/- mice
that developed arthritis following immunization with CII/CFA. The average maximum
severity was determined by averaging the highest severity reached in arthritic mice only.
B6 IFN- -/- averaged a maximum score of 9.0 ± 1.41 among 7 arthritic mice while the
lone arthritic B6 wild type mouse achieved a maximum score of 4. B. Average number
of inflamed limbs per arthritic mouse in B6 and B6 IFN- -/- mice. Arthritic B6 IFN- -/mice averaged 2.43 ± 0.49 arthritic limbs while the arthritic B6 wild type mouse had one
arthritic limb.
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multiple affected limbs. Thus, these data imply that IFN- acts as a regulator of
autoimmune response in B6 mice.

Regulation of Immune Cell Function by IFNImmune Cell Subset Analysis
To determine if the absence of IFN- was altering the cellular immune responses
to CII in mice expressing I-Ab, the production of anti-CII immunoglobulins, the
proliferative response of T cells to CII determinants, and their production of cytokines
was examined. IFN- is predominantly a cytokine produced by T cells of the Th1
phenotype, and has regulatory effects on immune cells such as macrophages, B cells, Th1,
Th2, and Th17 T cells (74, 75). One major role of IFN- is the promotion of Th1
differentiation and the inhibition of Th2 or Th17 cells. As a cell mediated inflammatory
disease, the pathogenesis of CIA could be affected by alterations in the numbers of B
cells or Th1 and Th2 T cells present following immunization with CII. Since the absence
of IFN- in the B6 IFN- -/- mouse may alter the differentiation of T cells into the various
T cell subtypes, we investigated the autoimmune response of B6 and B6 IFN- -/- mice
that were immunized with CII.
Wild type or IFN- -/- B6 mice were immunized with CII/CFA emulsion and
lymphocytes were collected from the draining popliteal lymph nodes 10 days later.
These lymphocytes were stained with fluorescently labeled antibodies to identify immune
cell subpopulations via FACS analysis. The
TCR was used to identify T cells, CD19
expression to identify B cells, CD4 expression to identify Th cells, and CD8a to identify
Tc cells. Similar percentages of T and B cells were found to be present in the two mouse
strains. In the B6 WT mice, 47.2 ± 8.2% of lymphocytes were found to be B cells as
indicated by positive CD19 staining compared to 43.9 ± 14.9% in the B6 IFN- -/- group
(p = 0.57). Similar percentages of T cells were also found between the two strains as
indicated by positive staining for
TCR. 48.8 ± 8.4% of lymphocytes were observed
to be T cells in the B6 group compared to 53.3 ± 15.2% in the B6 IFN- -/- group (p =
0.55) (Fig 3.3ABE). Th or Tc subsets were then measured by examining the percentage
of lymphocytes that stained positive for both
TCR and CD4 or CD8a. The B6 group
+
was found to have a higher percentage of CD8 Tc cells than the B6 IFN- -/- group (p <
0.0001), while the B6 IFN- -/- group was found to have a higher percentage of Th cells (p
< 0.0002). In the B6 group, 53.3 ± 3.1% of T cells were positive for CD8a compared to
42.7 ± 0.7% in the B6 IFN- -/- group. Conversely, 54.6 ± 1.1% of T cells stained positive
for CD4 in the B6 IFN- -/- group compared to 44 ± 3.7% in the B6 group (Fig 3.3CDF).
As noted earlier, IFN- has potent regulatory effects on cellular differentiation, however
these data indicate that there are only minor alterations in the cellular makeup of the
immune response in B6 IFN- -/- mice following immunization with CII. The number of
B cells versus T cells is unaffected. However, the number of CD4+ or CD8+ cells is
slightly altered in the B6 IFN- -/- mouse with 10% increase in CD4+ and a 10% decrease
in CD8+ cells. These data indicate that the absence of IFN- does not abrogate CD4+ T
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Figure 3.3
Lymphocyte Compartment of CII-Immunized B6 and B6 IFN- -/Mice.
The absence of IFN- in B6 IFN- -/- mice does not alter the percentage of B or T cells in
draining lymph nodes following immunization with CII/CFA. However, the percentage
of CD8a+ Tc cells are slightly reduced with a concurrent increase in CD4+ Th cells.
Lymphocytes were recovered from the draining lymph nodes of B6 IFN- -/- or B6 wild
type mice immunized with CII/CFA and stained with anti-CD19, anti-TCR, anti-CD4,
and anti-CD8a. ABE. The numbers of B and T cells were not significantly different (p =
0.65, p = 0.63) between lymphocytes from B6 wild type (N = 5) and B6 IFN- -/- (N = 4)
mice. B6 mice had 47.2 ± 8.2% CD19+ B cells while B6 IFN- -/- mice had 43 ± 14.9%
CD19+ B cells. B6 mice had 48.8 ± 8.4% TCR+ T cells while B6 IFN- -/- mice had 53.3
± 15.2% TCR+ T cells. CDF. When lymphocytes were gated on TCR+ T cells and
examined for expression of CD8a+ Tc cells or CD4+ Th cells a significant decrease in
CD8a+ Tc cells (p < 0.001) and increase in CD4+ Th cells (p < 0.002) was observed. B6
mice had 53.3 ± 3.1% CD8a+ Tc cells while B6 IFN- -/- mice had 42.7 ± 0.7% CD8a+ Tc
cells. When Th cells were examined, B6 mice had 44.0 ± 3.7% CD4+ Th cells while B6
IFN- -/- mice had 54.6 ± 1.1% CD4+ Th cells.
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cell development, rather, the CD4+ complement of T cells in the B6 IFN- -/- cells
increases without IFN- . Though Th1 differentiation may be inhibited by the absence of
IFN- , Th2 or Th17 differentiation is negatively regulated by IFN- and the increases in
CD4+ cells in the IFN- -/- mouse may be in these subsets (74, 76). However, these
changes are small and may not be biologically significant. In both wild type and IFN- -/B6 mice, nearly half of the TCR+ T cell population is CD4+ while the remaining TCR+ T
cells express CD8+. This data indicates that the major mechanisms of immune
disregulation in the absence of IFN- are likely due to alterations in cellular function such
as cytokine production, rather than by altered cellular differentiation between T cells B
cells and the Tc or Th subtypes.
Anti-CII Immunoglobulin Production
Even though the pathogenesis of RA is considered to be primarily CD4+ T cell
mediated, one of the hallmarks of the disease is the generation of autoantibodies. In RA,
Ig directed against determinants in the Fc region of IgG is produced and is known as
rheumatoid factor (77). Other autoantibodies produced in RA include antibodies directed
against citrullinated proteins, CII, and glucose-6-phosphoisomerase (78, 79).
Complement activating IgM-IgG immune complexes form and are deposited in the joints
and likely contribute to the chronic inflammation that is characteristic of RA. In the CIA
model, the generation of autoantibodies with specificity for CII has been implicated as an
important mechanism in the pathogenesis of CIA (80-84). CIA can be induced in mice
when polyclonal antibodies purified from arthritic mice are passively transferred, or when
mice are injected with anti-CII monoclonal antibodies (80, 81, 85-88). In addition,
complement fixing antibodies have been shown to localize to the surface of articular
cartilage in a rat model of CIA (89). IFN- regulates production of antibodies by B cells
via several mechanisms. IFN- acts directly on proliferating B cells to induce Ig class
switching to IgG2a and by blocking IL-4 induced class switching to IgE and IgG1 (9092). IFN- also indirectly regulates antibody production by B cells via its regulation of
Th cell differentiation (93). Given the importance of immunoglobulins in the
pathogenesis of CIA and the contribution of IFN- in promoting of antibody production,
serum concentration of anti-CII Ig was examined in B6 and B6 IFN- -/- mice following
immunization with CII/CFA.
Sera were collected from B6 and B6 IFN- -/- mice 36 days following
immunization with CII in CFA emulsion, and the quantity of CII-specific Ig present in
the serum was measured by ELISA. Quantification of CII-specific antibody was
determined using an anti-CII antibody standard previously purified from mouse sera.
The concentration of CII-specific Ig was found to be higher in the serum obtained from
CII-immunized B6 IFN- -/- mice as compared to the CII-immunized B6 mice (p = 0.024).
B6 IFN- -/- serum contained anti-CII Ig at a concentration of 144 ± 88.9 µg/ml while the
B6 serum contained anti-CII Ig at a concentration of 33.3 ± 14.9 µg/ml (Fig 3.4). IgG
subclass potentially mediates joint destruction by two mechanisms, either by complement
activation or by activation of monocytes/macrophages via binding to Fc receptors present
on these cells. The different subclasses of IgG have differing ability to effect these two
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Figure 3.4
Increased Anti-CII Ig Production in B6 IFN- -/- Mice Immunized with
CII Compared to Wild Type.
Production of anti-CII Ig is elevated in B6 IFN- -/- mice compared to B6 WT mice. B6 or
B6 IFN- -/- mice were immunized with CII in CFA emulsion, and sera was collected 36
days later. CII-specific Ig previously prepared from mouse sera was used to quantify the
concentration of CII-specific Ig present in serum via ELISA. B6 IFN- -/- mice exhibit
significantly elevated levels of CII-specific Ig compared to wild type B6 mice (p =
0.024). B6 IFN- -/- serum contained anti CII Ig at a concentration of 144 ± 88.9 µg/ml
while the B6 serum contained anti-CII Ig at a concentration of 33.3 ± 14.9 µg/ml.
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processes. IgG2a, IgG2b, IgG2c all have complement activating ability while IgG1 and
IgG3 do not. The same variation is seen in the ability of the IgG subclasses to bind and
activate Fc receptors. In I-Ab-expressing mice the gene for IgG2a is absent, rather, IgG2c
replaces its functional activity (94, 95). Since the subclass of IgG expressed may effect
the development of arthritis in CIA, the subclasses of IgG present in sera from CIIimmunized wild type B6 and B6 IFN- -/- were measured by ELISA. When the subtypes
of IgG present in I-Ab-expressing mice, IgG1, IgG2b, IgG2c, and IgG3, were quantified,
increased levels of IgG2b were observed in the B6 IFN- -/- compared to the B6 wild type
(Fig 3.5). The ELISA resulted in an absorbance 3.30 ± 0.09 from the IFN- -/- sera
compared to the wild type absorbance of 0.23 ± 0.24 (p < 0.001). The other subclasses
were present at low levels and were not statistically different between groups. Arthritis
development in CIA is dependent on both the complement-fixing and Fc R binding
capability of antibodies. Mice lacking C5, Fc RI, or Fc RIII are resistant to CIA (96-98).
Despite the absence of IFN- , high levels of complement fixing CII-specific antibodies
are produced in B6 IFN- -/- mice. CII-specific antibodies of the IgG2b subclass have
been shown to be highly arthritogenic in a mechanism dependent on the high affinity
Fc RIII when used to induce arthritis in DBA/1 mice (99). Therefore, the increased
production of CII-specific IgG2b as a result of IFN- deficiency in B6 mice may be a
mechanism of increased susceptibility to CIA.
Proliferative Response
Previous work has indicated that IFN- -/- mice exhibit increased proliferative
response to antigen (65). Therefore, in order to determine if the absence of IFN- causes
a disregulated T cell proliferative response following immunization with CII, the I-Abrestricted T cell response against bovine CII was examined. 10 days following
immunization with CII, lymphocytes were removed from the draining lymph nodes of B6
or B6 IFN- -/- mice and re-stimulated in vitro with bovine CII for four days. The
proliferative response of the CII-specific T cells was measured using 3H-thymidine
incorporation. In both the B6 WT and IFN- -/- no statistically significant increases in T
cell proliferation were observed above the media control (Fig 3.6), although the
background level of proliferation appeared to be higher for the IFN- -/- T cells. This may
be indicative of the low antigenicity of CII in the I-Ab background, and CII-specific T
cells may be produced at levels too low to detect by this assay.
The CXB2 inbred mouse strain is an I-Ab-expressing strain of mice that is derived
from F1 crosses between C57BL/6 mice and the CIA-susceptible BALB/c mouse strains.
These mice are significant in that despite expression of I-Ab MHC class II they exhibit an
intermediate susceptibility to CIA, an example of how genetic background can affect
disease susceptibility. These mice develop a moderate to severe arthritis at around 60%
incidence. Since these I-Ab-expressing mice develop CIA at an incidence higher than
wild type B6 mice it was possible that these mice also would exhibit increased
proliferative response against CII, and this would allow the comparison of an CII
proliferative response in a CIA-susceptible I-Ab-expressing mouse strain with the
response in the IFN- -/- or wild type mice. I-Ab-expressing B6 and CXB2 mice were
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Figure 3.5
Increased Expression of IgG2b in B6 IFN- -/- Mice Immunized with
CII.
Expression of IgG subclass was measured in sera collected from wild type and IFN- -/B6 mice ten days following immunization with CII/CFA. The relative concentration of
each subclass was measured by HRP ELISA and quantified by absorbance at 490-650
nm. In the IFN- -/- B6 serum, the concentration of IgG2b was increased compared to the
wild type exhibiting an absorbance of 3.30 ± 0.09 compared to 0.23 ± 0.24 in the wild
type (p < 0.001). The other IgG subclasses did not exhibit statistically significant
differences in concentration. The background absorbance in serum free wells measured
less than 0.01 for all subtypes.
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Figure 3.6
Proliferative Response to Type II Collagen in Wild Type and IFN- -/B6 Mice.
Bovine CII does not induce proliferative responses in wild type or IFN- -/- B6 mice.
When stimulated with the 1(II) chain of CII for proliferation in culture, lymphocytes
recovered from the draining lymph nodes 10 days following immunization with native
bovine CII/CFA do not proliferate above media control. Proliferation was measured by
3
H-thymidine incorporation. Lymphocytes from B6 IFN- -/- mice exhibited an activity of
9117 ± 3816 DPM when stimulated with 1(II) compared to 7098 ± 1367 DPM when
cultured in media only. This is an insignificant difference (p = 0.42). Results were
similar in lymphocytes recovered from wild type B6 mice. Stimulation with 1(II)
resulted in an activity of 4289 ± 1613 DPM, while the media control had an activity of
4478 ± 557 DPM (p = 0.83). These results indicate that native bovine collagen is not
strongly immunogenic in I-Ab-expressing mice.
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immunized with native CII in an emulsion of CFA and lymphocytes were recovered from
the draining lymph nodes ten days later. These cells were stimulated with CII, the 1(II)
chain of CII, and pepsin, and proliferation was measured by 3H-thymidine incorporation.
Lymphocytes from the B6 mouse proliferated in response to CII and pepsin but not to
1(II) (Fig 3.7A). In the CXB2 mouse recall proliferative response occurred following
stimulation with pepsin, but not against the native CII or 1(II) (Fig 3.7B). The
proliferation data do not indicate that the absence of IFN- is causing increased in vivo
expansion of CII-reactive cells in the IFN- -/- B6 mouse. In all three strains of I-Abexpressing mice strong proliferation in response to CII stimulation was not observed.
Though CII-reactive T cells are being produced, which can be inferred due to the
production of CII-specific IgG, subclasses of which are dependent on T cell help.
Reduced proliferation of T cells in response to stimulation with CII may indicate that CIIreactive Th cells are not being produced at high levels or that activation of these cells is
negatively regulated by tolerance mechanisms including anergy or suppression by Treg
cells. An additional cause of low in vitro T cell proliferative response may be altered
antigen presentation by APC in culture. The absence of strong proliferation in response
to CII stimulation may indicate that functional mechanisms such as cytokine production
may play a larger role in CIA pathogenesis than proliferative responses to CII. In
addition, these results may indicate, as stipulated by the hypothesis that CII is a weak
antigen, that CII has low intrinsic ability to stimulate I-Ab-restricted T cells. Also, a
confounding result was also observed. This is the strong proliferative response seen
against pepsin. The purification of CII from tissue sources requires the use of pepsin. A
result of this is that pepsin contamination is present in the final CII product. In mice
expressing I-Ab, but not other CIA-susceptible strains that express I-Aq or I-Ar, the slight
pepsin contamination is antigenic and results in strong T cell responses that mask the
presence of weaker T cell responses against CII that may be present. This is evident in
the responses seen in the B6 mice in that when immunized with native CII strong recall
proliferative responses are seen against pepsin and not against the 1(II). The observed
proliferative response against native CII is likely directed against pepsin. During the
production of 1(II), native CII is heat denatured and protein monomers are separated by
column chromatography. This step reduces the levels of pepsin contamination to a
concentration below that which T cells respond. For this reason, in subsequent assays
requiring in culture stimulation of lymphocytes with CII, 1(II) was used.
Cytokine Production B6 versus B6 IFN-

-/-

The expression of proinflammatory cytokines by immune cells in response to
stimulation with antigen or bacterial products often has powerful biologic effects owing
to both redundant activities among cytokine family members and because of signaling
cascades that amplify the effects of small amounts of locally produced cytokines (100).
Due to the role of cytokine signaling in the differentiation and function of T cell subsets
early in the developmental stages of an immune response, cytokines likely are key
mediators of autoimmune pathogenesis. Th1, Th2, and Th17 differentiation and function
is influenced and mediated by cytokine production (74). Cytokines produced by these
cells potentially direct the function of macrophages, monocytes, synovial fibroblasts, and
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Figure 3.7
Proliferative Response to CII in Mice Expressing MHC Class II of the
b
I-A Haplotype.
Lymphocytes obtained from CII-immunized B6 or CXB2 mice do not proliferate when
stimulated in culture with CII antigens. A. Lymphocytes were obtained from the
draining lymph nodes of B6 mice were immunized with bovine CII/CFA. In culture,
proliferation was observed in response to stimulation with bovine CII (bCII), and pepsin,
but not to 1(II). B. Lymphocytes obtained from CXB2 mice proliferated in response to
stimulation with pepsin, but not 1(II) or bCII. The proliferation of the B6 cells in
response to bCII and pepsin, but not 1(II) indicates that low proliferative responses in
B6 mice to bCII are due to trace amounts of pepsin present in the CII rather than to CII
determinants. The CXB2 mice tended to have a higher threshold of reactivity against
pepsin so trace amounts in the bCII prep did not stimulate T cell proliferation while a
higher concentration of pepsin did.
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osteoclasts to disease promoting state (45). The production of IFN- is a major effector
function of Th1 cells, therefore absence of the IFN- gene clearly alters Th1 immune
responses. This may disrupt regulation of the immune response causing aberrant
production of other inflammatory cytokines and promoting disease progression. For this
reason, the cytokines produced by B6 IFN- -/- lymphocytes were examined. A panel of
13 cytokines was selected based on their association with Th subtype or known influence
on CIA pathogenesis. Measurement of cytokines produced by lymphocytes from B6 and
B6 IFN- -/- mice was performed using a multiplexed bead assay. To measure IFN- ’s
influence on the production of cytokines during the activation of T cells, lymphocytes
were obtained from the spleens of naïve B6 and B6 IFN- -/- mice and then stimulated in
culture for three days with anti-CD3 and anti-CD28 monoclonal antibodies. Following
stimulation, the concentration of cytokines present in the supernatant was measured. A
number of cytokines expressed by lymphocytes from B6 IFN- -/- T cells following
stimulation in culture was significantly altered from wild type (p < 0.05) (Fig 3.8). In the
IFN- -/- derived cells, cytokines produced by all three Th subsets were increased. Levels
of the Th1 cytokine, IL-2, were elevated, as were the Th2 cytokines, IL-4, IL-5, and IL-13
and the Th17 cytokine IL-17. In addition, the proinflammatory cytokines IL-1 , IL-6,
TNF- , M-CSF, and GM-CSF were elevated in the IFN- -/- cultures. Two cytokines,
IL-15 and IL-18, were not differentially expressed between the two cultures. This
cytokine expression profile indicates that in the absence of IFN- there is a significant
change in the expression of proinflammatory cytokines by T cells. IFN- is known to
negatively regulate the function of Th2 and Th17 subsets (12, 13). The increases in Th2
and Th17 derived cytokines indicates that in the absence of Th1 produced IFN- those
subsets are more active, and indeed, if these in vitro effects on cytokine production
mediated by the absence of IFN- correlate with in vivo effects, they may represent
mechanistic aspects of arthritis pathogenesis in the B6 IFN- -/- CIA model.

I-Ab CII-Determinant Studies
One of the mechanisms of IFN- ’s regulation of immune response may lie in the
regulation of weak T cell stimulation, such as those that may be involved in the
generation of autoimmunity (29). In CIA, the antigen that promotes T cell activation and
the subsequent development of arthritis is CII. It is the nature of the immune system that
T cell antigens are presented to T cells by MHC molecules. Evolutionary mechanisms
have produced various MHC alleles that by their possession of structurally different
antigen binding sites increase the diversity of antigenic determinants presented to T cells
for immune surveillance. However, this also means that for a given protein antigen
different antigenic determinants may be presented by different MHC alleles. This means
that MHC alleles such as I-Aq and I-Ar present in CIA-susceptible mouse strains likely
present distinct CII determinants from those presented by MHC alleles present in CIA
non-susceptible strains such as I-Ab in the B6 mouse. Additionally, if the CII
determinant presented by I-Ab is of low affinity for the MHC or the TCR, it may be
weakly stimulatory to T cell activation, and therefore conferring resistance to CIA in
I-Ab-expressing mice such as in the B6 strain. IFN- may regulate T cell activation to
weakly stimulating determinants by creating conditions that inhibit T cell activation in
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Figure 3.8
The Absence of IFN- Significantly Alters Cytokine Production in
Culture Following Stimulation of T Cells with Anti-CD3 and Anti-CD28.
Splenocytes from naïve wild type or IFN- -/- B6 mice were stimulated in culture with
anti-CD3 and anti-CD28 antibody. Cytokine concentration in culture supernatants was
then measured by multiplexed bead assay. Cells from IFN- -/- mice produced higher
levels of the cytokines IL-1 , IL-4, IL-5, IL-6, IL-17, TNF- , IL-15, M-CSF, IL-2, IL13, and GM-CSF (*p < 0.01, **p < 0.05).
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response to weak antigens or, IFN- ’s absence may create conditions that are permissive
to T cell activation. Therefore, to determine if an I-Ab-restricted CII determinant was
weakly antigenic, and to determine if IFN- ’s role in regulating T cell responses to an IAb-restricted determinant mediates the pathogenesis of CIA, we sought to identify an IAb-restricted CII determinant, and investigate its interaction with MHC, TCR, and its role
in stimulating immune responses in I-Ab-expressing mice.
To identify CII determinants, a set of peptides that duplicated the amino acid
sequence of human CII was created. These peptides are 15-mer sequences that
progressively overlap by 12 amino acids. This CII peptide library was then used to
stimulate proliferation of lymphocytes obtained from I-Ab-expressing mice immunized
with CII. Though stimulation with native CII did not induce proliferative response it was
thought that due to the simplified processing by antigen presenting cells and the relatively
higher molar concentration of antigen compared to the concentration of antigen that
would be present with the use of native CII, unmeasurable T cell proliferative responses
against native CII or 1(II) chain would be amplified by the use of peptide.
Mice expressing I-Ab or HLA-DR1 (as a control for proliferation) were
immunized with bovine CII/CFA and lymphocytes from the draining lymph nodes were
used in a proliferation assay against the CII peptide library. Naïve splenocytes from a
TCR transgenic mouse (qCII24) were also used as a positive control. T cells from
qCII24 mice express a T cell receptor that is specific for a previously defined CII
determinant. The lymphocytes obtained from DR1 mice strongly proliferated when
stimulated in culture with the three peptides 91,92, and 93 which contain the core DR1
binding determinant FKGEQGPKG (101), while lymphocytes from qCII24 mice, which
respond to the determinant IAGFKGEQG (102), proliferate in response to the peptides
90, 91, and 92 as expected. The three I-Ab-expressing strains of mice, the B6, B6
IFN- -/-, and CXB2, exhibit differential susceptibility to CIA. However, T cells from the
three I-Ab-expressing strains did not proliferate when stimulated with any of the peptides
from the CII library (Fig 3.9).
The bovine CII sequence is 98% homologous with human CII when the leader
sequence is removed with only 18 mismatches over 1029 amino acid residues. However,
the lack of a detectable proliferative response in lymphocytes derived from the B6, B6
IFN- -/-, or CXB2 mice immunized with bovine CII and stimulated in vitro with the
human CII derived peptide library raised the possibility that an I-Ab-restricted CII
determinant lies in an area of non-homologous sequence. To address this issue, B6 or
CXB2 mice were immunized with human CII and stimulated in vitro with the CII peptide
library. As in mice immunized with bovine CII, increased proliferation to a specific
peptide determinant was not observed when human CII was used as the immunogen (Fig
3.10). This indicates that the lack of proliferation observed when the mice were
immunized with bovine CII was not due to sequence differences between the bovine and
human CII.
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Figure 3.9
Proliferative Response to CII-Library Peptides by T Cells from Mice
of Various MHC Class II Background.
ABC. When immunized with bovine CII in CFA emulsion mice expressing MHC of the
haplotype I-Ab do not exhibit proliferative response when stimulated for proliferation by
peptides from the CII peptide library. DE. I-Aq- or DR1-expressing mice immunized
with CII in CFA emulsion respond to determinant peptides present in the CII peptide
library with large proliferative responses as measured by 3H-thymidine incorporation.
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Figure 3.10 Proliferative Response to Human Type II Collagen by T Cells from
Mice Expressing I-Ab.
Lymphocytes were obtained from the draining lymph nodes of mice 10 days following
immunization with human CII/CFA. B6 and CXB2 lymphocytes were stimulated in
culture for proliferation with peptides from a CII peptide library. Proliferative response
above background was not observed in response to CII peptides in lymphocyte cultures
from either mouse strain.
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Development of CII-Specific T Hybridomas
The absence of proliferative response in both the susceptible and non-susceptible
mouse strains expressing I-Ab prevented identification of an I-Ab-restricted CII
determinant by this method. The difficulty in identification of CII determinants by this
method may be an indication of the low immunogenicity of CII, and is consistent with the
hypothesis that CII contains low affinity determinants to which T cell responses are
regulated by IFN- . The possibility that CII contains no T cell determinants is not likely
due to the fact CIA susceptibility occurs in mice expressing the I-Ab haplotype, and these
mice generate anti-CII antibodies of the IgG class ((69) and Fig 3.4, 3.5). Without the
presentation of CII derived peptides by I-Ab-expressing APC to CD4+ T cells, it is highly
unlikely that CII-specific IgG antibody response would develop.
As a second approach to identifying CII determinants presented by I-Ab, T cell
hybridomas were produced from I-Ab-expressing mice immunized with CII. This method
increases the sensitivity of identifying T cells specific for CII by immortalizing rare T
cells that respond to CII in vivo, and allows large numbers of cells to be screened for
antigenic specificity. The minimal in vitro proliferation in response to CII made the
production of T cell hybridomas difficult since only small numbers of proliferating cells
were available for fusion. Strategies were developed to optimize the proliferative
response to CII in order to increase the chances for development of T cell hybridoma
lines for determinant analysis. Both CIA-susceptible, B6 IFN- -/- CXB2, and nonsusceptible, B6, I-Ab-expressing strains of mice were immunized with CII as a source of
CII-specific T cells. The pro-proliferative cytokines IL-2 and IL-12 were used in culture
or given to mice prior to immunization with CII. CD4+ T cells were sorted by magnetic
bead to increase the numbers of CII-specific cells available for recall responses. Finally,
highly stimulatory CD11c+ activated dendritic cells were purified via magnetic bead from
spleens and used as APC to present CII. However, none of these strategies proved
successful in producing T cell hybridomas from I-Ab-expressing mice that produced IL-2
in response to stimulation with CII.
CXB2, B6, and B6 IFN- -/- mice were immunized with bovine CII and
lymphocytes were recovered from the draining lymph nodes and re-stimulated for
proliferation in vitro with the 1(II) chain of CII. After three days, the proliferating cells
were expanded with IL-2 and fused to -/ - BW5147 cells. After selection with G418 a
total of 400 clones were produced. The T cell hybridomas were then screened for CII
specificity by stimulation with 1(II) to induce IL-2 production. Of the 400 T cell
hybridomas produced, a total of ten were found to produce IL-2 in response to
stimulation with 1(II) (Fig 3.11), and all of these came from the CXB2 mice. The
production of IL-2 in response to stimulation with 1(II) indicates that these T cell
hybridomas have specificity for CII. This made possible the identification of specific CII
determinants by the use of the CII peptide library.
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Figure 3.11 IL-2 Production by H2-IAb-Restricted T Cell Hybridomas.
Ten T cell hybridoma clones were produced that possess T Cell Receptors with
specificity for CII determinants. T cell hybridoma cell lines were produced by the fusion
of BW5146 cells with T cells obtained from CXB2 mice immunized with native bovine
CII. To identify T cell hybridoma cell lines with TCR specificity against CII
determinants, IL-2 production by the T cell hybridomas in response to stimulation with
1(II) was measured by HT-2 cell survival. T cell hybridoma cultures were stimulated
with APC plus 1(II) or media only. After three days, culture supernatants were added to
HT-2 cell cultures, and the survival of HT-2 cells as measured by the production of MTT
was assayed by absorbance at 570 minus 690 nm the following day. Clones AC3, AE10,
AF3, AH9, CD5, CD7, CG9, DD12, EB1, and EB7 produced IL-2 in response to
stimulation with 1(II) but not media. This result indicates that these T cell hybridoma
clones possess TCR specific for CII determinants.
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Identification of Determinant
Production of I-Ab-restricted T cell hybridomas specific for CII allowed the use of
the CII peptide library to identify CII antigenic determinants. Since the library peptides
progressively overlap, the production of IL-2 by the T cell hybridomas stimulated by
sequential library peptides also enable identification of the core amino acid sequence of
the determinant. The CII-specific T cell hybridomas were subcloned from single cell
cultures to produce monoclonal population, and stimulated for IL-2 production with the
CII peptide library to identify CII determinants. To do this, the T cell hybridoma clones
were mixed together in equal proportions and splenocytes from CXB2 mice were used as
APC to present library peptides to the CII responsive T hybridoma cells as shown in Fig
3.12A. IL-2 production by the T cell hybridomas was detected when they were
stimulated by peptides 176 and 177, CII(511-526) and CII(514-529), corresponding to
the sequences GAQGLQGPRGL(Hyp)GT(Hyp)G and GLQGPRGL(Hyp)GT(Hyp)GTD.
These CII peptides were subsequently tested for their ability to stimulate each of the T
hybridoma clones (Fig 3.12B). Four of the 10 clones were found to respond to the
CII(511-526) and CII(514-529) peptides (Fig 3.12B). The remaining clones were then
retested against the CII-library as before, yet none produced IL-2 in response to any of
the peptides. The production of IL-2 by the T cell hybridomas in response to peptides
covering the CII sequence from amino acid 511-529 indicates that an I-Ab-restricted CII
determinant lies in this region. The T cell hybridomas that responded to tissue derived
1(II) but not synthesized peptides may be due to the absence of posttranslational
modifications, such as glycosylation, on the synthesized peptides.
The Core Binding Determinant for the I-Ab T Hybridomas Is CII(517-525) GPRGLPGTP
The first domains of the two subunits of the MHC class II molecule form an open
ended groove in which peptides bind and are presented to T cells. The nature of this
peptide MHC interaction is such that a core nine amino acid sequence binds within the
groove with the remaining amino acid residues extending out the open ends of the
binding groove. Analysis of the structure of the MHC class II molecules and the peptides
that bind to them has led to the conventional identification of 4 to 5 binding pockets
referred to as p1, p4, p6, p7, and p9. The number of the pocket corresponds to the amino
acid residue of the core determinant that fits into the respective pocket. Correspondingly,
there are several amino acid residue side chains that are oriented toward the interface
with the TCR - residues 2, 3, 5, and 8. Analysis of different epitopes that can bind the
I-Ab molecule has resulted in the identification of a binding motif for this class II
molecule. For the I-Ab molecule, large hydrophobic, aromatic, or aliphatic side chains
usually fill the p1 pocket. Pockets p4, p6, and p9 bind neutral to hydrophobic residues
with small side chains preferred. Pockets p4 and p6 exclude aromatic and charged side
chains. Finally, I-Ab can accommodate the lack of side chains in the p1, p4, p6, and p9
pockets due to strong N terminal and p7 interactions (103, 104).
The response of the T cell hybridomas to only peptides 176 and 177 indicates that
the core CII sequence that binds I-Ab is located within the 12 amino acid overlap of these
two peptides, corresponding to CII(514-525) (Fig 3.13). However, the size of the
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Figure 3.12 IL-2 Production by I-Ab-Restricted T Cell Hybridoma Clones in
Response to Stimulation with CII-Library Peptides.
Stimulation of CII-specific T cell hybridomas with an overlapping CII peptide library
allowed the identification of an I-Ab-restricted CII determinant. A. The ten T cell
hybridomas that produced IL-2 in response to CII were mixed together and stimulated
with a CII peptide library. IL-2 production by the T cell hybridomas was then assayed by
HT-2 cell survival as determined by the production of MTT. Data is expressed as the
absorbance at 570 minus 690 nm of experimental wells compared to positive control
containing 62 ng/ml IL-2. Two peptides promoted the production of IL-2 by those cells,
peptides 176 and 177 corresponding to the CII sequence from 511-528. B. Each T cell
hybrid was then tested individually to the stimulatory peptides. Of the ten T cell
hybridoma cell lines, four produced IL-2 in response to the two peptides. Six of the
hybrids respond to native CII, but not to peptide. To find units/ml of IL-2 supernatants
from T cell hybridoma cultures were serially diluted in cultures of HT-2 cells. The
dilution of T cell hybridoma supernatants that supported HT-2 cell survival is the
units/ml of IL-2.
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Figure 3.13 The I-Ab-Restricted CII Determinant.
Stimulation of T cell hybridomas with the CII-library peptides 176 and 177 induces IL-2
production as measured by HT-2 cell survival, highlighted in red. These peptides
correspond to CII(511-528). Due to the overlapping progression of amino acid residues
among the library peptides, there is a 12 amino acid stretch that is common to both of the
stimulatory peptides 176 and 177, CII(514-525). Since these two peptides stimulate the
T cell hybridomas and peptides 175 and 178 do not, it can be inferred that within these 12
amino acid residues a determinant capable of binding I-Ab and stimulating the T cell
hybridomas is present. The nonstandard amino acid residue hydroxyproline is converted
from proline residues by the enzyme prolyl hydroxylase whenever the motif GXP occurs
in collagen. In this figure, hydroxyproline is represented with the letter B.
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binding groove within the MHC class II molecule is only large enough to contact directly
with a nine amino acid long determinant, which is referred to as the “core”. To determine
the core residues that bind the MHC class II molecule and to further characterize the
interaction of the peptide in the T cell receptor complex, a set of 15 analog peptides
covering the CII sequence present in the two stimulatory peptides was produced with an
alanine residue substituted at each position. This set of peptides was then used to
stimulate the CII-reactive T cell hybridoma cells. When stimulated with alanine
substituted peptides, IL-2 production by the four T cell hybridoma clones was reduced in
two distinct clonotypic patterns. In clones AF3 and AE10 T cell hybridoma stimulation
as measured by IL-2 production was reduced, starting with the Gln at position 516 and
extending to the Thr at position 524 excluding the two Gly at 517 and 523 (Fig 3.14AB).
In clones AH9 and DD12 the pattern is similar but extends from the Pro at position 518
to the Thr at position 524 (Fig 3.14CD). This reduction in stimulation indicates that the
residues located from 516 to 524 are required for stimulation of the T cell hybridomas
and likely represent the core of the determinant that interacts with the binding groove of
the I-Ab molecule. These data also imply that these I-Ab-restricted T cell hybridomas
utilize at least two clonally different TCR in their recognition of the CII peptide.
To find the relative contribution of each residue in stimulating the T cell
hybridomas, titration experiments were performed (Fig 3.15). In all four clones,
stimulation of the T cell hybridomas was highly dependent on the 5 residues from 518 to
522, PRGLHyp. When these residues were individually substituted with Ala there was
no measurable IL-2 production even at the highest concentration of peptide. These data
indicate that these residues are required for formation of the I-Ab/peptide/TCR complex,
and these are likely part of the determinant core. The Gln at position 516 and the Thr at
position 524 when substituted with Ala resulted in decreased stimulation of the T
hybridomas upon titration at a rate that exceeded the control, and therefore indicates that
these two residues also play a prominent role in the stimulation of these T cell
hybridomas. Ala substitutions of the remaining residues had little effect on antigen
presentation indicating that these amino acid residues are likely not key contact points
within the ternary complex. When the sequence of this core determinant of CII(517525), GPRGLHypGTHyp, is compared to the published motif for I-Ab it is observed that
only one frame of the amino acid sequence fits well with the binding pockets located at
p1, p4, p6, p7, and p9. This frame includes the Gly at positions 517 and 520 filling
pockets p1 and p4, and the Hyp at positions 522 and 525 filling the p4 and p9 pockets.
The two Gly have small side chains and one would not expect them to make large
contributions to the overall binding of the determinant, although side chains from the I-Ab
molecule may make contact with the backbone of the peptide at these locations, thus
helping to stabilize the binding. This may be why the Gln at position 516 is required for
stimulation of the T cell hybridoma clones even though it lies outside of the core
determinant. Since MHC class II contains an open ended binding groove amino acids
outside of the core region can contribute to binding stability or TCR interaction. In
addition the sensitivity of T hybridoma stimulation to Ala substitution is potentially an
indication of low stability of the CII determinants interaction with the I-Ab molecule, as
individual Ala substitution at six of the nine core residues strongly reduces T cell
hybridoma stimulation.
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Figure 3.14 IL-2 Production by CII-Reactive T Cell Hybridomas in Response to
Stimulation with Alanine Substituted CII(512-526).
CII-reactive clones were stimulated for IL-2 production using alanine substituted peptides
covering the CII(512-526) determinant previously shown to stimulate these CII-specific
clones. AB. Clones AF3 and AE10 show reduced IL-2 production when stimulated with
APC and 50 g peptides with substitutions Q515A, P517A, R518A, G519A, L520A,
Hyp521A, and T523A. CD. Clones AH9 and DD12 show reduced IL-2 production
when stimulated with APC and 50 g peptides with alanine substituted at P517A,
R518A, G519A, L520A, Hyp521A, and T523A. The failure to promote IL-2 production
when these residues are substituted with alanine, which has no significant side chain,
shows the relative importance of these residues in the TCR complex. The core
determinant for these clones and H2-IAb binding lies in this region, highlighted in red.
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Figure 3.15 Stimulation of CII-Specific I-Ab-Restricted T Cell Hybridomas by
Titrated Alanine Substituted Determinant Peptides.
Substitution with alanine affects the concentration at which the CII(512-526) determinant
is capable of stimulating IL-2 production in the CII-specific T hybridomas. Production of
IL-2 by alanine substituted peptides was measured by HT-2 cell survival in wells titrated
with the supernatants of co-cultures of CII-specific T cell hybridomas, I-Ab-expressing
APC, and alanine substituted peptides of various concentrations. The ability of each
peptide to promote IL-2 production by the T cell hybridoma was compared to the native
sequence A512. Q513, G514, L515, G517, G523, P525, and G526 (blue) all resulted in
titration curves that were similar to the control (purple). P518, R519, G520, L521, and
P522 (red) did not stimulate IL-2 production at any measured concentration. Two
peptides, Q516 and T524 (green), required higher concentrations than the control to
stimulate IL-2 production. This indicates that these two peptides bind the TCR complex
at lower affinity than the control bovine CII peptide, indicating that these residues are key
contact points within the TCR complex.
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I-Ab-Restricted Cellular Responses to CII Determinant
Proliferative Response
Having identified an I-Ab-restricted determinant present in CII, the ability of this
determinant to stimulate T cell proliferative responses was examined. This is especially
significant given that the previous measurements of proliferative response against
nativeCII and 1(II) failed to exhibit measurable responses. For these experiments, two
peptides were synthesized that covered the core binding region of the determinant
peptide, CII(512-526) and CII(512-528). These two peptides were chosen based on the
core determinant identified by the T cell hybridomas. Often, peptides that contain only
the core determinant exhibit reduced immunogenicity, and in the CII(512-526) peptide,
the core CII determinant is only one residue removed from the end of the peptide.
Therefore to increase the immunogenicity of the peptide, two residues were added to the
C terminus to make the CII(512-528) peptide. CXB2 mice were immunized with
CII/CFA and lymphocytes were recovered from the draining lymph nodes ten days later.
These lymphocytes were then stimulated for four days and proliferation was measured by
3
H-thymidine incorporation. Following immunization with CII, neither peptide elicited
an in vitro proliferative response by the T cells from the CXB2 mouse (Fig 3.16A).
While these data are similar to the lack of proliferative responses we observed in our
earlier studies (Fig 3.7), we had hoped that the longer version of this CII peptide would
enhance its ability to re-stimulate T cells in vitro. As a second approach to demonstrating
the immunogenicity of this peptide, mice were immunized with the peptides and their T
cells were tested for their ability to proliferate in vitro. To increase the concentration of
CII-specific T cells in the recall assay, enrichment of CD4+ cells was performed via
magnetic bead separation. Cells were obtained from the draining lymph nodes and
stimulated in culture with either CII(512-526) or CII(512-528). As shown in Fig 3.16B,
proliferation was not stimulated by the shorter CII(512-526) peptide in either mouse, but
in the B6 mouse significant proliferation was induced by the longer CII(512-528) peptide
(Fig 3.16CD).
The advent of recall proliferation against the longer CII(512-528) peptide in the
B6 mouse, and in both the B6 and CXB2 mouse following enrichment of CD4+ T cells
indicates that the determinant sequence identified by the T cell hybridomas was capable
of stimulating T cell proliferation in vivo. The absence of proliferative responses against
native CII may be a consequence of the determinant acting as a weak antigen requiring
the use of enrichment steps to detect low in vivo responses of effector T cells. In
addition, the differential response of the CII(512-526) peptide versus the CII(512-528)
peptide highlights the contribution of amino acids beyond the core determinant to I-Ab
binding or TCR binding of the I-Ab/peptide complex. In the shorter peptide the sequence
extends only one amino acid beyond the core, whereas in the longer peptide there are
three amino acids beyond the core determinant. It appears that the addition of these
amino acids increased the potency of this peptide, raising T cell immune response to
detectable levels.
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Figure 3.16 Proliferative Response of Lymphocytes from I-Ab-Expressing Mice
Stimulated with CII Determinants.
When I-Ab-expressing mice were immunized with native bovine CII, CII(512-526), or
CII(512-528) in CFA emulsion and the draining lymph nodes were recovered ten days
later. These cells were then stimulated in culture for proliferation with the CII
determinants CII(512-526) and CII(512-528) with or without enrichment of CD4+ by
magnetic bead cell sorting. A. When native CII is used as the immunogen, lymphocytes
from CXB2 mice do not proliferate as measured by 3H-thymidine incorporation when
stimulated with CII(512-526) or CII(512-528). B. When CII(512-526) is used as both
the immunogen and the stimulating antigen, lymphocytes from B6 mice do not
proliferate. C. When CXB2 mice were immunized with CII(512-528) proliferation in
response to stimulation with CII(512-528) was not observed. However, when these cells
were enriched for CD4+ cells proliferation in response to stimulation with CII(512-528)
was induced. D. When B6 mice were immunized with the longer CII(512-528)
determinant stimulation with CII(512-528) induced proliferation. Proliferation was
increased three fold when the lymphocytes were enriched for CD4+ cells by magnetic
bead cell sorting. The control shown represents lymphocytes that were sorted for CD4+
cells but not stimulated with CII(512-528). (*p < 0.01)
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Recently, chicken derived CII has been identified as arthritogenic in B6 mice
when used in place of bovine CII to immunize mice for induction of CIA (105, 106).
Examination of the CII sequences for mouse, bovine, human, and chicken CII indicated
that the bovine sequence differs in two places from the human, mouse, and chicken
sequences in the 512-528 peptide. In the bovine sequence, position 512 is serine
compared to alanine in the other three species. At position 518 the bovine sequence is an
alanine compared to proline in the human, mouse, and chicken sequences (Fig 3.17).
Based on our current model, the alanine at position 518 is the p2 residue of the
determinant, a position that likely serves as a TCR interaction site (Fig 3.14). The
alanine in the bovine sequence may explain the low proliferative response when native
bovine CII is used as the immunogen for in vitro proliferation assays (Fig 3.6, 3.7,
3.16AB).
To test the immunogenicity of native chicken CII versus native bovine CII in
I-Ab-expressing mice, CXB2 mice were immunized with chicken or bovine CII in CFA
and proliferative responses against the two synthetic peptides and bovine 1(II) were
measured by 3H-thymidine incorporation using cells obtained from the draining lymph
nodes of the immunization site. When immunized with chicken CII, recall proliferative
responses were observed against both synthetic peptides CII(512-526) and CII(512-528).
No proliferation was seen in response to recall with bovine 1(II). When bovine CII was
used as the primary antigen no proliferation was observed upon recall with either CII
peptides, CII(512-526) and CII(512-528), or against the bovine 1(II) (Fig 3.18). These
results may explain the differential susceptibility to CIA when CII produced from
different sources, chicken or bovine, is used as the immunogen to induce CIA. Bovine
CII contains an alanine at a key binding location, p2 of the core determinant, and this
apparently reduces the immunogenicity of CII in the I-Ab background as evidenced by
the reduction in stimulation of the T cell hybridomas using the alanine analog. In
contrast, the chicken CII at that location contains a proline, which appears to increase the
immunogenicity of the I-Ab-restricted CII determinant (Fig 3.15). This may explain why
wild type B6 mice develop CIA when immunized with chicken CII and not with bovine
CII. However, in B6 IFN- -/- mice, bovine CII, of low antigenic potential, is capable of
inducing CIA due to disregulation of immune function as a result of the absence of
IFN- . In contrast, in the wild type mouse chicken derived CII, a stronger antigen than
bovine CII, is capable of stimulating a pathogenic immune response in a normal immune
background.
Induction of Tolerance by CII Determinant
In order to demonstrate the significance of the I-Ab-restricted peptide in driving
the development of autoimmunity, we used the 512-528 peptide to induce tolerance in B6
mice and protect them from arthritis. This protection occurs via active suppression or via
clonal deletion of CII-reactive CD4+ T cells (107-110). If the CII(512-528) determinant
is the sequence to which self-reactive T cells respond during the pathogenesis of CIA
then pre-administration of CII(512-528) to CXB2 mice should inhibit T cell responses in
these mice and therefore protect from CIA. To induce tolerance, 200 g of CII(512-528)
dissolved in PBS or PBS alone was injected into the orbital plexus of CXB2 mice. Three
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Figure 3.17 CII-Determinant Sequence Homology.
Human, mouse, and chicken CII have identical sequence from amino acid number 512 to
528 in contrast to the bovine sequence which contains two mutations: A512S and P518A.
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Figure 3.18 Proliferation in Response to Stimulation with CII Antigens in
Lymphocytes from I-Ab-Expressing Mice Immunized with Native Chicken or
Bovine CII.
Following immunization with CII lymphocytes obtained from CXB2 mice do not
proliferate when stimulated in culture with CII(512-526), CII(512-528), or bovine 1(II).
When the immunizing antigen is chicken derived CII, proliferative responses are
observed following stimulation both CII(512-526) and CII(512-528) but not bovine
1(II).
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days later the mice were immunized with CII/CFA emulsion and monitored for
development of arthritis. The PBS control group developed arthritis at 50% incidence
and achieved a maximum severity score of 4.3. The mice tolerized with CII(512-528)
developed arthritis at 29% incidence and achieved a maximum severity score of 3.0. In
addition, arthritis in these mice developed at a later time point compared to the PBS
control mice developing arthritis on days 45 and 38, respectively (Fig 3.19). The
inhibitory effect of CII(512-528) on the development of CIA indicates that this CII
determinant is an important component in the T cell autoimmune response that drives
CIA pathogenesis in I-Ab-expressing mice.

Measurement of Binding Affinity of CII Determinants for I-Ab
In order to test the hypothesis that IFN- regulates weak T cell responses, the
affinity of CII determinants for the I-Ab molecule was measured. Two experimental
systems were used to identify the affinity of CII determinants for I-Ab. The first was a
bioinformatic approach that used an algorithm based peptides known to bind I-Ab to
calculate the binding affinity for I-Ab of discrete peptides present in the CII molecule. In
the second approach, CII-library peptides and known I-Ab binding peptides were used to
competitively bind a recombinant soluble form of I-Ab. However, for various reasons
these experiments were not entirely successful and yielded inconclusive data about the
nature of CII binding to I-Ab. A complete description of this data is located in the
Appendix.

Discussion
Examination of immune function in IFN- B6 mice did not reveal major defects in
the immune function in response to immunization with CII/CFA emulsion. When cell
subset analysis was performed, large alterations in B cell and T cell numbers were not
observed. Th and Tc populations were also similar between CII-immunized wild type and
IFN- -/- mice, as there were only minor differences in CD8+ and CD4+ T cell percentages.
Despite previous indications that IFN- deficient mice have increased T cell proliferative
responses (65), increases in T cell proliferation in response to stimulation with native CII
were not observed. This may be due to CII being a low affinity antigen for I-Ab, thus
stimulating a weak T cell response that is below our method of detection. The major
differences in immune function following immunization with CII/CFA in the IFN- -/mouse appear to be changes in anti-CII antibody and cytokine production. When serum
concentrations of anti-CII antibodies were measured, the levels in IFN- -/- B6 mice were
increased in comparison to the wild type B6 response. There were also changes in the
anti-CII IgG subtype in the IFN- -/- mouse. While IFN- is known to induce Ig class
switching to the IgG2a subclass B6 mice do not express IgG2a, instead, they express
IgG2c. When anti-CII Ig subclasses were measured by ELISA there was no significant
decrease in anti-CII IgG2c production compared to the wild type B6 mice as might be
expected due to the absence of IFN- . However, there was a large increase in the
production of anti-CII IgG2b. This subclass of Ig has both complement fixing activity
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Figure 3.19 Tolerization of CIA-Susceptible CXB2 Mice with CII-Determinant
Peptide.
Prior to immunization with bovine CII in CFA emulsion CXB2 mice were injected
intravenously with CII(512-528) or PBS to induce tolerance. A. Mice tolerized with
CII(512-528) develop arthritis at lower instance and on a delayed schedule than control
mice injected with PBS. B. Mice tolerized with CII(512-528) develop arthritis at a lower
severity than control.
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and binds to the high affinity Fc RIII, promoting activation of immune cells. In addition
anti-CII antibodies of the IgG2b subclass are capable of inducing arthritis when used in
antibody induced arthritis models (99).
The major change in immune response of IFN- -/- B6 mice that occurs following
immunization with CII/CFA that potentially promotes the development of autoimmunity
appears to be disregulated cytokine production. This is consistent with the hypothesis
that as a regulatory cytokine, IFN- directs the nature of the immune response and in its
absence disregulation occurs that is permissive to the development of autoimmunity. The
cytokine milieu is of paramount importance during the initial stages of an immune
response. The cytokines present during this stage can direct the type of T cell immune
response that occurs. This is due in part to the self-reinforcing nature of immune
responses. For example, T cells of the Th1 phenotype proliferate and produce the
proinflammatory cytokines IL-2 and IFN- . These cytokines feed back to both drive
expansion of Th1 response and inhibit Th2 response. This is also true of Th2 responses
where the production of IL-4 and IL-10 feed back to reinforce Th2 responses and inhibit
Th1 responses. Though in some aspects an immune response is self-reinforcing, it is also
true that normal immune responses are self-limiting. As the immune response
progresses, immune mechanisms such as anergy and the activation of Treg cells can come
into play to halt the unrestricted development of an immune response. It is in this selflimiting process that the absence of IFN- may result in the progression of autoimmunity
in the IFN- -/- B6 mouse. We propose that the absence of IFN- has altered the immune
response to such an extent that self-limiting mechanisms are impaired and autoimmunity
develops. We see an indication that this disregulation occurs when the cytokines
produced in response to T cell stimulation in cells from IFN- -/- B6 mice were
quantitated. In cultures of these cells there is greatly increased production of cytokines
associated with all three effector T cell subsets, Th1, Th2, and Th17. Cytokines such as
IL-2, IL-4, IL-5, IL-13, and IL-17, as well as proinflammatory cytokines downstream of
these cytokines IL-1 , TNF- , M-CSF, and GM-CSF, are all overproduced in
comparison to the T cells from B6 mice. It is interesting to note that cytokines associated
with all three Th subclasses of T cells are upregulated. In the absence of IFN- one would
expect increases in Th2 and Th17 responses, however, the production of IL-2, IL-1 ,
TNF- , M-CSF, and GM-CSF following stimulation of T cells indicates that even Th1
responses are upregulated in the absence of IFN- .
One of the mechanisms of IFN- ’s regulation of immune response may lie in the
regulation of weak T cell responses. In CIA, the antigen that promotes T cell activation
and the subsequent development of arthritis is CII. It is the nature of the immune system
that T cell antigens are presented to T cells by MHC molecules. Evolutionary
mechanisms have produced various MHC alleles that by their possession of structurally
different antigen binding sites increase the diversity of antigenic determinants presented
to T cells for immune surveillance within a mammalian species. However, this also
means that for a given protein antigen different antigenic determinants may be presented
by different MHC alleles. This means that MHC alleles such as I-Aq and I-Ar present in
CIA-susceptible mouse strains can present physically distinct CII determinants from
those presented by MHC alleles present in CIA non-susceptible strains such as I-Ab in the
54

B6 mouse. If the CII determinant presented by I-Ab is of low affinity for the MHC or the
TCR it may be weakly stimulatory to T cell activation, and therefore conferring
resistance to CIA in I-Ab-expressing mice such as in the B6 strain. One mechanism of
IFN- ’s regulation of T cell activation likely is mediated by the promotion of
proinflammatory cytokine expression. Signaling by these cytokines at the time of antigen
exposure may potentiate T cell activation when they are stimulated with weakly
immunogenic determinants. Therefore, to determine if an I-Ab-restricted CII determinant
was weakly antigenic, and to determine if IFN- ’s role in regulating T cell responses to
an I-Ab-restricted determinant mediates the pathogenesis of CIA, we identified an I-Abrestricted CII determinant, and investigated its role in stimulating immune responses in
I-Ab-expressing mice.
Initial assays that measured T cell responses to bovine CII indicated that there
were minimal T cell responses to CII in several strains of I-Ab-expressing mice that were
either susceptible or non-susceptible to CIA. Immunization with bovine CII did not
result in measurable T cell proliferative responses in wild type B6, IFN- -/- B6, or CXB2
mice when lymphocytes from these mice were stimulated in culture with either native CII
or a peptide library derived from CII sequence. This indicated that I-Ab CII determinants
were weakly antigenic as hypothesized. While this supports the concept that I-Abrestricted CII determinants in B6 mice are not conducive to autoimmunity except in the
case of disregulation mediated by IFN- , it made difficult the identification of an I-Abrestricted CII determinant for detailed analysis. To solve this problem, T cell hybridomas
were produced from lymphocytes obtained from I-Ab-expressing mice previously
immunized with CII. This allowed the immortalization and expansion of low frequency
I-Ab-restricted T cells with specificity to CII determinants. Stimulation of these T cell
hybridomas with a CII peptide library resulted in one CII determinant identified, located
at position 514-525 of the CII molecule (amino acid sequence GLQGPRGLHypGTHyp).
Once identified, we further characterized the binding characteristics of the determinant
for the components of the TCR complex, and the ability of the determinant to stimulate
immune responses in I-Ab-expressing mice.
The structure of MHC class II molecules is such that there are 4 to 5 binding
pockets in an open ended binding groove to which specific amino acids within the
antigenic peptide orient. The size of the binding groove dictates that there is a 9 amino
acid core sequence within the determinant that closely associates with the MHC to
stabilize binding via hydrogen bonding, hydrophobic interactions, ionic binding, and van
der walls forces with hydrophobic interactions at the binding pockets usually providing
the greatest contribution to overall stability of the MHC/peptide complex. The open
ended nature of MHC class II molecules, however, results in amino acids that extend
beyond the core also contributing to MHC/peptide stability. Once bound to the MHC the
peptide is made available for binding of the TCR. Binding of the TCR to the
MHC/peptide forms the TCR complex which initiates signaling within the T cell that
causes its activation. In order to identify the core determinant and to assess the
contribution of each amino acid to the formation of the TCR complex, an alanine
substituted panel of analog peptides with individual substitutions at each position from
CII(512-526) was created and used to stimulate the CII-reactive T cell hybridomas.
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When the T cell stimulatory characteristics of the alanine panel were examined the core
determinant was identified as CII(514-528) or GPRGLHypGTHyp. Furthermore, within
the core determinant the amino acids from CII(518-522), PRGLHyp, are required for T
cell stimulation, while the Q and T at positions 516 and 524 also contribute to stability of
the TCR/Peptide/MHC complex.
While stimulation of T hybridoma cells with the CII determinant and the alanine
substituted peptide shows the contribution of the amino acids within the determinant to
formation of the TCR complex and T cell stimulation, the affinity of the determinant for
I-Ab can only be inferred by this method. Therefore to directly measure the affinity of
the determinant for I-Ab we used both a bioinformatic approach and direct binding assays
between the CII determinant and a soluble recombinant form of I-Ab. When binding
affinity of CII for I-Ab was calculated using the MHC class II binding algorithm SMMalign, there were no sequences present in CII that were shown to bind at high affinity,
including the CII determinant that was identified by the use of the T cell hybridomas.
We next used a binding assay to experimentally measure the binding affinity of CII
sequence for I-Ab. To do this, we generated a soluble form of I-Ab to be produced in
insect cells. However, multiple attempts to produce soluble I-Ab failed to generate a
recombinant form of I-Ab that would bind CII peptides in vitro. This prevented the direct
measurement of the binding affinity of CII determinants.
Therefore, we sought to measure the ability of the identified CII determinant to
stimulate T cell responses in I-Ab-expressing mice and to determine its contribution to the
pathogenesis of CIA in susceptible strains. CII(512-526) and CII(512-528), CII peptides
that correspond to the I-Ab CII determinant and native CII were used to immunize B6 and
CXB2 mice so the T cell responses to the determinant could be measured. When the CII
peptides were used to stimulate proliferation in lymphocytes recovered from these mice it
was found that the shorter CII(512-526) peptide was not strongly immunogenic failing to
stimulate proliferation in either mouse strain. However, the longer CII(512-528) peptide,
when used at the primary antigen was able to stimulate proliferative response in the B6
cells when stimulated in culture, and in both mice when enrichment of CD4+ was
performed prior to stimulation in culture. These results indicated that the CII determinant
identified here is capable of stimulating in vivo T cell responses in I-Ab-expressing mice,
and these CII-restricted T cells responses to this CII determinant may promote the
development of autoimmune arthritis. To test this concept, CIA-susceptible CXB2 mice
were tolerized with CII(512-528) and immunized with CII to induce CIA. When arthritis
developed in these mice, it was observed that prior tolerization with CII(512-528)
reduced both the incidence and severity of inflammation indicating that the CII(512-528).
Therefore, the CII(512-528) peptide does indeed mediate autoimmune arthritis in the I-Ab
background.
These data indicate that IFN- regulates immune function in response to
immunization with CII. In the absence of IFN- , alterations in immune function occur
including increases in the expression of proinflammatory cytokines and production of
complement-fixing anti-CII antibodies that promote autoimmune arthritis. A weakly
immunogenic I-Ab-restricted determinant present in CII was also identified and
characterized. This determinant is capable of stimulating T cell responses in I-Ab56

expressing mice, and is implicated in the pathogenesis of CIA. In IFN- -/- B6 mice
disregulation of immune function mediated by the absence of IFN- likely increases T
cell responses to this CII determinant and allows the development of autoimmunity to
progress.
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Chapter 4. Interferon and the Pathogenesis of Inflammatory
Arthritis
Introduction
IFN- is a pluripotent mediator of immune function, regulating cytokine
production and subsequently the cellular communication of immune and accessory cells
responsible for disease progression in autoimmune arthritis. The absence of this cytokine
has the potential to fundamentally change the cellular communication that occurs as the
immune response initiates and progresses.
We have previously shown that the lack of IFN- in a CIA non-susceptible strain,
B6, converts this strain to one that is highly susceptible. This conversion is likely
mediated by alterations in immune function due to the absence of IFN- signaling,
changes including inflammatory cytokine production, autoantibody generation, and
increased T cell activation to weakly antigenic CII determinants. Ultimately,
disregulated activation of CII-specific T cells mediated by these processes results in the
development of autoimmunity. In light of IFN- ’s emerging role as a master regulator of
cellular differentiation and cytokine production, we have developed the following
hypothesis. If IFN- acts as a key regulator of immune function, directing the activation,
differentiation, and cytokine production of both immune and accessory cells during the
development of an inflammatory response, then removal of IFN- by genetic ablation,
such as in the B6 IFN- -/- mouse, causes disregulation of normal immune regulatory
processes, resulting in aberrant cytokine production and immune cell activation. As a
result of this disregulation, in the B6 IFN- -/- mouse, the absence of IFN- allows
progression to autoimmunity. Therefore, to investigate how immune function is
perturbed in the absence of IFN- , and how that disregulation results in the progression of
a pathogenic autoimmune response, we examined how gene expression, cytokine
production, cellular response, and disease progression is altered in the absence of IFN- .
The first step in identifying the mechanism by which absence of IFN- promotes
progression to disease was to obtain data that describes the changes in cytokine
production and cellular function that occur when immune cells encounter antigen in the
absence of IFN- . The CIA-susceptible B6 IFN- -/- mouse model provides an ideal
system to compare the cellular responses of a non-pathogenic immune response, as seen
in the resistant B6 mouse strain, to one that does progress to autoimmune disease. The
CIA model has been widely studied as a model of RA, and has been instrumental in
identifying mechanisms of pathogenesis as well as developing new therapeutics. CII
dependent immune cell activation, the production and involvement of anti-CII antibodies,
and proinflammatory cytokines produced in the joint synovium that mediate pathogenesis
have all been characterized to some extent in this model. Since the two mouse strains are
congenic and immunization with CII is pathogenic in the IFN- -/- and not the wild type,
the immune response in the both strains following CII immunization can be examined in
detail and compared to one another. Alterations in the immune response in terms of
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immune cell function and cytokine production of the B6 IFN- -/- mouse from that of the
wild type are likely to be mediated either directly or indirectly by the absence of IFN- .
If these alterations direct the pathogenic mechanisms of CIA, it is highly probable that
those mechanisms are responsible for conferring susceptibility to CIA in the B6 IFN- -/mouse.
Cytokines are local mediators of cellular activity, whose numerous effects include
cell growth and activation, inflammation, immunity, and differentiation (45). In RA,
there is an abundance of cytokines at the site of inflammation, including TNF- , IL-1 ,
IL-6, GM-CSF, IL-8, IL-10, IFN- IL-2, and TGF (111). Activated immune cells and
synoviocytes such as fibroblasts or epithelial cells produce these cytokines. Often
cytokines form interconnected regulatory networks where the expression of one cytokine
either promotes or inhibits the expression of others by either an autocrine or paracrine
mechanism. For example IFN- promotes its own expression by supporting the
differentiation of Th1 cells, and inhibits the production of IL-4 or IL-17 by inhibiting the
differentiation of Th2 or Th17 cells. Also, in many cases expression of proinflammatory
cytokines is required for disease activity as is shown by knock out mouse models. For
example, the proinflammatory cytokines GM-CSF, TNF- , and TGF activate cells that
effect joint destruction including monocytes, macrophages, fibroblasts, and osteoclasts
within the joint synovium. In the following studies, we examine the relationship between
IFN- and the expression of proinflammatory cytokines in order to identify the
mechanism by which CIA susceptibility is conferred in the B6 IFN- -/- mouse. Using a
combined molecular and cellular approach, our data indicate that IFN- ’s regulation of
the expression of IL-18 BP plays a prominent role in this CIA model.

Results
The Role of IFN- in Regulating Gene Expression
Expression Array of Wild Type versus IFN-

-/-

B6 Mice

The types and quantity of cytokines expressed in the immune system milieu both
during and immediately following antigen stimulation can play a significant role in T cell
and accessory cell differentiation and function. The ultimate outcome of a T cell immune
response in terms of which subtype of CD4+ T cells is activated is tightly controlled by
the interplay of signaling in Th1, Th2, Th17, and T regulatory cells. IL-12 and IFNpromote Th1 development while antagonizing Th2 development; the opposite is true for
the cytokine IL-4 which antagonizes Th1 cell differentiation and promotes Th2 responses.
A similar reciprocal agonist-antagonist arrangement exists between Th1 and Th17 cells.
Whereas IFN- inhibits Th17 function, IL-17 inhibits Th1 function. Since a key effector
function of Th1 cells is the production of IFN- , in the B6 IFN- -/- mouse, the lack of
IFN- expression must alter Th1 cell function by either preventing the differentiation of
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competent Th1 cells, by severely limiting their effector function, or by the lack of
feedback inhibition of a pathogenic Th17 response.
We propose that reduced Th1 mediated effector function results in a perturbation
of the function of immune cells throughout the immune system resulting in a
disregulation phenotype. This potential disregulation would explain the differential
susceptibility to disease in the B6 IFN- -/- model. In order to determine which genes are
regulated by IFN- in the context of CIA, a gene expression array was performed using
mRNA from lymphocytes obtained from the draining lymph nodes of wild type and
IFN- -/- B6 mice immunized with bovine CII in an emulsion of CFA. Three female B6 or
B6 IFN- -/- age matched between three and four months were immunized with a total of
100 l of 2 mg/ml CII in CFA emulsion. The draining lymph nodes were excised ten
days later and the total RNA was recovered from lymphocytes. This RNA was checked
for quality with an Agilent Technologies 2100 bioanalyzer to test the quality of the RNA
and determine its concentration. Following quality assurance, the mRNA was analyzed
by microarray using an Affymetrix GeneChip Mouse Genome 430 2.0 Array.
After the expression chip data were analyzed, one set of data from a B6 IFN- -/mouse was found to be of poor quality and these data were excluded from subsequent
analysis. Among the remaining three wild type chips and the two IFN- -/- chips, 1612
genes were shown to be significantly differentially expressed (p ≤ 0.05) among the
45,101, probe sets present on the chip representing 34,000 mouse genes (Fig. 4.1). This
list of genes was then analyzed using Ingenuity Pathways Analysis software. This
software is a research tool that identifies networks of genes based on known signaling
connections. This tool allowed the identification of those genes among the 1612
differentially expressed that are present in signaling networks or those related to
immunological function. This analysis revealed 41 signaling networks with 10 or more
genes present among the differentially expressed genes. As a final step, genes were then
examined manually for differentially expressed immune regulatory genes, especially
those associated with rheumatoid arthritis or autoimmunity.
A select group of differentially expressed genes between the wild type and
IFN- groups were identified as likely to be involved in the pathogenesis of CIA due to
their roles as immune signaling molecules, immune effector molecules, and mediators or
indicators of inflammation (Fig 4.2, 4.3). The data are represented as fold difference in
expression. To obtain these values, the average of the normalized fluorescence for each
group was converted to a ratio by dividing the value obtained from the wild type cells by
the value obtained from the IFN- -/- derived cells. These values were then converted to
the fold difference between the two groups by subtracting the inverse of the WT/IFN- -/ratio from zero. The result of this calculation is that a gene expressed more highly in the
wild type cells will have a positive value while a gene with higher expression in the
IFN- -/- cells will have a negative value.
-/-

Genes encoding immune signaling molecules that include immune modulating
cell surface receptors and soluble cell signaling molecules such as cytokines and
chemokines were found to be differentially expressed (Fig 4.2A). In the wild type
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Wild Type

IFN-

-/-

1612 Genes
p ≤ 0.05

Figure 4.1
Genes Differentially Expressed between Wild Type and IFN- -/- B6
Mice in Response to Immunization with CII/CFA.
Wild type and IFN- -/- mice were immunized with CII/CFA. Ten days later, mRNA was
isolated from lymphocytes recovered from draining popliteal lymph nodes and examined
for gene expression with an Affymetrix GeneChip Mouse Genome 430 2.0 Array.
45,101 probe sets representing 34,000 mouse genes were examined for differential
expression. Of these, 1612 genes were observed to be differentially expressed with a
significance greater than p ≥ 0.05. Blue represents higher expression, and red represents
lower expression.
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Figure 4.2
Intercellular Signaling Molecules Differentially Expressed between
Wild Type and IFN- -/- B6 Mice.
Wild type and IFN- -/- B6 mice were immunized with CII/CFA, and ten days later
lymphocytes were recovered from draining lymph nodes. These cells were used to
produce mRNA for use in a gene expression array. Selected differentially expressed
genes with immunological relevance to arthritis pathogenesis are shown. Data is
represented as the fold difference in gene expression between cells from wild type and
IFN- -/- B6 mice. A. Cytokine and chemokine signaling molecules that are differentially
expressed between the two groups. B. Membrane bound receptors and ligands with
immunomodulatory effects on immune cell function. For all genes shown, p ≤ 0.05.
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Figure 4.3
Markers of Inflammation and Joint Remodeling Genes Differentially
Expressed between Wild Type and IFN- -/- B6 Mice.
Wild type and IFN- -/- B6 mice were immunized with CII/CFA, and ten days later
lymphocytes were recovered from draining lymph nodes. These cells were used to
produce mRNA for use in a gene expression array. Selected differentially expressed
genes with immunological relevance to arthritis pathogenesis are shown. Data is
represented as the fold difference in gene expression of between cells from wild type and
IFN- -/- B6 mice. A. Markers of inflammation. B. Immune effector proteins. C. Joint
structural and remodeling enzymes. For all genes shown, p ≤ 0.05.
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mouse, chemokine (C-X-C motif) ligand 14 (CXCL14), IL-5, IL-12 , IL-12 , IL-15,
IL-18, and IL-18 binding protein (IL-18 BP) are all up regulated compared to the IFN- -/mouse. In the IFN- -/- mouse, the expression of chemokine like factor super family 3
(Cklfsf3), IL-17D, and interleukin 1 receptor accessory protein (IL-1RAP) are
upregulated in comparison to expression in the wild type mouse. Cell surface molecules
and receptors were also identified as differentially expressed between the two mouse
groups (Fig 4.2B). In the wild type mouse, TLR-3, TLR-7, Fc receptor high affinity 1
alpha polypeptide (Fc R1 ), interleukin 2 receptor alpha chain (IL-2R ), CD86 antigen,
and integrin alpha 4 were all upregulated in comparison to expression in the B6 IFN- -/cells.
A third set of genes that were differentially expressed between the two mouse
groups include markers of inflammation such as heat shock proteins (Fig. 4.3A), immune
effector molecules such as immunoglobulins (Fig 4.3B), or joint structural proteins or
remodeling enzymes (Fig 4.3C). In the wild type mouse, heat shock protein 8, cartilage
oligomeric matrix protein, chitinase 3 like 4, and mast cell protease 4 and 5 are
overexpressed compared to the IFN- -/- mouse. In the IFN- -/- mouse, heat shock protein
1A, Ig heavy chain, defensin beta 9, chondroitan sulfate proteoglycan 2, phospholipase
A2 group VI, and the matrix metalloproteinases 15 and 19 are overexpressed over the
wild type mouse. These genes encode proteins that could affect arthritis pathogenesis at
several different levels including 1. The level of immune cell activation through altered
cytokine and regulatory molecule expression. 2. The level of immune effector function
via altered Ig expression. 3. The level of joint inflammation by disregulated joint
remodeling. Together, these changes could result in the disregulation of the immune
response that leads to development of autoimmune arthritis. One important consideration
in the analysis of these data is that both groups of mice were immunized with bovine CII
in Mtb containing CFA emulsion. So the wild type mouse is undergoing a normal
inflammatory response to the CFA, and one would expect to see inflammatory mediators
expressed in this mouse. In the wild type mouse, normal regulatory processes limit the
progression of the immune response so autoimmunity does not develop. In the IFN- -/mouse however, immune regulation is altered allowing the progression to the
autoimmune inflammatory disease, CIA.
Many of the genes identified by the expression array have been linked to the
development of RA or CIA (Table 4.1). When one examines the genes that are
overexpressed in the IFN- -/- mouse a pro-arthritogenic pattern emerges. In addition to
evidence of joint remodeling by the overexpression of such genes as chondroitan sulfate
proteoglycan 2, and the matrix metalloproteinases 15, and 19, two key cytokines with
immunomodulatory functions are identified as differentially expressed between the wild
type and IFN- -/- mouse. These include increased expression of the proinflammatory
cytokine IL-17 and the reduced expression of IL-18 and IL-18 BP in the IFN- -/- mouse.
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Table 4.1
The Role of Differentially Expressed Genes between Wild Type and
-/IFN- B6 Mice Immunized with CII/CFA in the Pathogenesis of RA and CIA.
Gene

Function

Arthritis Pathogenesis

Chemokine (C-X-C) Ligand 14

Cellular recruitment of
lymphocytes via CCR5

Expression upregulated in
spontaneous arthritis
models1

Chemokine like factor super
family 3

Cellular recruitment of
lymphocytes via CCR5

Increased gene copy
number increases risk of
RA development2

Interleukin 5

B cell growth and
differentiation3

Influences production of
autoantibodies via effects
on B cells

Interleukin 12

Promotes IFN- and Th1
cellular responses

Blockade inhibits severity
of CIA4

Interleukin 12

Promotes IFN- and Th1
cellular responses

Blockade inhibits severity
of CIA4

Interleukin 15

T cell proliferation and
homing, promotes
production of TNF-

Present in RA synovial
fluid5
Overexpression
exacerbates CIA6

Interleukin 17 D

Proinflammatory cytokine IL-17 family members
promotes expression of
linked to synovial
IL-6, IL-8, GM-CSF, IL- destruction in RA7, 8
1 , TGF , TNF- , and
PGE2

Interleukin 18

Proinflammatory cytokine
induces production of
TNF- , GM-CSF, IFNby synovial membrane

Induces expression of
proinflammatory
cytokines in RA
synovium9

Interleukin 1 receptor accessory
protein

Stabilizes binding of IL-1
to its receptor

Inhibits CIA by
scavenging IL-110

Interleukin 18 binding protein

Binds and inhibits activity Binds and inhibits activity
of IL-18
of IL-1811, 12
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Table 4.1

(continued).
Gene

Function

Arthritis Pathogenesis

TLR 3

Pattern recognition
receptor for dsRNA
induces NF- B and Type
1 Interferons

Immune signaling and
activation, may promote
expression of
proinflammatory
cytokines in RA11, 13

TLR 7

Pattern recognition
receptor for ssRNA

Immune signaling and
activation, may promote
expression of
proinflammatory
cytokines in RA13

Fc Receptor, IgE high affinity 1, Mast cell activation
alpha peptide

Immune cell activation
and inflammation

Fc Receptor, IgE high affinity 1, Mast cell activation
alpha peptide

Immune cell activation
and inflammation

Interleukin 2 receptor alpha
chain

Cellular receptor for IL-2
T cell growth,
differentiation, survival

T cell function

CD86 Antigen

CTLA4 ligand, dendritic
cell maturation marker

Upregulated in RA
synovium14
Blockade inhibits CIA15

Integrin alpha 4

Subunit of VLA-4
(VCAM-1 Receptor),
cellular localization

VCAM expression in RA
synovium is elevated
compared to normal16

Heat shock protein 1A, and 8

Indicators of cell stress
and inflammation

Marker of inflammation

Ig Heavy Chain (J558)

Immune effector
molecule

Autoantibody

Defensin beta 9

Cytotoxic and
microbiocidal peptide
produced by neutrophils

Defensin beta family
members mediate
articular cartilage
remodeling17
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Table 4.1

(continued).
Gene

Function

Arthritis Pathogenesis

Cartilage oligomeric matrix
protein

Cartilage Structural
protein

Marker of joint
remodeling

Chondroitin sulfate
proteoglycan 2

Cartilage Structural
protein

Marker of joint
remodeling

Mast Cell Protease 4

Chymase produced by
mast cells

Connective tissue
remodeling18

Mast Cell Protease 5

Chymase produced by
mast cells

Connective tissue
remodeling18, 19

Matrix Metalloproteinase 15

Remodeling enzyme

Synovial remodeling20

Matrix Metalloproteinase 19

Remodeling enzyme

Synovial remodeling20
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The Role of IL-18 and IL-18 BP
There is growing evidence that the interactions of IL-18 and IL-18 BP may play a
role in regulating the immune response that leads to the development of RA. IL-18 is a
proinflammatory cytokine that is in the IL-1 superfamily. Its expression is widespread,
being produced by monocytes, macrophages, articular chondrocytes, synovial fibroblasts,
and osteoblasts (132). Once activated by caspase-1 dependent cleavage from its
precursor form, it functions to promote the production of proinflammatory cytokines in
the joint synovium including IFN- , GM-CSF, IL-1 and TNF- . The production of
these cytokines is potentiated by the coexpression of IL-12 and IL-15 (120, 133). In RA,
IL-18 expression has been detected in the synovial compartment and tissues of patients
afflicted with RA (132, 134). In CIA-susceptible mouse strains such as DBA1,
neutralization of IL-18 by the use of anti-IL-18 monoclonal antibodies, or through the use
of IL-18 BP reduces the clinical scores of arthritis severity (135).
IL-18 BP is a soluble glycoprotein produced largely by monocytes that forms part
of a feedback regulatory circuit that modulates the activity of IL-18. Two biologically
active isoforms of IL-18 BP, IL-18 BPc and IL-18 BPd, are produced in mouse with IL18 BPd having the most potent activity. In culture, when IL-18 BP is present at an
equimolar concentration with IL-18, the IFN- inducing activity of IL-18 on NKO cells
(an NK cell line) stimulated with IL-12 and IL-18 is reduced by 95 percent (136). IL-18
has also been shown to promote the production of IFN- by Th1 cells (137). Since IL-18
BP inhibits IL-18 signaling, this results in feedback inhibition of IL-18 activity.
Increased IL-18 signaling causes increased IFN- production, which then causes
increased IL-18 BP production. IL-18 BP then “feeds back” to reduce IL-18 activity. In
the IFN- -/- mouse, there is no production of IFN- . The result of this is reduced
production of IL-18 BP and therefore increased levels of free IL-18 available for binding
to its receptor. Reduction of IL-18 BP production in the absence of IFN- was
experimentally observed in the gene expression array of wild type B6 versus IFN- -/mice. Expression of IL-18 BP is reduced in the IFN- -/- mouse. Its expression is over
seven fold lower in the IFN- -/- mouse than in the wild type. Since IL-18 BP expression
is induced by IFN- , and IL-18 is known to contribute to or modulate the pathogenesis of
RA and CIA, decreased expression of IL-18 BP due the absence of IFN- in the IFN- -/mouse results in increased levels of free IL-18 available for signaling, and thus increasing
its activity. Increased activity of IL-18 would increase expression of proinflammatory
cytokines such as TNF- and GM-CSF following immunization with CII, and potentially
contributing to CIA susceptibility in the IFN- -/- mouse.
IFN- and IL-17 Activity
A strongly proinflammatory family of cytokines has been identified as a critical
pathway in the development of chronic autoimmune arthritis. These cytokines include
the six IL-17 family members, IL-17 A-F. IL-17A and IL-17F are produced by Th17
cells. Th17 response is distinguished from proinflammatory Th1 response by the absence
of production of IFN- , T-bet, or GATA-3. Th17 cell differentiation can be induced in
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culture by the addition of the cytokines IL-6, and TGF when naïve T cells are stimulated
with LPS, and in addition to the production of IL-17, Th17 cells also produce the
proinflammatory cytokines IL-6, TNF- , and GM-CSF. IL-17 family members exhibit
multiple immune regulatory functions via induction of cytokine production in multiple
cell types including fibroblasts, endothelial cells, epithelial cells, keratinocytes, and
macrophages. These cells produce the cytokines IL-6, IL-8, G-CSF, GM-CSF, IL-1 ,
TGF and TNF- and the inflammatory mediator PGE2 in response to IL-17 ligation.
All of which have been implicated in the pathogenesis of RA. IL-17D was identified as
overexpressed in the IFN- -/- B6 mouse by the gene expression array (Fig 4.2A).
Interestingly, though IL-17 family members are known to be associated with RA, IL-17D
is preferentially expressed in skeletal muscle and nervous tissue and not previously
associated with arthritis (138).
Expression of IL-18 and IL-17 Regulated Genes
Based on their known proinflammatory function, increases in the expression of
IL-18 and IL-17 are likely linked to the increased susceptibility of CIA in the IFN- -/mouse. To reinforce the expression array data and to further examine the functional
changes that occur in the autoimmune response due to the absence of IFN- , the
expression of specific immune related genes was measured via real time PCR using two
approaches. First, a traditional real time PCR using probes selected on their basis of IL18 and IL-17 signaling or arthritis relevance was used to confirm the expression level of
select genes identified from the microarray data. Second, a real time PCR array focused
on a panel of immune response genes was used to quantify the expression of 90 genes
that effect or regulate immune function. These assays serve a two-fold purpose. They
double check the expression data of the expression array, and also measure the expression
of cytokines downstream of IL-18 and IL-17 signaling.
Real Time PCR
Four wild type or IFN- -/- B6 mice were immunized with CII in an emulsion of
CFA and ten days later mRNA was isolated from cells from the draining lymph nodes.
Taqman real time PCR probes were used to measure the expression of IL-17A, IL-5,
IL-1 , IL-6, IL-4, GM-CSF, TGF 1, IL-18, TNF- , IL-15, IL-10, IL-12 , and IL-18 BP.
The difference in expression of the two mouse strains is reported as ct to indicate the
relative expression of mRNA between the two groups. To derive this value, the number
of cycles (ct) required for fluorescence to reach a predetermined threshold value is
normalized to the expression of a “housekeeping” gene that is assumed to be expressed
equally in all conditions. The mRNA expression level of structural proteins is often used
for this purpose, and the structural protein actin was used in these assays. Subtraction
of the housekeeping gene ct value from the ct value of the experimental is known as the
ct and represents a normalized expression value for the experimental gene. The ct
value from one experimental group is then subtracted from the ct of the other group
( ct). This value can be either positive or negative and represents the difference in
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cycle number between the two groups for a PCR reaction to reach the threshold
fluorescence value. Based on the design of the data analysis, a negative ct value
indicates higher expression in the IFN- -/- while a positive value indicates higher
expression in the wild type. The ct value grows exponentially, doubling with each cycle
of the PCR reaction. For this reason, 2 raised to the power of - ct is the fold difference
in expression between the two groups for a given gene. In this assay, IL-17A, IL-5,
IL-1 , IL-6, IL-4, and GM-CSF were all expressed higher in the IFN- -/- than in the wild
type (Fig 4.4). Conversely, in the wild type, IL-15, IL-10, IL-12 , and IL-18 BP were
overexpressed compared to the IFN- -/- B6 group. TGF , IL-18, and TNF- were
expressed at similar levels in both mouse groups. These data indicate that in the IFN- -/there is an increase in proinflammatory cytokines, IL-17, IL-6, and IL-1 , were expressed
at high levels in the IFN- -/- mice. In addition, IL-18 BP, which negatively regulates the
proinflammatory cytokine IL-18, has reduced expression in the IFN- -/- mice. Therefore,
the absence of IFN- potentially mediates CIA susceptibility in IFN- -/- mice by
promoting proinflammatory cytokine expression, an effect that may in part be a result of
decreased production of IL-18 BP.
Microfluidics Real Time PCR
A real time PCR array was used to analyze the difference in expression of a
focused set of immune response genes in lymphocytes from CII-immunized wild type
and IFN- -/- mice. In this assay, a microfluidics plate that measures the expression of 90
immune related genes that include cytokines, chemokines, immune regulators, growth
factors, and inflammatory markers was used. This approach expands the analysis of
immune response gene expression in a quantitative manner. As in the gene expression
array and the previous real time PCR assay, mRNA was purified from lymphocytes
obtained from wild type or IFN- -/- B6 mice 10 days following immunization with
CII/CFA. This mRNA was then examined for quality and them converted to cDNA for
use in the real time PCR assay. While the expression of most of the genes were not
statistically different between the two groups of cells, several proinflammatory cytokines
were found to be expressed at a significantly higher level in lymphocytes derived from
the B6 IFN- -/- mice. IL-15, IL-17A, IL-18, IL-1 , and TGF were all found to be
upregulated in the B6 IFN- -/- mice (Fig 4.5). In addition, two genes, CXCR3 and Gzmb,
were differentially expressed between wild type and IFN- -/- B6 mice with a statistical
significance of p < 0.05. CXCR3 is a chemokine receptor that binds, interferon inducible
T cell- chemoattractant (CXCL11), interferon-inducible protein 10 (CXCL10), and
monokine induced by -interferon (CXCL9) (139). This receptor mediates lymphocyte
migration and is preferentially expressed on Th1 cells and NK cells (140, 141). Gzmb is
a serine protease expressed by Tc cells and NK cells and is part of their complement of
effector proteins that mediate targeted cell death (142, 143).
The two real time PCR assays reinforce the concept developed from the gene
expression array that in the absence of IFN- a proinflammatory state is induced. This
state appears to be largely mediated by the upregulated expression of proinflammatory
cytokines. In the IFN- -/- mice there is increased production of IL-17, IL-1 , IL-6,
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Figure 4.4
Differential Expression of Cytokine Genes between Wild Type and
-/IFN- B6 Mice Immunized with CII/CFA.
Wild type or IFN- -/- B6 mice were immunized with CII/CFA emulsion and lymphocytes
were recovered from the draining popliteal lymph nodes ten days later. mRNA was
isolated from these cells and used to perform Real Time PCR analysis of cytokine gene
expression. Data is represented as the ct of IFN- -/- minus wild type, and represents
the difference in cycle times between the wild type and IFN- -/- required to reach a
threshold value of PCR amplification. Positive values indicate higher gene expression in
the wild type cells while negative values indicate higher expression in the IFN- -/- derived
cells. In the IFN- -/- derived lymphocytes, expression of IL-17A, IL-5, IL-1 , IL-6, IL-4,
and GM-CSF mRNA was higher than in the wild type cells. TNF- , IL-15, IL-10, IL12 and IL-18 BP mRNA expression was higher in the wild type B6 cells. (*p < 0.05)
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Figure 4.5
Differential Expression between Wild Type and IFN- -/- B6 Mice
Immunized with CII/CFA Measured by Immune Panel Real Time PCR Array.
mRNA was prepared from lymphocytes recovered from the draining lymph nodes of wild
type or IFN- -/- B6 mice 10 days following immunization with CII/CFA. This mRNA
was converted to cDNA for use in a microfluidics based real time PCR assay of immune
related genes. Most genes were not significantly differentially expressed between the
wild type and IFN- -/- derived cells, but increased expression of several proinflammatory
cytokines occurred in IFN- -/- derived cells. These cytokines include: IL-15, IL-17A, IL1 , IL-1 , and TGF . (*p ≤ 0.05)
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GM-CSF, and TGF . Each of these cytokines has been linked to arthritis development in
CIA, and their upregulation in the absence of IFN- likely contributes to arthritis
susceptibility in the IFN- -/- B6 mice. Of specific interest, the real time PCR data also
supports a role for IFN- ’s regulation of IL-18 and IL-18 BP signaling in the
pathogenesis of CIA. The gene expression array, and the real time PCR indicated that
IL-18 expression was slightly higher in wild type compared to IFN- -/- cells, and these
data were supported by the microfluidics real time PCR data but that difference was not
statistically significant. Similarly, the production of IL-18 in stimulated wild type and
IFN- -/- cells in culture was found to be similar when measured by ELISA (Fig 3.8). In
contrast, the expression of IL-18 BP was significantly higher in wild type B6 mice (Fig
4.4). In the gene expression array and the real time PCR analysis, the expression of
IL-18 BP was found to be significantly upregulated in the wild type cells as compared to
the B6 IFN- -/-. Thus, one of the roles of IFN- appears to be regulation of IL-18 BP
expression. The net effect in the B6 IFN- -/- model appears to be that in the absence of
IFN- , the function of IL-18 is left unregulated due to the absence of IL-18 BP,
conferring susceptibility to CIA.
Modification of Disease Activity by Exogenous IL-18 Binding Protein
The expression data obtained via the real time PCR supports the concept that
IL-18 BP is playing a protective role in the development of arthritis in the wild type B6
mouse. In the wild type mouse, expression of IL-18 BP was elevated over that of the
IFN- -/- mouse, and several cytokines downstream of IL-18 signaling were seen to be
elevated in the IFN- -/- mice including IL-1 , GM-CSF, and TGF 1. If the low
expression of IL-18 BP in the IFN- -/- is permissive to the development of CIA and
negative regulation of IL-18 in the wild type mediated by IL-18 BP protects from the
development of CIA, then exogenous administration of IL-18 BP to the IFN- -/- strain
should reduce the incidence or severity of CIA in the IFN- -/-.
To test this concept, IFN- -/- B6 mice were injected intraperitoneally with either 1
mg of recombinant murine IL-18 BPd in 200 l PBS or with 200 l PBS every 24 hours
for 10 days. On the second day of this regimen, all mice were immunized with CII/CFA
to induce CIA. The development of arthritis in each group was monitored and scored for
disease incidence and severity. In the IFN- -/- B6 mice treated with IL-18 BPd, only 13%
of the mice developed arthritis (Fig 4.6A). The development of arthritis in the treatment
group was also delayed until day 40 following immunization with CII. In the control
mice, treated with PBS, arthritis incidence was significantly higher (p < 0.01), occurring
in 63% of the mice, and developed 22 days earlier (day 18) than in the IL-18 BPd treated
mice (Fig 4.6AB). There was also a marked difference in the severity of arthritis
observed in the PBS control mice in comparison to the mice treated with IL-18 BPd. In
the PBS treated mice the highest severity score observed was 15 out of a possible 16, and
for all mice averaged 8.8 out of 16. In the group treated with IL-18 BPd, arthritis severity
was significantly lower than in the PBS control group, with the highest severity score
reached being 4 out of 16, and the inflammation was short lived (Fig 4.6C, 4.7A).
Arthritis severity as judged by the number of arthritic limbs was also significantly lower
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Figure 4.6
Administration of IL-18 BP to B6 IFN- -/- Mice Protects against CIA.
-/B6 IFN- mice were injected intraperitoneally with 200 µg of recombinant IL-18 BPd
or PBS as a negative control daily for 10 days. On the second day of this regimen the
mice were immunized with CII/CFA emulsion in the tail to induce CIA. The mice were
then observed for arthritis development and severity. A. Total incidence of arthritis in
control PBS (n = 10) treated B6 IFN- -/- (n = 9) mice is 63% compared to 13% in IL-18
BP treated mice. In the IL-18 BP treated mice, arthritis arises at a delayed time point
following immunization with CII/CFA starting on day 40 compared to day 18 in control
mice. B. In IL-18 BP treated mice severity per arthritic mouse is approximately half that
of the control mice, 8 in IL-18 BP treated mice versus 4 in control mice. C. The
dynamics of arthritis were also altered. The PBS control mice exhibited a prolonged
active disease period while IL-18 BP treated mice only exhibiting a brief flare of
inflammation that quickly subsided over 2-3 days. (*p < 0.01)

76

16

A.

Severity

12

8

4

0

PBS

IL-18 BPd

Treatment Group

Number of Limbs

4

B.

3

2

1

0

PBS

IL-18 BPd

Treatment Group
Figure 4.7
In IFN- -/- B6 Mice, Severity and Limb Involvement of CIA Are
Reduced Following Treatment with IL-18 BP.
10 B6 IFN- -/- mice were injected intraperitoneally with 200 µg of recombinant IL-18
BPd or PBS as a negative control daily for 10 days. On the second day of this regimen
the mice were immunized with CII/CFA emulsion in the tail to induce CIA. A. The
average highest severity was 8.8 out of a maximum 16 in the PBS control mice while in
the IL-18 BP treated mice the lone arthritic mouse developed arthritis with a severity of
4. B. The number of limbs affected with arthritis among arthritic mice averaged 2.6 in
the PBS group and 1 in the IL-18 BPd treated mice.
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in the IL-18 BPd treated group. The number of limbs in each group that were affected
with arthritis averaged 2.6 in the PBS control group and 1.0 in the IL-18 BPd treated
group (Fig 4.7B). Thus, treatment with IL-18 BPd protects IFN- -/- B6 mice from the
development of CIA, delays the onset, and reduces the severity.
To more clearly understand the pro-arthritogenic effects of IL-18 in the
development of CIA, wild type B6 mice were treated with exogenous IL-18 and
immunized with CII in CFA emulsion. In an experiment similar to the administration of
IL-18 BPd, wild type B6 mice were injected intraperitoneally with either 200 g
recombinant murine IL-18 in 200 l PBS or with PBS alone every 24 hours for 10 days.
On day two following the first injection with IL-18 or PBS, the mice were immunized
with CII/CFA emulsion and monitored for the development of arthritis. When treated
with IL-18 or PBS, none of the wild type B6 mice developed arthritis (data not shown).
While it is difficult to make a conclusion from these negative results, two likely
explanations seem plausible. First, IL-18 alone may not be sufficient to confer
susceptibility in the B6 mouse. Other factors upstream of IL-18 upregulation may be
required. Second, production of IFN- is not impaired in the B6 mouse, and the gene
expression data indicates that IL-18 BP is produced at high levels compared to the
IFN- -/- B6 mouse. The negative feedback pathway that regulates IL-18 activity (IL-18
promotes IFN- production, which in turn promotes IL-18 BP production) may increase
levels of IL-18 BP in order to neutralize the extra, exogenously administered IL-18. The
self-regulating nature of the normal immune system in the wild type B6 mouse may be
capable of mitigating the effects of the extra proinflammatory signal and thus avoids
autoimmunity.

Alterations in Function Due to Cytokine Regulation by IL-18, IL-17, and
IFNAlterations in Proliferative Response
The gene expression data and the protection from arthritis by IL-18 BPd, indicates
a role for IL-18, IL-18 BP, and IL-17 downstream of IFN- regulation of CIA
pathogenesis. Studies by others have indicated a T cell proliferative defect in IFN- -/mice (65). Disregulated proliferation of T cells in the absence of IFN- -/- has been
implicated as a potential pathogenic mechanism in autoimmune models of CIA and EAE.
Baseline proliferation of lymph node cells either in the absence of antigen stimulation or
T cell proliferation following immunization with antigen and stimulation in culture with
either CII, Mog(35-55) or microbial antigens is increased in cells from IFN- -/- B6
compared to wild type cells (65, 144-146). Both IL-18 and IL-17 have proinflammatory
functions that support the differentiation and expansion of many immune cell types
including T cells, NK cell, and monocytes/macrophages, either by acting directly on
target cells, or through induction of other proinflammatory cytokines (120, 137, 147,
148). Since the actions of these cytokines are regulated by IFN- , increased proliferation
observed in cells from IFN- -/- mice may be due to the activity of IL-18 or IL-17.
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To test this concept, exogenous IL-18, IL-18 BPd, IFN- , and IL-17 was added to
cultures of splenocytes from either naive wild type or IFN- -/- B6 mice, and proliferation
in response to anti-CD3 and anti-CD28 stimulation was measured by 3H-thymidine
incorporation. In control cultures without exogenous cytokine, the proliferation in
response to anti-CD3 and anti-CD28 stimulation was greatly increased in the IFN- -/cells compared to the wild type (Fig 4.8A). Proliferation in the IFN- -/- cells was 122,000
± 3000 DPM versus 31,000 ± 5,000 DPM in the wild type, clearly indicating an enhanced
proliferative state in the IFN- -/- cells (p < 0.05). The cells were then stimulated with
anti-CD3 and anti-CD28 antibodies in the presence of 5 g/ml IL-18 BPd, 6 ng/ml IFN- ,
240 ng/ml IL-18, or 8 ng/ml IL-17 (Fig 4.8B). To illustrate the differential effect of these
cytokines on the proliferative response of cells from wild type or IFN- -/- B6 mice, the
proliferation in each culture condition was normalized to the proliferation observed in the
control cultures, and is displayed as the percentage of the control. The addition of
exogenous cytokines affected the proliferation of wild type cells to a greater extent than
the IFN- -/- derived cells. In the wild type, the addition of IL-18 enhanced the
proliferative response to 284 ± 41% of the control cell response (p < 0.05). In the IFN- -/cells, proliferation was 120 ± 1% of the control (p < 0.05). When IL-18 BPd was added
to the cell cultures, there was a large suppressive effect on proliferation in the wild type
cells, but not in the IFN- -/- derived cells. The wild type cells proliferated at only 50 ±
5% of the control. The wild type cells stimulated with IL-17 did not proliferate more
than control cells while in the IFN- -/- derived cells proliferation was slightly higher, 110
± 5% of the control (p < 0.05). The addition of IFN- significantly suppressed IFN- -/derived cell proliferation (p < 0.05), but not wild type cells. While statistically
significant, the small changes in proliferation observed in the IFN- -/- derived cells when
co-cultured with IFN- or IL-17 may not be biologically significant given the greatly
increased proliferative response observed when these cells were stimulated with anti-CD3
and anti-CD28 alone. These data indicate that IL-18 has strong pro-proliferative effects
on T cells, with IL-18 strongly supporting proliferation of T cells from wild type B6 mice
and to a lesser extent in IFN- -/- cells. In wild type cells, this pro-proliferative effect of
IL-18 is regulated by IL-18 BP, indicated by the suppression of proliferation when extra
exogenous IL-18 BPd is added. In IFN- -/- derived cells, addition of IL-18 BPd is less
effective in inhibition of proliferative response to anti-CD3 and anti-CD28 stimulation.
This is perhaps due to reduced endogenous IL-18 BP production, or is an indication that
proliferation on these cells is supported by the action of other proinflammatory cytokines
in addition to IL-18 such as IL-17, TNF- , IL-1 , or GM-CSF, all of which have been
shown to be increased in IFN- -/- cells following stimulation (Fig. 3.8). Since expression
of IL-18 BP is mediated by IFN- and as indicated here, IL-18 BP regulates T cell
proliferative responses in wild type mice, this data reinforces the concept that IFN- is a
regulator of autoimmune development, and one mechanism of this regulation may be by
the inhibition of T cell proliferation.
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Figure 4.8
Exogenous Administration of Proinflammatory Cytokines or IL-18
BP Alters the Proliferative Response of Splenocytes from Both Wild Type and IFN-/B6 Mice When Stimulated in Culture with Anti-CD3 and Anti-CD28.
Splenocytes from naïve B6 or B6 IFN- -/- mice were stimulated in culture with anti-CD3
and anti-CD28 monoclonal antibodies in the presence of exogenous IL-18 BPd (5 µg/ml),
IFN- (6 ng/ml), IL-18 (240 ng/ml), and IL-17 (8 ng/ml). Proliferation was measured by
3
H-thymidine incorporation. A. When stimulated with anti-CD3 and anti-CD28
splenocytes from B6 IFN- -/- mice proliferated to a greater extent than wild type B6
derived cells. B6 IFN- -/- splenocytes proliferated four fold more than the B6 wild type
derived cells. B. In order to measure the effect of exogenously added IL-18 BPd, IFN- ,
IL-18, and IL-17 on the proliferative response of splenocytes from wild type IFN- -/- B6
mice, proliferation in the presence of each cytokine and IL-18 BPd was normalized to the
proliferation observed without exogenous cytokine or IL-18 BPd. This allows
comparison of alterations in proliferative response in each culture condition, and
comparison of the relative effect on proliferation between the wild type and IFN- -/- B6
derived splenocytes. In the wild type B6 derived cells addition of IL-18 or IL-18 BP,
increased or decreased proliferative response, respectively. In the IFN- -/- B6 derived
cells, there were minor alterations in proliferative response when IL-18, IL-18 BP, IFN- ,
or IL-17 were added. IL-18, and IL-17 significantly promoted increased proliferation in
the IFN- -/-derived cells while IFN- significantly reduced proliferative response.
However, these changes are small compared to the high proliferation observed without
exogenous addition of cytokines and may not be biologically relevant. (*p < 0.05)
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Alterations in Cytokine Production
One key concept in understanding cytokine regulation of immune function is that
cytokines do not operate independently, but in cytokine networks that consist of both
stimulatory and inhibitory signals, the balance of which determines the ultimate outcome
in terms of cell differentiation, function, and immune response. To better understand
how cytokine networks that are permissive to autoimmunity develop in the IFN- -/- mice
cytokine production by T cells from wild type and IFN- -/- B6 mice were measured.
Splenocytes from naïve wild type or IFN- -/- B6 mice were stimulated in culture for three
days with anti-CD3 and anti-CD28 and supernatants were analyzed for cytokine
expression using a multiplexed ELISA. Cytokines that were shown to have differential
expression between wild type and IFN- -/- B6 mice in the above gene expression and
cellular assays were selected based on whether or not their expression is stimulated by
IFN- , IL-18, or IL-17, and their relevance to CIA pathogenesis. To assess the role of
IFN- , IL-18, and IL-17 on the production of these cytokines in the stimulated
splenocytes from wild type and IFN- -/- B6, exogenous recombinant IFN- , IL-18, IL-17
and IL-18 BPd was titrated at concentrations spanning their effective dose in culture.
When the concentration of cytokines produced by the stimulated cells was examined it
was noted that in the wild type cells there was a dearth of cytokine production following
stimulation. Only IFN- was produced at high levels (Fig 4.9AC). This was in contrast
to the production of cytokines in the stimulated IFN- -/- cells. In these cells there was
increased production of IL-2, GM-CSF, IL-13, IL-4, IL-17, IL-5, TNF- , M-CSF, IL-6,
and IL-1 with anti-CD3 and anti-CD28 stimulation only (Fig 4.9BD). When exogenous
cytokines were added to the cell cultures many modulating effects on cytokine production
were noted. The addition of IL-18 BPd had contradictory effects on cytokine production
in both wild type and IFN- -/- cells. In the wild type T cells, both IFN- and IL-17
expression increased with the addition of IL-18 BPd (Fig 4.9AC). In the IFN- -/- cell
cultures, titration with IL-18 BP promoted increased production of IL-2, GM-CSF, IL-13,
IL-4, IL-17, TNF- , IL-5, IL-6, and IL-1 (Fig 4.9BD). IL-18 had potent effects on
cytokine production in both wild type and IFN- -/- derived cells. Treatment of wild type
derived cells in culture with IL-18 promoted increased production of IFN- , GM-CSF,
IL-13, IL-4, IL-2, IL-17, TNF- , IL-6, IL-1 , IL-5, and M-CSF (Fig 4.10AC). In the
IFN- -/- derived cells, stimulation with IL-18 promoted increased production of IL-13,
GM-CSF, IL-17, and IL-5 (Fig 4.10BD). The addition of IL-17 to wild type cell
promoted increased TNF- production (Fig 4.11AC). In the IFN- -/- culture, addition of
IL-17 caused increases in the expression of IL-13, IL-4, and TNF- (Fig 4.11CD).
Addition of IFN- had minimal effects on the wild type cultures causing increased
expression of only IL-17 (Fig 4.12AC), but in the IFN- -/- derived cell cultures, there was
a dampening effect on cytokine production inhibiting the production of all cytokines
measured (Fig 4.12BD). These data illustrate the complex effects of IL-18, IL-17, and
IFN- on the development of cytokine networks. IL-18 has potent effects on the
production of proinflammatory cytokines in both the wild type and IFN- -/- cultures
which is consistent with a role for IL-18 and IL-18 BP in the regulation of CIA
pathogenesis. IL-17 has less of a role in the stimulation of cytokines and seemed to
potentiate cytokine production in the IFN- -/- rather than have strong inductive effects.
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Figure 4.9
Modification of Lymphocyte Cytokine Expression by IL-18 BPd in
Lymphocyte Cultures Stimulated with Anti-CD3 and Anti-CD28.
Splenocytes from naïve B6 and B6 IFN- -/- mice were stimulated in culture with antiCD3 and anti-CD28 monoclonal antibodies in the presence of IL-18 BPd titrated over its
effective dose. AC. There was decreased production of cytokines in stimulated wild
type derived cells compared to IFN- -/- derived cells with only IFN- produced at high
levels in the wild type cells. When stimulated with anti-CD3/CD28 in the presence of IL18 BPd increased production of IFN- and IL-17 was observed. BD. Conversely, antiCD3/CD28 stimulation of IFN- -/- derived cells resulted in increased production of IL-2,
GM-CSF, IL-13, IL-4, IL-17, TNF- , IL-5, M-CSF, IL-6, and IL-1 when compared to
the wild type cells. Titration with IL-18 BP promoted increased production of IL-2, GMCSF, IL-13, IL-4, IL-17, TNF- , IL-5, IL-6, and IL-1 .
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Figure 4.10 Modification of Lymphocyte Cytokine Expression by IL-18 in
Lymphocyte Cultures Stimulated with Anti-CD3 and Anti-CD28.
Splenocytes from naïve B6 and B6 IFN- -/- mice were stimulated in culture with antiCD3 and anti-CD28 monoclonal antibodies in the presence of IL-18 titrated over its
effective dose. AC. Treatment of wild type derived cells in culture with IL-18 promoted
increased production of IFN- , GM-CSF, IL-13, IL-4, IL-2, IL-17, TNF- , IL-6, IL-1 ,
IL-5, and M-CSF. BD. In the IFN- -/- derived cells, stimulation with IL-18 promoted
increased production of IL-13, GM-CSF, IL-17, and IL-5. The expression of IL-4, MCSF, TNF- , IL-6, and IL-1 were unaffected, yet were produced at high levels when
compared to the wild type derived cells.
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Figure 4.11 Modification of Lymphocyte Cytokine Expression by IL-17 in
Lymphocyte Cultures Stimulated with Anti-CD3 and Anti-CD28.
Splenocytes from naïve B6 and B6 IFN- -/- mice were stimulated in culture with antiCD3 and anti-CD28 monoclonal antibodies in the presence of IL-17 titrated over its
effective dose. AC. When wild type derived cells were stimulated with anti-CD3/CD28
in the presence of IL-17, only increased production of TNF- was observed. BD.
Addition of IL-17 to IFN- derived cells promoted increased production of IL-13, IL-4,
and TNF- .
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Figure 4.12 Modification of Lymphocyte Cytokine Expression by IFN- in
Lymphocyte Cultures Stimulated with Anti-CD3 and Anti-CD28.
Splenocytes from naïve B6 and B6 IFN- -/- mice were stimulated in culture with antiCD3 and anti-CD28 monoclonal antibodies in the presence of IFN- titrated over its
effective dose. AC. In wild type derived cells, most cytokines were unaffected by the
addition of IFN- , however, decreased production of TNF- , and increased production of
IL-17 was observed. BD. Addition of IFN- to stimulated cells derived from IFN- -/mice had inhibitory effects on cytokine production. Production of all cytokines measured
decreased as IFN- was added to the cultures.
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These data also illustrate the role of IFN- as a regulatory cytokine. This suppressive
effect of IFN- on the production of proinflammatory cytokines in the IFN- -/- culture
indicates that suppression of proinflammatory cytokine production may be one
mechanism by which IFN- protects against the development of CIA in wild type B6
mice.

Discussion
In these studies we sought to identify a mechanism for alterations in the cytokine
milieu mediated by IFN- that regulate a pathogenic immune response that leads to
autoimmunity. To identify this mechanism, alterations in the gene expression and
functional markers of immune response between wild type and IFN- -/- B6 mice
immunized with CII were investigated in order to identify potential autoimmune
mediators that develop as a result of IFN- deficiency. These studies identified a number
of genes whose expression was altered by the absence of IFN- . Among these genes, a
specific cytokine signaling pathway, IFN- ’s regulation of IL-18 BP expression, was
identified as an important mediator of the pathogenesis of autoimmune arthritis. IL-18
BP expression was reduced in the IFN- -/- mouse and was shown to protect from the
development of CIA. In addition, the production of proinflammatory cytokines is
increased in the absence of IFN- , resulting in altered T cell effector function that
potentially promotes susceptibility to autoimmune arthritis in IFN- -/- B6 mice.
The expression of genes that are regulated by IFN- , and that contribute to
arthritis pathogenesis during the development of CIA, were identified by comparing
mRNA expression in lymphocytes obtained from wild type and IFN- -/- B6 mice
immunized with CII/CFA. The use of a gene expression array identified 1612 genes
expressed at statistically significant distinct levels between the two strains of mice. This
is nearly 5% of the 34,000 genes measured, and indicates that IFN- plays a major role in
regulating gene expression during the initial immune response to CII. The gene
expression array provided a starting point to uncover the pathogenic mechanisms that
lead to autoimmunity in the IFN- -/- B6 mouse. A number of genes that are directly
related to immune function were differentially expressed between the wild type and
IFN- -/- mice, including cytokines and chemokines, immune cell receptors, and tissue
remodeling genes that possibly contribute to joint destruction during active inflammation.
However, while only IFN- -/- B6 mice are susceptible to CIA, it is important to note that
the wild type mouse was also immunized with CII/CFA. Even without the CII
component, CFA is strongly immunogenic. The Mtb present in CFA stimulates Th1
responses, while the paraffin oil stimulates innate immune mechanisms (149). The strong
IFN- response to the Mtb in the wild type mouse may explain the increased expression
in these mice of several cytokines including IL-5, IL-12, and the immune receptors TLR
3 and TLR 7. However, when one examines the genes that are differentially expressed in
the IFN- -/- mouse, a pro-arthritogenic pattern of gene expression emerges, and many of
the genes identified by the expression array have been linked to the development of RA
or CIA. In the IFN- -/- mice, these differentially expressed genes include increased
expression of the cell trafficking molecule Clfsf3 whose expression has been linked to
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increased risk of RA (113). In addition, evidence of increased joint remodeling in
IFN- -/- mice is observed in the overexpression of genes including chondroitan sulfate
proteoglycan 2, and the matrix metalloproteinases 15, and 19. Additionally, two
cytokines with immunomodulatory functions are identified as differentially expressed
between the wild type and IFN- -/- mouse. These include increased expression of the
proinflammatory cytokine IL-17 and the reduced expression of IL-18 BP in the IFN- -/mouse.
The expression of both IL-18 and IL-17 has been linked to the development of
autoimmunity in both human and rodent models (22, 120, 150). Based on their known
proinflammatory function, increases in the expression of IL-18 and IL-17 are likely
linked to the increased susceptibility of CIA in the IFN- -/- mouse. Therefore, to further
examine the functional changes that occur in the autoimmune response due to the absence
of IFN- , the expression of specific immune related genes was quantitated using real time
PCR. These data indicated that in the absence of IFN- there is upregulated expression of
the proinflammatory cytokines IL-17, IL-1 , IL-6, GM-CSF, and TGF . Each of these
cytokines had been linked to arthritis development in CIA, and their upregulation is
consistent with the concept that the absence of IFN- , a proinflammatory phenotype is
created that mediates arthritis susceptibility in the IFN- -/- B6 mice. The real time PCR
data also supports a role for IFN- regulation of IL-18 and IL-18 BP signaling in the
pathogenesis of CIA, as the expression of IL-18 BP was significantly higher in wild type
B6 mice that are resistant to CIA. IL-18 BP forms part of a feedback regulatory circuit
that modulates the activity of IL-18 (151). Increased IL-18 signaling causes increased
IFN- production, which then promotes increased IL-18 BP production. IL-18 BP then
binds to IL-18 and prevents its signaling through the IL-18 receptor. IFN- regulation of
IL-18 BP makes sense as a regulator of autoimmune pathogenesis in CIA. Since in the
IFN- -/- mouse there is no production of IFN- , the result of this is reduced production of
IL-18 BP and therefore increased levels of free IL-18 available for binding to its receptor.
IL-18 BP expression is induced by IFN- , and IL-18 is known to contribute to or
modulate the pathogenesis of RA and CIA, decreased expression of IL-18 BP due to the
absence of IFN- in the IFN- -/- mouse results in increased levels of free IL-18 available
for signaling, thus increasing its activity and promoting the development of autoimmunity
in IFN- -/- B6 mice. In order to test this concept that IFN- ’s regulation of IL-18 BP
mediates arthritis pathogenesis, the development of CIA was monitored in wild type or
IFN- -/- B6 mice immunized with CII and treated with exogenous IL-18 BP. When
treated with exogenous IL-18 BP, IFN- -/- B6 mice were protected from the development
of CIA with reduction in both the incidence and severity of arthritis. These results
confirm that IL-18 BP plays a significant role in promoting the development of CIA in
IFN- -/- B6 mice.
Having identified IL-18 BP and implicating the expression of proinflammatory
cytokines including IL-17 as mediators of autoimmune arthritis in the IFN- -/- mouse, we
next sought to identify functional mechanisms by which IL-18/IL-18 BP and IL-17 alter
immune response to promote autoimmunity. To do this, we examined the functional
responses of stimulated T cells from wild type and IFN- -/- B6 mice in terms of altered

87

proliferative and cytokine production of T cells when stimulated with anti-CD3 and antiCD28 in culture and supplied with exogenous IL-17, IL-18, IFN- , and IL-18 BP.
Proliferation of T cells in response to stimulation with anti-CD3/CD28 was significantly
increased in the IFN- -/- cells when compared to the wild type and is consistent with
published data that the absence of IFN- expression induces a pro-proliferative state. The
most significant alteration in proliferation occurred when IL-18 or IL-18 BP was added to
the cultures of wild type cells. In these cultures addition of IL-18 significantly increased
proliferation in response to CD3/CD28 stimulation while the addition of IL-18 BP
inhibited proliferation in response to CD3/CD28 stimulation of wild type cells. In
IFN- -/- cells, proliferative responses to CD3/CD28 stimulation were also altered when
exogenous cytokine was added. When IFN- was added to the cultures, proliferative
responses were slightly inhibited, while IL-17 or IL-18 slightly enhanced the proliferative
response. However, though statistically significant, these small alterations may not be
biologically significant given the magnitude of proliferation observed in IFN- -/- cells in
response to CD3/CD28 stimulation. The alterations observed in the wild type cells when
co-cultured with IL-18 or IL-18 BP and the high proliferative response observed in the
IFN- -/- cells supports a role for proliferative defects mediated by IFN- and IL-18 as a
potential mechanism of arthritis susceptibility in IFN- -/- B6 mice. We propose that in
the IFN- -/- B6 mice, proliferation of T cells is disregulated, while in the wild type mice
proliferation is controlled, in part by the negative regulation of IL-18 signaling mediated
by IL-18 BP. Evidence of this regulation is the increased or reduced proliferation
observed when IL-18 or IL-18 BP, respectively, is added to T cell cultures. In the
IFN- -/- B6 there is reduced production of IL-18 BP that allows increased signaling of
IL-18 resulting in increased T cell proliferative responses.
One aspect of our hypothesis that IFN- regulates autoimmune susceptibility is
that in the absence of IFN- global alterations occur in the immune system milieu that
cause a pro-inflammatory phenotype mediated by cytokine signaling that regulates
susceptibility to autoimmunity. The previous studies described here have indicated that
proinflammatory cytokines are expressed at high levels in IFN- -/- mice and that IL-17
and IL-18 have particular importance in the regulation of autoimmunity. However, to
understand autoimmune pathogenesis it is important to consider that cytokines do not
operate independently of one another. Instead, immune and accessory cells produce
networks of cytokines that provide both stimulatory and inhibitory signals to immune
cells. The balance of these signals ultimately directs the final outcome of an immune
response. In order to identify how the absence of IFN- regulates these networks and to
characterize the role of IL-17 and IL-18 in this regulation, cytokine production by
lymphocytes from wild type or IFN- -/- B6 mice was measured in culture supernatants
following stimulation in culture with anti-CD3 and anti-CD28 antibodies. When
cytokine levels were measured in these cultures it was observed that the IFN- -/- derived
cells produced an abundance of cytokines when compared to the wild type derived cells
including those associated with both an inflammatory Th1 or Th17 response and those
associated with a Th2 response. This is consistent with our earlier observations that
cytokine production is upregulated in the IFN- -/- B6 mice following immunization with
CII/CFA. The most significant regulatory mechanism identified by this assay is the

88

influence of IL-18 on cytokine expression when added to wild type cell cultures
stimulated with anti-CD3/CD28 and the influence of exogenous IFN- when titrated in
cultures of IFN- -/- derived cells. IL-18 induces production of cytokines in the wild type
derived cells in a pattern that closely resembles the expression pattern of cytokines
produced by IFN- -/- derived cells, either with or without exogenous cytokine
administration. In addition, when IFN- is titrated in cultures of stimulated IFN- -/- cells
there is a inhibition of cytokine production. This result supports the concept that in the
IFN- -/- the development of a pro-arthritogenic cytokine network is mediated by
increased IL-18 signaling likely due to decreased production of IL-18 BP in the absence
of IFN- . Surprisingly, the addition of IL-17 did not seem to greatly alter cytokine
production. IL-17 induced only minor increases in cytokine production in IFN- -/derived cells, and had little or no effect on wild type derived T cells.
These studies have identified mechanisms by which IFN- mediates arthritis
susceptibility. Consistent with our hypothesis that IFN- acts as a regulator of immune
function, alterations in immune function were identified as a result of IFN- deficiency
that likely mediate susceptibility to autoimmunity and CIA in IFN- -/- B6 mice. Among
these changes, alterations in cytokine production, proliferative response, and gene
expression were observed. A key pathway of IFN- ’s regulation of autoimmune
susceptibility was identified as IFN- ’s regulation of IL-18 signaling via its influence on
the production of IL-18 BP. This pathway was shown to directly regulate CIA
susceptibility as exogenous IL-18 BP protected against the development of CIA when
administered to IFN- -/- mice at the time of antigen exposure. These observations about
the nature of immune function during an autoimmune response increases our
understanding of the regulatory processes that protect from autoimmune development and
may potentially serve as models in the design of therapeutic treatments for autoimmune
disease.
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Chapter 5. Conclusion
In the autoimmune disease, RA, the initial events of the autoimmune response are
poorly defined. However, several aspects of RA pathogenesis have been identified. For
example, CD4+ Th cells have been implicated in RA pathogenesis due to linkage of HLADR to increased susceptibility to RA (152). Proinflammatory cytokines have also been
implicated in driving the pathogenic immune response in RA. The expression of T cell
derived cytokines including IL-2, IFN- , and IL-17, has been observed in the synovial
fluid of arthritic joints during RA (21, 22, 153, 154). These T cell derived cytokines
promote the production, in the RA joint synovium, of a number of inflammatory
macrophage and fibroblast derived cytokines including IL-1, IL-6, IL-15, IL-18, TNF- ,
and GM-CSF. Though inflammatory cytokine-producing CD4+ Th cells, stimulated by
autoantigens presented by MHC class II molecules have been implicated in the
pathogenesis of RA, the exact mechanisms by which autoantigen stimulation and
cytokine signaling interact to activate T cells and cause autoimmunity remains elusive,
and many questions remain about how Th derived cytokines promote autoimmunity. For
this reason, the use of mouse models in the study of RA has the potential to provide
needed insight into the mechanisms of autoimmune development that lead to autoimmune
disease. CIA is a mouse model of RA that mimics the human disease in many aspects.
The histopathology of CIA resembles RA with similar cartilage and bone erosions and
cellular infiltrate into the joint synovium (155). In addition, the pathogenesis of CIA
appears to be similar to RA. As in RA, CIA susceptibility among mouse strains is
strongly linked to MHC class II haplotype, implicating CD4+ Th cells in the pathogenesis
of CIA (69). Finally, the expression of proinflammatory cytokines is similar in RA and
CIA. The T cell derived cytokines IL-2, IFN- , and IL-17 as well as downstream
proinflammatory cytokines IL-1, IL-6, IL-15, IL-18, TNF- , and GM-CSF are all
produced in the joint synovium during CIA (21, 156, 157). For these reasons, the mouse
model of CIA provides an ideal system in which to examine autoimmune mechanisms
that may provide insight to the pathogenesis of the human autoimmune disease RA.
In mice, susceptibility to CIA is strongly linked to expression of the MHC class II
alleles I-Aq and I-Ar (55, 56, 69). Mice that express other MHC class II alleles such as IAb in the B6 mouse are non-susceptible to CIA. Consistent with previous theory of MHC
based susceptibility to autoimmunity we hypothesized that CII, the inducing antigen for
CIA, contains determinants that bind I-Ab only with low affinity and reduces the
immunogenicity of CII in I-Ab-expressing mice, and therefore confers resistance to I-Abexpressing mice such as the B6 strain. Recently, a CIA model was described in which
the removal of the gene expressing the cytokine IFN- results in the conversion of CIA
non-susceptible B6 mice to full CIA susceptibility (17). The discovery that susceptibility
to autoimmunity was solely mediated by the absence of the Th1 produced
proinflammatory cytokine, IFN- , was paradoxical to conventional dogma that
autoimmune pathogenesis was mediated by CD4+ Th1 T cells, and has caused a
reexamination of the role of these cells and the role of cytokines in autoimmune
development. In light of the discovery that IFN- mediates autoimmune susceptibility,
that CII likely contains weakly antigenic I-Ab determinants, and that the cytokine milieu

90

is of paramount importance in autoimmune development, we hypothesized that in the
IFN- -/- B6 mouse, the absence of IFN- alters immune function in terms of T cell
activation, proliferation, and cytokine production. We propose that as a result of these
alterations in immune function, a disregulated proinflammatory phenotype develops in
which a pro-autoimmune cytokine milieu is created that supports the activation of CIIspecific T cells by weakly antigenic CII determinants and allows the progression to
autoimmunity. Therefore, in order to test this hypothesis, we examined functional
alterations that occur in IFN- -/- B6 mice following immunization with CII and sought to
characterize I-Ab-restricted determinants present in CII that support T cell activation and
the progression to autoimmunity.
Since we believed that CII contains I-Ab-restricted determinants of low
immunogenic potential, and that the T cell response to these determinants was mediated
by IFN- , we examined the immunogenicity of CII in both CIA-susceptible and nonsusceptible mouse strains that express I-Ab. To do this, we immunized wild type B6
mice, which are non-susceptible to CIA, and IFN- -/- B6 or CXB2 mice, which are
susceptible to CIA, with CII and examined the proliferative responses of T cells from
these mice when stimulated with CII or a library of peptides derived from CII sequence
in culture. When proliferative responses to CII were examined in these three strains of
mice it was found that there were minimal T cell responses to CII. This indicated that
I-Ab CII determinants were weakly antigenic as hypothesized. However, other
explanations of the weak proliferative response observed in these cells following
stimulation are possible. For example, regulatory T cells may be present that inhibit
proliferation in response to stimulation with CII. Also, the absence of IFN- may reduce
proliferative response in vitro by altering the expression of costimulatory molecules on
the surface of APC. IFN- is known to promote the activation of macrophages and
dendritic cells (158), and promotes the expression of both MHC class II and
costimulatory molecules including CD80/CD86 (159). If T cell costimulation is altered
in the absence of IFN- , weak proliferative responses may be observed in response to
antigen presented by APC that have not been activated. Several experiments are possible
to test this possibility. One method to test this possibility would be to use a control
antigen other than CII such as Mog or CytC that is known induce proliferation of I-Abrestricted T cells (160, 161). In vitro proliferation of I-Ab-restricted T cells obtained from
immunized IFN- -/- B6 mice would rule out ineffectual antigen presentation by APC as a
mechanism of reduced proliferative response in the IFN- -/- background.
While there appeared to be minimal T cell proliferative response to CII
determinants in I-Ab-expressing mice, we believed that CII-reactive T cells were being
produced. Evidence for this was that anti-CII IgG subclasses are produced in these mice
following immunization with CII (69). Since the switch from IgM to IgG production by
B cells is driven by T cells, this evidence of CII-specific IgG strongly indicated a CIIspecific T cell response was occurring in vivo. We sought to identify these T cells and
the CII determinants they recognize by producing I-Ab-restricted T cell hybridomas from
wild type B6, IFN- -/- B6, and CXB2 mice immunized with CII. Hybridoma generation
allowed the low frequency CII-specific T cells to be immortalized and expanded for
subsequent determinant analysis. While various attempts were made to produce these T
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cell hybridomas in wild type and IFN- -/- B6 mice, the production of these cells proved
successful in only the CXB2 mouse strain. Stimulation of these CII-specific T cell
hybridomas with a CII peptide library allowed the identification of an immunodominant
I-Ab-restricted CII determinant, located at position 514-525 of the CII sequence.
Structurally, MHC class II molecules contain an open ended binding grove in which nine
amino acids can bind closely. The peptide determinant interacts closely with the MHC
class II molecule in this region through interactions with the carbon backbone of the
peptide and via a series of hydrophobic pockets within the MHC molecule referred to as
p1, p4, p6, p7, and p9. Also, due to the open ended nature of the binding groove, amino
acids of the peptide that extend beyond the nine amino acid core can contribute to
binding stability (162). In order to experimentally define the core determinant, and to
assess the contribution of each amino acid within the CII determinant to the formation of
the ternary complex, the T cell hybridomas were stimulated with a panel of alanine
substituted analog peptides with individual substitutions at each position from CII(512526). Analysis of T cell hybridoma stimulation by these analog peptides allowed the
identification of the core determinant as CII(517-525). Interestingly, it was found that
substitution with alanine at five of the positions within the nine amino acid core
completely abrogated T cell stimulation. This is unusual in that similar studies, in which
alanine substituted analog peptides were used to stimulate CII-specific T cell hybridomas
restricted to other MHC class II haplotypes, including DR1 and I-Aq, the substitutions
were well tolerated and tended to reduce rather than completely inhibit T cell stimulation
by the analog peptide (101, 163). This may be an indication that the stability of the I-Ab
CII determinant within the peptide/MHC /TCR complex is low and therefore highly
sensitive to slight changes in affinity mediated by the alanine substitutions. As an
additional approach to determine the immunogenic properties of the I-Ab-restricted CII
determinant, we used a bioinformatic method, the MHC binding algorithm SMM-align,
to calculate the affinity of CII for I-Ab MHC. These calculations indicated that there
were no sequences present in CII that bind I-Ab with high affinity, including the CII(512528) determinant identified by the T cell hybridomas.
Characterization of CII and CII(512-528) indicates that CII determinants weakly
bind I-Ab. Evidence for this include the low proliferative responses of T cells following
stimulation with CII, the weak stimulatory characteristics of alanine substituted analog
determinant peptides, the identification of the core binding residues of CII(517-525), and
the observation that amino acid differences among CII from different species (mouse,
chicken, and bovine) may cause the altered immunogenicity of CII from the different
species. Reduced TCR affinity for peptide determinants reduces the activation of T cells
for those determinants. A low affinity determinant engages fewer T cell receptors and
would cause reduced signaling, thus resulting in reduced T cell activation (164). In a
mouse model of MS, EAE, there is evidence that IFN- may regulate T cell responses to
weak antigens (165). In one study by Brian Evavold, a low affinity variant of the
encephalogenic peptide Mog(35-55) was used to induce EAE. The use of this peptide
variant in wild type B6 mice results in attenuated disease severity and reduced CD4+ T
cell proliferative responses. However, when IFN- -/- or IFN- R-/- mice are immunized
with the variant peptide, both increased encephalogenicity and CD4+ T cell proliferative
responses are increased in a manner independent of IL-17 (165). The increased immune
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response to the low affinity Mog determinant observed in the EAE model bears a striking
resemblance to the responses observed in the CIA model to the determinant identified
here, and may be a mechanism of IFN- regulation of disease susceptibility in the IFN- -/CIA model. CII derived from chicken or bovine sources differs in one amino acid in the
CII(517-525) core region, P518A. This mutation between the two species may explain
why chicken derived CII is arthritogenic in the B6 mouse while the bovine derived CII is
not. The bovine derived CII determinant is likely of lower affinity than the chicken
derived determinant. Additional studies are needed to define how the weak CII
determinant present in bovine CII affects T cell response in the IFN- -/- B6 mice.
Measurement of T cell proliferation in wild type and IFN- -/- B6 mice in response to
stimulation with both chicken and bovine determinants would identify if IFN- is
regulating T cell responses to this low affinity determinant and potentially mediating CIA
susceptibility by this mechanism. In the CIA model, immunization with peptide does not
induce arthritis. This is likely due to the absence of CII-specific antibodies that are
produced only when native collagen is used as the immunogen. An experiment that
would be useful in characterizing low affinity determinants in the pathogenesis of CIA
would be to co-immunize wild type or IFN- -/- B6 mice with both native bovine CII and
peptide determinants derived from either chicken or bovine sequence. Enhanced CIA in
wild type mice when co-immunized with higher affinity CII determinants would indicate
that variation in affinity of CII determinants mediates arthritis susceptibility. In the
IFN- -/- B6 mice enhanced CIA with higher affinity determinants as opposed to low
affinity determinants would indicate that determinant affinity mediates arthritis
susceptibility in these mice.
Having identified a low affinity I-Ab-restricted CII determinant in vitro, we next
sought to confirm its relevance to CIA pathogenesis in vivo. To do this we measured the
proliferative response of T cells from I-Ab-expressing mice immunized with CII(512528), and examined the ability of the CII(512-528) peptide to induce tolerance when
given to CXB2 mice prior to immunization with CII to induce CIA. When T cells from
B6 or CXB2 mice were stimulated with CII(512-528) a proliferative response was
observed. Also, tolerizing CXB2 mice with CII(512-528) prior to immunization with CII
reduced both the incidence and severity of the resulting arthritis. These studies
confirmed that the CII(512-528) determinant was capable of stimulating a T cell
proliferative response in vivo, and its suppression of CIA indicated that this determinant
is responsible for mediating autoimmune development in I-Ab-expressing mice.
The data described above are consistent with our hypothesis that CII contains at
least one low affinity determinant that mediates autoimmune development, and that in
I-Ab-expressing mice T cells specific for this determinant are produced. The activation of
these T cells in response to this low affinity determinant may be a point at which IFNregulates the development of autoimmunity in B6 mice. By its influence on immune cell
differentiation, activation, and cytokine production, IFN- serves as master regulator of
immune function. In IFN- -/- B6 mice, it is likely that alterations in these immune
processes mediated by the absence of IFN- in IFN- -/- B6 mice allows activation of T
cells to weak CII antigens and promotes autoimmune development. Therefore, in order
to determine the mechanism by which the absence of IFN- promotes autoimmunity we
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examined the alterations in the cytokine milieu that occur in IFN- -/- B6 mice, and
examined changes in the immune cell functions of proliferation, differentiation,
autoantibody production, and cytokine production that occur following T cell stimulation
in the IFN- -/- B6 mouse.
Major alterations in immune function in response to CII immunization that occur
in IFN- -/- B6 mice appear to be primarily in cytokine and autoantibody production, and
in T cell proliferative responses when T cells are stimulated nonspecifically. When B
cells, T cells, and the T cell subtypes that develop following immunization with CII were
examined by flow cytometry, no significant differences in cell differentiation were
observed. However, when cytokine production was measured by ELISA, increases in
Th1, Th17, and Tc associated cytokines were observed in cultures of IFN- -/- derived T
cells compared to wild type derived cells following stimulation with anti-CD3 and antiCD28 antibodies. Similarly, levels of anti-CII antibodies, especially the complement
fixing IgG subtype IgG2b, were also increased in IFN- -/- B6 mice when compared to
wild type mice following immunization with CII. Also, while CII-specific T cell
proliferative responses were too weak to detect differences between wild type and
IFN- -/- B6 mice, when T cells from these mice were stimulated nonspecifically with antiCD3 and anti-CD28 monoclonal antibodies, increased proliferation in IFN- -/- derived
cells was observed in comparison to the wild type cells. While all of these changes
potentially contribute to increased susceptibility to CIA in the IFN- -/- B6 mouse it is
likely that the immune mechanisms of proliferation, and autoantibody production are
downstream effects of altered cytokine production in the IFN- -/- B6 mouse. Immune cell
differentiation is mediated by the cytokine milieu, for example Th1 cell differentiation is
promoted by IFN- and inhibited by IL-4 and IL-10, Th17 differentiation is promoted by
IL-6 and TGF (166), while Th2 differentiation is promoted by IL-4 and IL-10 and
inhibited by IFN- . Similarly, antibody production by B cells is influenced by cytokine
signaling, IL-5 promotes B cell growth (114) and differentiation while IFN- promotes Ig
class switching to IgG2a and IL-4 promotes Ig class switching to IgE and IgG1 (90-92).
In order to determine how the absence of IFN- effects global changes in the
cytokine milieu, and to determine how these changes potentially alter immune function to
produce a disregulation phenotype that results in increased susceptibility to CIA in
IFN- -/- B6 mice, gene expression analysis by microarray was performed using mRNA
from lymphocytes obtained from wild type and IFN- -/- B6 mice immunized with CII.
This analysis identified a number of genes that were differentially expressed between
wild type and IFN- -/- B6 mice including immune signaling molecules, immune effector
molecules, and mediators or indicators of inflammation. While several genes were
identified as upregulated in the IFN- -/- mice that may be effectors of the destructive
inflammation that is characteristic of autoimmune arthritis, two genes were identified that
are likely mediators of autoimmune susceptibility. These genes were the
proinflammatory cytokine IL-17, identified as upregulated in the IFN- -/- mouse, and the
negative regulator of IL-18, IL-18 BP, identified as downregulated in the IFN- -/- mouse.
IL-17 is a strongly proinflammatory cytokine that is produced by Th17 cells that also
produce the proinflammatory cytokines, IL-6, TNF- , and GM-CSF. IL-17 further
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promotes inflammation by stimulating the production of IL-6, IL-8, G-CSF, GM-CSF,
IL-1 , TGF , and TNF- by fibroblasts, endothelial cells, epithelial cells, keratinocytes,
and macrophages (167). Its influence on RA pathogenesis has been identified by its
expression in RA synovium, and by knock out mouse models in which the absence of IL17 reduces the development of CIA (45, 150). IL-18 is also a proinflammatory cytokine
that has been linked to autoimmune pathogenesis in RA. IL-18 is expressed in the RA
synovium, and functions to promote the expression of proinflammatory cytokines
including IFN- , GM-CSF, IL-1 , and TNF- by synoviocytes (120). Furthermore,
removal of IL-18 by knock out models or by the use of anti-IL-18 antibodies reduces the
severity of CIA (132). IL-18 BP is a negative regulator of IL-18 and is produced by
macrophages and endothelial cells stimulated by IFN- (123). As a negative regulator of
the proinflammatory cytokine IL-18 whose expression is promoted by IFN- , IL-18 BP
likely plays a large role in the susceptibility to CIA in IFN- -/- mice. Further evidence of
IL-18 BP’s role in mediating arthritis susceptibility is the increased expression of
cytokines including IL-1 , GM-CSF, and TGF 1 that are downstream of IL-18 signaling
in IFN- -/- B6 mice. In IFN- -/- B6 mice immunized with CII, expression of these genes
is observed to be upregulated compared to wild type B6 mice as measured by real time
PCR. In addition, when the levels of these cytokines are measured by ELISA in the
supernatants of T cells stimulated in culture with anti-CD3/CD28 antibodies, the
concentration of these cytokines is increased in the IFN- -/- cells as compared to the wild
type. These data provide compelling evidence that a major mechanism of IFNregulation of CIA susceptibility is the promotion of IL-18 BP expression. In this model,
IFN- mediated expression of IL-18 BP by wild type mice is high, and protection from
autoimmunity is conferred. In IFN- -/- B6 mice, the absence of IFN- reduces expression
of IL-18 BP and allows increased signaling by IL-18, and the proinflammatory function
of IL-18 likely promotes the susceptibility to autoimmunity in IFN- -/- B6 mice. To test
this model of IL-18 BP regulation of autoimmunity, IFN- -/- B6 mice were treated with
exogenous IL-18 BP concurrently with CII immunization to induce CIA. This treatment
protected CIA-susceptible mice from the development of disease, delayed onset, and
reduced the severity of arthritis. These data confirm that IFN- mediated IL-18 BP
expression regulates autoimmune development in these mice.
Having confirmed IL-18 BP’s role in mediating autoimmune susceptibility in an
in vivo model, we further characterized the mechanism by which IL-18/IL-18 BP
signaling mediates immune development by examining the effects of IL-18 and IL-18 BP
on the proliferation and cytokine production of T cells from wild type and IFN- -/- B6
mice stimulated with anti-CD3 and anti-CD28 antibodies. When added to stimulated T
cell cultures, IL-18 promoted T cell proliferation, while addition of IL-18 BP inhibited
the proliferation of wild type T cells. These data indicate that in wild type mice, one
mechanism of autoimmune regulation may be through reduced IL-18 dependent T cell
proliferation mediated by high levels of endogenous IL-18 BP. Furthermore, when
cytokine production was examined in stimulated T cell cultures, it was observed that wild
type cells had reduced cytokine production compared to stimulated IFN- -/- T cells.
When IL-18 was added to these cultures, the wild type cells produced cytokines in a
pattern that closely resembled the cytokine production of stimulated IFN- -/- T cells.
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Additionally, when stimulated IFN- -/- T cells were supplied with exogenous IFN- there
was a reduction in cytokine production. These data indicate that there is a regulatory
loop between IL-18 and IFN- that serves to mediate the production of cytokines by T
cells following antigenic stimulation.
Concepts of immune function identified in these studies has allowed the
development of a model to that illustrates how IFN- regulates immune function, and
how in IFN- -/- mice, autoimmunity occurs. In this model, T cell interaction with a low
affinity CII determinant in an immune milieu that consists of abnormal cytokine signaling
mediated by the absence of IFN- allows activation of CII-specific T cells. The absence
of IFN- both causes a reduction in the expression of IL-18 BP and alters the function of
Th1 cells. The reduced production of IL-18 BP increases IL-18 signaling and increases
the influence of this proinflammatory cytokine on the function of both effector T cells
and cells within the joint synovium that mediate the chronic inflammation and erosive
joint destruction that is characteristic of autoimmune arthritis.
Fig 5.1 illustrates the function of T cells in wild type B6 mice following
immunization with CII/CFA. In this model, immunization with CII/CFA stimulates an
adaptive immune response that is primarily of the Th1 phenotype. Differentiation of Th1
cells is promoted by the presence of Mtb in the CII/CFA emulsion that promotes the
production of IL-12, and therefore drives differentiation of T cells towards the Th1
phenotype (149). These cells produce Th1 associated cytokines, especially IFN- , that
promote a cell mediated immune response. However, several mechanisms exist in B6
mice that limit the progression of this response to autoimmunity. These include negative
regulation by Treg cells and feedback inhibition of Th1 effector function mediated by
cytokine signaling. In addition, B6 mice express MHC of the I-Ab haplotype. Since CII
is weakly immunogenic in this MHC background, possibly due to the low affinity of CII
determinants for I-Ab MHC, the expansion of Th1 T cells is not particularly robust, and is
particularly sensitive to negative regulation. The negative regulation that protects wild
type B6 mice from the development of autoimmunity is mediated in part by the
expression of IL-18 BP. IL-18 BP expression by macrophages and epithelial cells is
induced by IFN- produced by the developing Th1 cells. The IL-18 BP binds to IL-18
extracellularly and prevents it from binding to IL-18 receptors present on Th cells, and
therefore abrogates the proinflammatory effects of IL-18 (151). Since the Th cell
response to CII determinants presented by I-Ab MHC is not strong, the reduction of the
proinflammatory signal mediated by IL-18 is sufficient to limit T cell response to CII in
wild type B6 mice.
In IFN- -/- B6 mice, the absence of IFN- alters the immune milieu both prior to
and following immunization with CII/CFA, and results in a pro-autoimmune phenotype.
As shown in Fig 5.2 and Fig 5.3, the absence of IFN- disrupts immune regulatory
mechanisms resulting in altered cytokine production, Th cell differentiation, and disease
progression. In IFN- -/- B6 mice immunization with CII/CFA stimulates an adaptive
immune response to CII resulting in the generation of Th1, Th17, and Th2 subsets of CIIspecific T cells. However, since IFN- cannot be produced in these mice, Th1 effector
function is limited. The malfunctioning effector response of Th1 cells both disrupts
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Figure 5.1
Model of Immune Response in Wild Type B6 Mice.
In wild type B6 mice, regulation of immune response prevents uncontrolled progression
to autoimmunity. Each Th cell subtype is regulated by both autocrine and paracrine
mechanisms. Cytokines produced by an effector Th subtype can inhibit the function of
development of other Th responses. In addition, an uncontrolled continuously expanding
immune response is inhibited by feedback inhibition. For example, Th1 type T cell
response is self-limited by IFN- . IFN- promotes IL-18 BP expression by monocytes,
macrophages, and synovial epithelium. This in turn reduces IL-18 signaling leading to
reduced expression of IFN- and Th1 cell function. In a regulated immune response,
these mechanisms prevent the progression to autoimmunity.
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Figure 5.2
Model of Immune Response in IFN- -/- B6 Mice.
In IFN- -/- B6 mice, autoimmune arthritis develops as a result of dysfunctional immune
regulation. The absence of IFN- causes abnormal Th1 cell response, highlighted in
green. Without IFN- , regulatory mechanisms that would normally inhibit the
progression of an immune response to a low affinity T cell determinant fail to activate,
particularly the production of IL-18 BP. As a result, abnormal Th cell differentiation and
function occurs. Th1 cell response is reduced while Th17 and Th2 responses increase,
leading to production of cytokines that promote inflammation and the activation of
synoviocytes that mediate the erosion of cartilage and bone.
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Figure 5.3
Model of Th2 Response in IFN- -/- B6 Mice.
Th2 response is increased in the absence of IFN- . The lack of negative regulation of Th2
cell differentiation mediated by IFN- leads to the activation and disregulated function of
Th2 cells. B cell stimulation of B cells by Th2 cells, and the production of Th2 associated
cytokines promotes the production of CII-specific antibodies by B cells and promotes
disease immune complex mediated complement activation, and FcR mediated activation
of macrophages and lymphocytes. Production of Th2 cytokines contributes to the
disregulation of Th1 and Th17 responses that promote autoimmunity.

99

regulatory mechanisms that would limit autoimmune progression and promotes the
expansion and effector function of disease promoting Th17 and Th2 subsets (21, 76). The
absence of IFN- production by Th1 cells fails to stimulate the production of IL-18 BP by
macrophages and synovial epithelium. The effect of reduced production of IL-18 BP is
increased T cell stimulation by the proinflammatory cytokine IL-18. In contrast to wild
type B6 mice, in IFN- -/- B6 mice I-Ab-restricted CII-specific T cells encounter low
affinity CII determinants in the presence of increased proinflammatory signaling
mediated by IL-18 and activate. In addition, the absence of IFN- alters how the CIIspecific T cells differentiate. IFN- inhibits the differentiation of both Th17 and Th2 T
cell subtypes (21, 76, 168). Therefore as CII-specific T cells activate and differentiate,
the Th17 and Th2 cells begin to dominate the immune response due to disregulated
proliferation of these T cell subtypes. This has direct effects on the mechanisms of
arthritis pathogenesis. Coinciding with the expansion of these cells is the production of
cytokines including IL-17 and GM-CSF. Along with IL-18, these cytokines act directly
on synoviocytes to promote inflammation in the joint and initiate cartilage and bone
erosion (45, 132, 150, 157, 169). Disregulated Th2 cell function also promotes arthritis
pathogenesis in IFN- -/- B6 mice. Since IFN- inhibits Th2 cell differentiation and
expansion, in the absence of IFN- the activity of these cells is increased. Following
activation, CII-specific Th2 cells produce high levels of IL-4, IL-5, and IL-13, which
promotes B cell maturation, differentiation, and proliferation and allows Th2 dependant
CII-specific antibody production by activated B cells (170). These alterations in the
immune milieu, disregulated cytokine production, disregulated immune cell
differentiation, and disregulated feedback inhibition of immune response, all deriving
from the absence of IFN- in IFN- -/- B6 mice, allow progression autoimmunity and
directly promote arthritis pathogenesis.
The identification of an I-Ab-restricted CII determinant that stimulates T cells has
the potential to greatly expand our understanding of the pathogenic mechanisms of
autoimmune arthritis. In other mouse strains that are susceptible to CIA, the
identification of a CII determinant restricted to the MHC haplotypes expressed in these
mice such as I-Aq in the DBA/1, and DR1 in humanized B10 mice, allowed the
development of MHC class II tetramer based assays to identify CII-specific T cells in
these mice that are generated in response to immunization with CII and to study their
pathogenic function. This allows subtle changes in immune response to autoantigen to be
examined in exquisite detail (171). This ability expands the capability to investigate the
mechanisms of autoimmune pathogenesis and also provides a tool to directly measure the
efficacy of autoimmune therapy by measuring alterations in T cell immune response that
may occur from treatment with therapeutic agents. For example, using flow cytometric
methods, CII-specific T cells identified with CII tetramer can be examined for activation
and cell subset markers. In addition, cell sorting technology allows the isolation of CIIspecific T cells for further in vitro study or adoptive transfer. The identification of an
I-Ab-restricted CII determinant provides the ability to generate CII I-Ab tetramers, and
this would greatly expand our ability to investigate the mechanisms of pathogenesis in
this altered-cytokine model of autoimmune arthritis.
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One limitation of previous studies of the autoimmune mechanisms of CIA is the
relatively small number of knock out mice available in the genetic backgrounds that are
susceptible to CIA such as the DBA/1 strain. Therefore, in order to study how specific
genes mediate autoimmune pathogenesis many months of breeding and backcrossing are
required to generate knock out mice on these backgrounds. The identification of an I-Abrestricted CII determinant has the potential to facilitate the study of specific genes in the
pathogenesis of autoimmune arthritis. As one of the most widely studied mouse strains,
numerous knock out B6 models have been developed including those with inflammatory
cytokines like IL-17, IL-12, IL-1 , and other immune modulating genes. The use of
these B6 knock out strains to analyze immune cell function in response to the CII
autoantigen identified here using either CII I-Ab tetramer or the use of more traditional
methods such as measurement of proliferation and cytokine production has the potential
to identify the detailed regulatory pathways by which these genes mediate autoimmunity.
Though the identification of an I-Ab-restricted CII determinant has the potential to
provide insight into the generation of a pathogenic T cell response during autoimmune
development, further avenues of investigation remain to fully characterize autoantigen
specific T cell responses in the CIA model. One immunodominant I-Ab determinant
present in CII has been definitively identified here, yet it is likely that other epitopes are
present in CII that are capable of binding to I-Ab MHC molecules and stimulating T cells.
Some evidence of this possibility can be inferred from the binding of CII determinants to
DR1 and the predicted binding of 29 low affinity CII determinants to I-Ab. Recent
unpublished observations have indicated that T cells specific for “minor” CII
determinants other than the immunodominant CII(257-274) epitope are generated in
DR1-expressing mice and can be stimulated in vivo following CII immunization. For
I-Ab, other low affinity CII determinants are likely to be present as indicated by the 29
predicted low affinity sequences. These low affinity determinants may prove to be
important regulators of autoimmunity, potentially mediating the generation or function of
Treg cells that inhibit the development of effector T cells against stronger CII antigens, or
by promoting anergy of CII-reactive T cells when these low affinity CII determinants are
presented by APC in the absence of costimulatory signaling.
The identification of IL-18 BP as a mediator of autoimmune susceptibility has
provided insight into the pathogenic mechanisms of autoimmune arthritis. Yet for
several reasons, it is likely that this pathway alone does not comprise all of IFN- ’s
regulation of autoimmune susceptibility. While the gene expression array allowed the
identification of IL-18 BP as differentially expressed between wild type and IFN- -/mice, there remain 1611 other genes that were identified as differentially expressed
between the two mice. Many of these genes are of unknown function, and therefore may
prove to be important immune mediators of as yet unknown immune regulatory
pathways. Furthermore, the gene expression array data represents the gene expression of
all the cells obtained from the lymph nodes, and includes mRNA from T cells, B cells,
macrophages, dendritic cells, and all other cells present at the time that the mRNA was
isolated from the lymph node cells. For this study, this cell diversity was useful since IL18 BP is produced largely by macrophages, and may not have been identified in a more
restricted cell population analysis. However, microarray analysis based on discrete cell
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types from IFN- -/- mice has the potential to expand our knowledge of how IFNmediates immune response of individual cell types. One potential experiment that would
be extremely useful in discerning autoimmune T cell responses would be gene expression
analysis of CII-specific T cells. If CII I-Ab tetramer were to be generated using the CII
epitope defined here, these cells could be sorted by flow cytometry. mRNA could then
be isolated from discrete CII-specific T cell populations for examination of their gene
expression. Not only would this be useful for examination of IFN- mediated immune
regulation, but also any of the other knock out models that exist in the B6 background.
When one considers the various T cell markers that could be used as sorting criteria, and
the vast number of knock out models available, these approaches could be combined to
generate a large amount of new data regarding autoimmune pathogenesis.
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Appendix. Binding of CII Determinant to I-Ab
In order to test the hypothesis that IFN- regulates weak T cell responses, the
affinity of CII determinants for the I-Ab molecule was measured. If the affinity for CII
determinants for I-Ab is low, then the ability of this peptide to stimulate a T cell response
would be reduced. In order to determine the strength of CII determinants in binding to
I-Ab, two methods were employed. The first method was a bioinformatic approach that
used an algorithm to predict the binding strength of potential determinants for I-Ab based
on the sequence of known I-Ab binding determinants. The second method was a
biochemical competition binding assay.

Bioinformatic Prediction of I-Ab Binding
A bioinformatic examination of the CII sequence was performed using the
binding prediction algorithm SMM-align (172). The binding affinity of CII for both I-Ab
and DR1 was calculated. DR1 serves as a control since CII determinants were known for
this molecule and could be compared to the calculated results. This method uses the
sequence of the determinants of various MHC class II molecules with known binding
affinity to calculate a weight matrix for each amino acid residue in a nonamer peptide
that corresponds to the binding groove of a MHC class II molecule. It does this by using
an algorithm that seeks to match calculated values of peptide determinants to known
affinity values. This calculation results in a binding affinity prediction for peptides in
terms of the IC50 required to bind a given MHC class II molecule. In a competitive
binding assay, the IC50 is the concentration of unlabeled peptide required to inhibit 50%
of the binding of labeled peptide. Therefore, lower IC50 values indicate higher binding
affinities (172). When the MHC class II algorithm was used to predict the binding
properties of the CII sequence from amino acid number -15 to 1060 against DR1 the data
indicated 294 weak binding sequences with an IC50 lower than 500 nM and 51 strong
binders with an IC50 lower than 50 nM. Binding affinity of CII for DR1 was
experimentally derived by competition assay of CII-library peptides with a labeled
peptide of a known DR1 determinant, CII(257-274). The experimental values match well
with the computed affinity of DR1 with regions of high binding matching the predicted
areas of elevated binding affinity in CII (Fig A.1AB). When the prediction algorithm
was used to calculate affinity values for the binding of CII to I-Ab only 29 low affinity
peptides were identified with calculated affinities between 50 and 500 nM (Fig A.1C).
No high affinity peptides (IC50 < 50 nM) were identified. This result indicates that
overall, the CII sequence likely has low affinity for I-Ab with no discrete sequences
within CII that have a predicted high affinity for I-Ab. The CII determinant identified by
the T cell hybridomas, CII(512-528), was one of the predicted low affinity peptides.

CII I-Ab Binding Assay
A requirement for the identification and subsequent measurement of binding
affinity of I-Ab-restricted CII determinants was the generation of soluble MHC Class II of
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Figure A.1 Prediction of CII Peptide Binding to the MHC Class II Alleles DR1
and I-Ab by SMM-align.
AB. When the scoring algorithm SMC-align is used to predict the binding affinity of
DR1 CII determinants, the predicted regions of high binding correlate well with the
experimental measurements of binding affinity. Affinity values in nM are log
transformed using the equation 1 – log50k (IC50 nM). Affinity values higher than 50,000
were assigned a transformed value of 0, higher values indicate stronger binding. B. In
the predicted CII determinants of DR1 many regions show high affinity for DR1 binding.
C. In contrast to the DR1, the prediction of CII binding to I-Ab is lower throughout the
CII sequence with no regions exhibiting high binding affinity above 50 nM. Highlighted
in red is a known determinant for HLA-DR1 present in the peptide library AB and the
putative CII determinant identified in this study C.

the b haplotype. Two strategies were employed to produce a soluble form of I-Ab in
insect cell lines. mRNA was recovered from the splenocytes of I-Ab-expressing B6 mice
and used to produce cDNA encoding the alpha and beta subunits of MHC class II in
which the transmembrane region was replaced with a leucine zipper by PCR. These
constructs were then cloned into drosophila or baculovirus expression vectors and
transfected into S2 cells or to infect SF9 cells, respectively.
An additional requirement for binding affinity measurements is a labeled peptide
known to bind I-Ab. In a competition binding assay, this peptide is used as the indicator
to compete with unlabeled test peptides for binding to I-Ab. To produce this indicator,
two peptides, known to bind I-Ab, Mog(35-55) (160) and CytC(43-58) (104, 161) were
synthesized with biotin groups added to the amino termini. As an empirical test of the
ability of these two peptides to bind I-Ab, B6 mice were immunized with Mog(35-55) or
CytC(43-58) in an emulsion of CFA. Lymphocytes were recovered from draining lymph
nodes ten days later, and re-stimulated in vitro with the biotinylated analogs of the two
peptides. Lymphocytes recovered from immunized mice proliferated in vitro as
measured by 3H-thymidine incorporation when stimulated with Mog(35-55) or CytC(4358) indicating that the peptides were functional and could bind I-Ab both in vivo and in
vitro (Fig A.2).
To assess the function of the biotinylated indicator peptides and the function of
the recombinant soluble I-Ab, the ability of the two indicator peptides to bind the soluble
I-Ab was measured using a binding assay. The two indicator peptides, and biotinylated
CII(257-274) as a negative control, were incubated with soluble I-Ab and the degree of
binding for each peptide over a range of concentrations was subsequently measured.
Peptide I-Ab complexes were allowed to form in solution and I-Ab was captured by
antibodies adhered to microtiter wells, and the levels of bound indicator peptide were
detected using europium labeled streptavidin. An increase in fluorescence indicates the
presence of biotinylated peptide bound to I-Ab. Binding of the Mog(35-55) peptide to S2
derived I-Ab occurred at a concentration greater than 0.1 µM (Fig A.3). No significant
binding was observed in either preparation of soluble I-Ab for the CytC(43-58) or the
CII(257-274) negative control peptide. These results indicated that Mog(35-55) peptide
bound to the S2 produced I-Ab. However, the Mog(35-55) peptide was observed to have
low solubility in the buffers required for the binding assay, forming a precipitate at high
concentrations. To examine whether or not this insolubility caused technical problems
with the binding assay resulting in non-specific binding, a titration of Mog(35-55)
peptide was performed using both the S2 and SF9 derived I-Ab and a mock binding assay
without I-Ab added (Fig A.4). In each test condition, fluorescence was observed when
the Mog(35-55) peptide was at a concentration above 1 M. This indicates that at high
concentrations the Mog(35-55) peptide binds non-specifically.
To directly measure the relative affinity of the CII peptide in comparison with
other known binders of I-Ab, the CII peptide library was used in a binding competition
assay with the soluble I-Ab produced above as well as a soluble DR1 molecule produced
previously as a positive control for the assay. In the binding assay, the library peptides
were used at a concentration of 5 M to compete for binding to I-Ab with 10 nM of biotin
labeled Mog(35-55). The Mog(35-55) peptide was used in this assay as it was the only
120

3H-Thymidine

(DPM/1000)

160
Antigen
Control
120

80

40

0

CytC

Immunogen

Mog

Figure A.2 I-Ab-Restricted Proliferation in Response to Stimulation with CytC
and Mog Peptides.
As an empirical test of Mog(35-55) and CytC(43-58) ability to bind I-Ab, the peptides
were used in CFA emulsion to immunize CXB2 mice. When lymphocytes obtained from
the draining nodes of the immunized mice were stimulated with their respective peptides,
robust proliferation of T cells over media control was observed (p < 0.001). This result
indicated that these peptides were indeed capable of binding I-Ab and were strong
inducers of T cell proliferation.
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Figure A.3 Binding of Mog, CytC, and CII Peptides to Soluble I-Ab.
Direct binding of known I-Ab determinants to recombinant soluble I-Ab produced in S2
cells was measured by fluorescence assay. Two biotinylated peptides known to bind
I-Ab, Mog(35-55) and CytC(43-58), and a biotinylated negative control peptide, CII(257274) were titrated with soluble I-Ab. Binding was observed for the Mog(35-55) but not
for CytC(43-58) or the negative control CII(257-274) peptides.
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Figure A.4 Binding of Mog(35-55) to I-Ab.
When Mog(35-55) was titrated for binding to either S2 or SF9 derived I-Ab or in a
negative control assay containing no MHC class II molecule increases in fluorescence
were observed in all three test conditions when the Mog(35-55) peptide was at a
concentration above 1 M.
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peptide that was observed to bind I-Ab. At this concentration, we hoped to avoid the nonspecific binding of the Mog(35-55) peptide observed at the higher concentrations while
still being able to detect competition with the CII peptides by increasing the gain of the
flurometer. Increased gain, amplifies the ability of the flurometer to measure low levels
of fluorescence yet has the drawback of causing increased background. In the DR1
binding assay the CII peptide library was used at 5 M to compete for binding to DR1
with 30 nM biotin labeled CII(257-274). Biotin labeled peptide bound to the MHC class
II molecules was detected using europium streptavidin and the resulting fluorescence was
measured. Data is expressed as the measured fluorescence subtracted from 10,000, the
maximum value possible, in order to facilitate data interpretation. Due to the
mathematical conversion, high values indicate that the CII peptide competed successfully
with the labeled peptide. When bound to DR1, the CII library successfully competes for
binding with the indicator peptide in 12 regions (Fig A.5A). In the assay competing CIIlibrary peptides with Mog(35-55) for I-Ab binding, no binding above background was
observed (Fig A.5B). Proliferation in response to stimulation with the CytC(43-58) and
Mog(35-55) peptides indicate that these peptides are functional antigens when presented
to T cells by I-Ab-expressing APC. In addition, the assay is technically sound as
indicated by the ability to detect binding of peptides to the DR1 molecule. However,
competition with CII peptides was not detectable. These data indicate that the
recombinant I-Ab is not performing well in these binding assays as Mog(35-55)
apparently binds at low concentration but there is no indication that CII(512-528)
competes.
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Figure A.5 Binding of CII Determinants to DR1 or I-Ab MHC Class II Molecules.
15 mer peptides derived from the human sequence of CII were used in competitive
binding assays with soluble DR1 or soluble I-Ab. A. Competition of library peptides
with labeled CII(257-274) resulted in the identification of 12 regions that bind DR1 with
elevated affinity. B. Competition of library peptides with soluble I-Ab did not exhibit
increased binding affinity at any region.
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